



Factors That Influence the Immune Response to Vaccination

Petra Zimmermann,^{a,b,c,d,e} Nigel Curtis^{a,b,c}

^aDepartment of Paediatrics, The University of Melbourne, Parkville, Australia

^bInfectious Diseases & Microbiology Research Group, Murdoch Children's Research Institute, Parkville, Australia

^cInfectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, Australia

^dDepartment of Pediatrics, Fribourg Hospital HFR, Fribourg, Switzerland

^eFaculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland

SUMMARY	2
INTRODUCTION	2
FACTORS INFLUENCING VACCINE RESPONSES	2
Intrinsic Host Factors	2
Age	2
Sex	5
Genetics	5
Comorbidities	5
Perinatal Host Factors	10
Gestational age	10
Birth weight	12
Breastfeeding	12
Maternal antibodies	12
Maternal infections during pregnancy	13
Other maternal factors	14
Extrinsic Factors	14
Infections	14
Parasites	16
Antibiotics, probiotics, and prebiotics	16
Microbiota	20
Preexisting immunity	21
Behavioral Factors	21
Smoking	21
Alcohol consumption	21
Exercise	21
Acute psychological stress	21
Chronic psychological stress	24
Sleep	24
Nutritional Factors	24
Body mass index	24
Nutritional status	25
Micronutrients (vitamins A, D, and E and zinc)	25
Enteropathy	25
Environmental Factors	25
Rural versus urban environment	25
Geographic location	27
Season	27
Family size	27
Toxins	27
Vaccine Factors	27
Vaccine type, product, and strain	27
Adjuvants	27
Vaccine dose	29
Administration Factors	29
Vaccination schedule	29
Vaccination site	29
Vaccination route	29
Needle size	30
Time of day	30
Coadministered vaccines	30
Coadministered drugs	31

(continued)

Citation Zimmermann P, Curtis N. 2019. Factors that influence the immune response to vaccination. *Clin Microbiol Rev* 32:e00084-18. <https://doi.org/10.1128/CMR.00084-18>.

Copyright © 2019 American Society for Microbiology. All Rights Reserved.

Address correspondence to Petra Zimmermann, petra.zimmermann@mcri.edu.au.

Published 13 March 2019

CONCLUDING REMARKS	31
ACKNOWLEDGMENTS	33
REFERENCES	33
AUTHOR BIOS	50

SUMMARY There is substantial variation between individuals in the immune response to vaccination. In this review, we provide an overview of the plethora of studies that have investigated factors that influence humoral and cellular vaccine responses in humans. These include intrinsic host factors (such as age, sex, genetics, and comorbidities), perinatal factors (such as gestational age, birth weight, feeding method, and maternal factors), and extrinsic factors (such as preexisting immunity, microbiota, infections, and antibiotics). Further, environmental factors (such as geographic location, season, family size, and toxins), behavioral factors (such as smoking, alcohol consumption, exercise, and sleep), and nutritional factors (such as body mass index, micronutrients, and enteropathy) also influence how individuals respond to vaccines. Moreover, vaccine factors (such as vaccine type, product, adjuvant, and dose) and administration factors (schedule, site, route, time of vaccination, and coadministered vaccines and other drugs) are also important. An understanding of all these factors and their impacts in the design of vaccine studies and decisions on vaccination schedules offers ways to improve vaccine immunogenicity and efficacy.

KEYWORDS antibodies, cellular, cytokines, humoral, immunization, immunoglobulin

INTRODUCTION

Vaccination is the most cost-effective life-saving medical intervention and is estimated to save at least 2.5 million lives each year (1, 2). Protection induced by vaccinations is mediated through a complex interplay between innate, humoral, and cell-mediated immunity (3, 4). Methods to quantify vaccine responses include measuring geometric mean antibody titers (GMTs), seroconversion rates (SCRs), seroprotection rates (SPRs), functional antibodies (by flow cytometric opsonophagocytosis assays), antibody avidity, B and T cell activation, lymphoproliferation, and cytokine responses. There is substantial variation between individuals in the immune response to vaccination, in both quantity and quality. For example, the antibody responses to yellow fever (YF) vaccination vary >10-fold between individuals (5), those to 7- and 13-valent conjugated pneumococcal (PCV7 and PCV13) and *Haemophilus influenzae* type b (Hib) vaccination up to 40-fold (6), and those to trivalent inactivated influenza vaccine (TIV) (7) and hepatitis B (HepB) vaccination >100-fold (6, 8). Similarly, cytokine responses to *Mycobacterium bovis* bacillus Calmette-Guérin (BCG) vaccination vary up to 10-fold (9). Other examples of differences in the quality of vaccine responses include a lower avidity of antibodies (10) or strength of cell-mediated immune responses (11) in neonates. These variations in vaccine responses have consequences for both protective efficacy and the duration of protection. Worryingly, a significant proportion of vaccine-preventable infections occur in vaccinated individuals (12). It is estimated that large numbers of vaccinated children are unprotected due to vaccine ineffectiveness, including 77 million from tuberculosis (TB) (following BCG vaccination), 19 million from measles, 18 million from poliomyelitis (following vaccination with inactivated polio vaccine [IPV]), and 10 million from pertussis and from pneumococcus (13).

In this review, we provide a general overview of factors that influence the immune response to vaccination (Fig. 1). A greater understanding of these factors offers opportunities to improve vaccine immunogenicity and efficacy.

FACTORS INFLUENCING VACCINE RESPONSES

Intrinsic Host Factors

Age. Age is an important factor that influences vaccine responses, especially in the extreme ages of life. Infants should receive immunizations as early as possible to minimize the time that they are susceptible to infections. However, neonates have a




FIG 1 Factors that influence the immune response to vaccination.

lower level of antibody production and, moreover, passively acquired maternal antibodies interfere with vaccine responses (14; P. Zimmermann, K. Perrett, N. Messina, S. Donath, N. Ritz, F. R. M. van der Klis, and N. Curtis, submitted for publication). Additionally, cell-mediated immune responses are less strong, and the response to T-independent polysaccharide antigens is poor (11). Studies in the 1950s sought to establish the optimal age to start vaccination (15, 16). These studies showed, for example, that oral polio vaccine (OPV) given during the first week of life leads to adequate serum antibody responses in only 30% to 70% of infants but that, when it is given after 4 to 8 weeks of age, it leads to adequate responses in nearly all infants (15). Similarly, the diphtheria-tetanus-pertussis (DTP) vaccine is less effective when the first dose is given within the first week of life than when it is given at 6 months of age (16) (Table 1). Results of studies investigating the immunogenicity of BCG given at different ages are conflicting, with some studies showing better immunogenicity when the vaccine is given after the age of 2 months than when it is given at birth (17) and others reporting lower immunogenicity when the vaccine is given at 4 months than when it is given at birth (18). HepB vaccine given in the first year of life leads to lower long-term antibody responses than those obtained when it is given later in childhood: only 40% of adolescents who were HepB vaccinated at birth had antibody levels of >10 mIU/ml at the age of 15 years (19), and after a booster dose, antibodies rose above this protective level in only half of individuals (19, 20). However, importantly, in contrast to antibody levels, the number of memory B cells does not decrease over time (21), and hence booster doses of this vaccine are not necessary.

The most-studied vaccine in relation to the effect of age on vaccine responses, by far, is the measles vaccine (10, 22–48). A meta-analysis of 20 studies shows that the proportion of infants seroconverting after one dose of measles vaccination increases from 50% at 4 months of age to 85% at 8 months and that GMTs are lower in children who receive their first dose before 9 months of age than in those who receive their first dose at an older age (49). Additionally, antibodies wane significantly more quickly in infants who receive the first dose of measles vaccine before the age of 9 months (49), and antibodies have significantly lower avidity when the first dose of measles vaccine is given before the age of 6 months than when it is given at 9 to 12 months of age (10).

TABLE 1 Results with regard to age from studies investigating intrinsic host factors that influence vaccine responses^a

Type of response	Vaccine: measurement [reference(s)]		
	Effective when given at birth	Lower vaccine responses in neonates and young infants	Lower vaccine responses in elderly people
Humoral responses	aP: GMTs (52, 53) HepB: SPRs (55) OPV: SPRs (15)	Diphtheria: SPRs (16) OPV: SPRs (15) Tetanus: SPRs (16) wP: SPRs (16)	Diphtheria: SPRs (60) HepA: GMTs (61, 63, 65, 142), SCRs (63, 76), SPRs (61, 62, 65, 142) HepB: GMTs (61, 69, 71, 73, 75, 77), SCRs (70, 71, 75, 80, 110), SPRs (61, 62, 66–69, 72–75, 77–79, 81) PPV23: GMTs (82–84) TBE: GMTs (88) Tetanus: GMTs (88), SPRs (60, 89) TIV: GMTs (87)
Cellular responses	BCG: Th1, Th2, Treg responses (18)	BCG: CD4 T cell response (17)	TIV: Th cell and cytotoxic T cell responses (86), lymphoproliferative responses (87)
Cytokine responses	BCG: IL-6 and IL-17 production (18)		TIV: IL-2 (85), IL-10 (87), and IFN- γ (87) production

^aAGGs, agglutinogens; aP, acellular pertussis; BCG, bacillus Calmette-Guérin; CD, cluster of differentiation; FHA, filamentous hemagglutinin; GMTs, geometric mean antibody titers; HepA, hepatitis A; HepB, hepatitis B; Hib, *Haemophilus influenzae* type b; HLA, human leukocyte antigen; HSV, herpes simplex virus; MHC, major histocompatibility complex; IFN, interferon; IL, interleukin; IPV, inactivated polio vaccine; MCV, meningococcal conjugate vaccine; MPV, meningococcal polysaccharide vaccine; OCV, oral cholera vaccine; OPV, oral polio vaccine; ORV, oral rotavirus vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine; PRN, pertactin; PRR, pattern recognition receptor; PT, pertussis toxin; SCRs, seroconversion rates; SPRs, seroprotection rates; TBE, tick-borne encephalitis; TGF, transforming growth factor; Th, T helper; TIV, trivalent inactivated influenza vaccine; TLR, Toll-like receptor; TNF, tumor necrosis factor; Treg, T regulatory cell; wP, whole-cell pertussis.

A recent large study summarizing randomized controlled trials (RCTs) shows that children who receive their first measles vaccine before the age of 12 months have lower SCRs and geometric mean concentrations (GMCs) than those of children who receive their first measles vaccine after the age of 15 months (50). Lower antibody concentrations persist after the second dose of measles vaccine (49, 50). In contrast, age at first measles vaccination does not influence cellular responses: no differences in *in vitro* T cell proliferation in response to measles virus were observed after starting vaccination at 4, 6, 9, or 12 months (30, 37, 38, 51).

Despite the fact that many vaccines have lower immunogenicity in neonates, it has been shown that for acellular pertussis (aP) (52, 53), BCG (54), HepB (55), and OPV (15) vaccines, vaccination can be effective in the neonatal age group when adjuvants and formulations are adapted to the function of the early immune system (56) (Table 1). The early neonatal immune system shows suboptimal interaction between antigen-presenting cells and T cells, leading to impairment of CD4 and CD8 T cell function and a polarization toward T helper type 2 (Th2) cells (57) and toward induction of memory B cells rather than antibody-secreting plasma cells (58, 59). T cells largely remain unaffected by passively acquired maternal antibodies.

In addition to those in early life, vaccine responses are also diminished in the elderly, who also have more rapid waning of antibodies. Elderly people have lower antibody responses to diphtheria (60), hepatitis A (HepA) (61–65), HepB (61, 62, 66–81), pneumococcal polysaccharide vaccine (PPV23) (82–84), TIV (85–87), tick-borne encephalitis (TBE) (88), and tetanus (60, 88, 89) vaccination (Table 1). After vaccination with TIV, elderly people also have lower cellular vaccine responses (85–87, 90). In contrast, one study reports higher antibody responses to TIV vaccination in elderly people, with a higher avidity of antibodies and slower antibody dissociation (91). Aging is accompanied by a shift toward anti-inflammatory interleukin-10 (IL-10), which is associated with a decline in CD8 T cells responsible for clearing influenza virus. Hence, adjuvants in TIV that stimulate inflammatory cytokines and suppress the IL-10 response would potentially enhance protection in this age group (92).

Notably, the influence of age on vaccine responses is not seen just at the extremes of age. For example, antibody responses to TIV are higher in children of 2 to 4 years of

age than in younger children (93), and GMTs after meningococcal conjugate vaccine (MCV-C) vaccination are higher in children over the age of 10 years than in younger children (94). The findings of studies that investigated the influence of age on vaccine responses are summarized in Table 1.

Sex. The findings across studies and meta-analyses investigating the effect of sex on vaccine responses are largely consistent (Table 2). Females have higher antibody responses to dengue (95), HepA (61–65, 96–104), HepB (61, 62, 66–78, 80, 100, 101, 105–117), Hib (118), IPV (119), rabies (120–122), smallpox (123), and TIV (124–134) vaccination, while males have higher antibody responses to diphtheria (135–138), MCV-A (139), PCV7 (140), PPV23 (83, 122, 140–144), and tetanus (88, 89, 119) vaccination. Additionally, females also have higher cellular responses to a herpes simplex virus (HSV) vaccine that is not currently used (145). Only a few studies report opposite findings, with higher antibody responses to diphtheria (60, 146), PCV13 (118), and tetanus (60, 147) vaccination in females, higher antibody responses to TIV (91) vaccination in males, or no difference between sexes in antibody responses to rabies (148) vaccination (Table 2).

Notably, even though females have an overall tendency to have higher antibody responses, faster waning of antibodies has been shown following HepA (103) and PPV23 (83, 144) vaccination.

Studies investigating sex differences in response to the measles-mumps-rubella (MMR) vaccine report less consistent findings. Some studies report higher GMTs or SPRs after measles (149), mumps (150), and rubella (151) vaccination and higher cytokine responses after measles (152) vaccination in females, while other studies report transiently higher GMTs and lymphoproliferative responses after rubella (153) vaccination and higher SCRs after measles (154) vaccination in males or no sex differences in GMTs after mumps (155) and rubella (156) vaccination or cytokine responses after rubella (156) vaccination (Table 2).

Reported sex differences in antibody responses to YF vaccine vary depending on the vaccine used (157–159). Interestingly, 3 to 10 days after YF vaccination, expression of 660 genes changes in women, while only 67 genes are expressed differently in men (160). Many of these differentially expressed genes are involved in the early innate immune response (160).

Genetics. Different ethnic groups living in the same location have varied responses to vaccination (64, 89, 161–166) and decline of antibodies (89), indicating a genetic influence on vaccine responses. Studies of twins estimate the degree of heritability to be 36 to 90% for humoral responses (167–173) and 39 to 90% for cellular responses, depending on the specific vaccine (167, 169) (Table 3).

One mechanism identified with variations in humoral (150, 174–190) and cellular (145, 150, 186, 191) vaccine responses is polymorphism in major histocompatibility complex (MHC) genes (summarized in Table 3). Further genetic factors are polymorphisms in pattern recognition receptors (PRRs), such as Toll-like receptor (TLR) or RIG-like receptor (RLR) genes (192–195) (Table 3). In addition, many single-nucleotide polymorphisms (SNPs) in other genes, for example, those coding for cytokines or cytokine, viral, or vitamin receptors, are also associated with variations in vaccine responses (182, 190, 192, 193, 196–211) (Table 3). Further, different expression levels of genes also influence vaccine responses. For example, individuals with increased expression of genes involved in early interferon signaling, antigen processing, and antigen presentation have higher antibody responses to TIV (194, 212).

Blood group antigens are important receptors or coreceptors for microorganisms. Additionally, they can also modify the innate immune response to infection (213). It is therefore likely that blood group antigens influence responses to vaccination. It has been suggested that a cholera subunit-killed oral vaccine is less efficient in individuals with blood group O (214, 215). In contrast, the oral cholera vaccine (OCV) has been reported to induce higher antibody concentrations in individuals with blood group O (216). This has not, however, been a consistent finding (217).

Comorbidities. Numerous studies have investigated vaccine responses in children with celiac disease (CD) (218–233) (Table 4). Most found that children with CD have

TABLE 2 Results with regard to sex from studies investigating intrinsic host factors that influence vaccine responses

Type of response	Vaccine and age group: measurement [reference(s)]			
	Higher vaccine responses in females	Higher vaccine responses in males	No difference in vaccine responses between females and males	Inconsistent findings in vaccine responses between females and males
Humoral responses	Dengue Adults: GMTs (95) Diphtheria Adults: SPRs (60), GMTs (146) HepA Children: GMTs (63, 142), SCRs (63), SPRs (142) Adults: GMTs (63, 65, 96–101, 142), SCRs (63, 101, 106), SPRs (65, 101, 103, 142) Adults with chronic liver disease: GMTs (102), SCRs (102) HIV-positive adults: SPRs (104) Elderly: GMTs (61), SPRs (61, 62) HepB Infants: GMTs (116) Children: GMTs (114, 115, 117) Adolescents: GMTs (105), SCRs (105) Adults: GMTs (69–71, 73, 76, 80, 100, 101, 107, 111), SCRs (70, 71, 76, 80, 101), SPRs (67–69, 72–75, 77, 78, 101, 107, 110, 111, 113) Adults on hemodialysis: SCRs (112) Diabetic adults: GMTs (108, 109), SPRs (108) Elderly: GMTs (61), SPRs (61) Hib Infants: GMTs (118) IPV Adults: SPRs (119) Measles Adolescents: GMTs (149) Mumps Children: GMTs (150) PCV13 Infants: GMTs (118) Rabies Children: SCRs (122) Adults: GMTs (120, 121) Rubella Children: SPRs (151) Adults: SPRs (151) Smallpox Adults: GMTs (123) Tetanus Adults: GMTs (60), SPRs (60), titers (147) TIV Adults: GMTs (90, 124, 126, 127, 129, 131, 133, 134), SPRs (90, 129, 133, 134) Elderly: GMTs (125, 130, 132), SCRs (130), SPRs (128)	Diphtheria Adolescents: titers (137) Adults: titers (135) Elderly: GMTs (138) MCV-A Adolescents: GMTs (139) Measles Infants: SCRs (154) PCV7 Elderly: GMTs (140) PPV23 Children: SCRs (122) Adult alcoholics: GMTs (142) Elderly: GMTs (83, 140, 141, 143, 144) Rubella Adolescents: GMTs (153) Tetanus Children: SPRs (89) Adults: GMTs (88), SPRs (89, 119) TIV Adults: GMTs (91)	Mumps Children: GMTs (155) Rabies Children: GMTs (148) Adults: GMTs (148) Rubella Children: GMTs (156)	YF Adults: GMTs (158, 159), SCRs (159), SPRs (157, 158)
Cellular responses	HSV Adults: CD4 T cell responses (145)	Rubella Adolescents: lymphoproliferative responses (153)		
Cytokine responses	Measles Children: IL-6 (152), IFN- γ (152), and TNF- α (152) production		Rubella Children: IL-10 (156) and IFN- γ (156) production	

TABLE 3 Results with regard to genetics from studies investigating intrinsic host factors that influence vaccine responses

Type of response	Vaccine (estimated degree of heritability in vaccine responses [%]) [reference(s)]	Variation in vaccine response and vaccine: MHC genes for which polymorphisms have been identified to be associated with variation in vaccine response [reference(s)]	Variation in vaccine response and vaccine: PRR genes for which polymorphisms have been identified to be associated with variation in vaccine response [reference(s)]	Variation in vaccine response and vaccine: proteins for which single-nucleotide polymorphisms in genes are associated with variations in vaccine responses [reference(s)]
Humoral responses	aP (53–65) (169) Diphtheria (49) (169) HepA (36) (170) HepB (61–91) (169–171) Hib (51) (172) Measles (90) (167, 168) Mumps (39) (168) OPV (60) (169) Rubella (46) (168) Tetanus (44) (169) Varicella (45) (173)	Higher antibody production HepB: HLA-DQB1*05 (178), HLA-DQB1*0602 (178), HLA-DQB1*0603 (178), HLA-DRB1*0102 (178), HLA-DRB1*0103 (178), HLA-DRB1*02 (176), HLA-DRB1*1301 (177, 178), HLA-DRB1*15 (178), HLA-DR7; DQ2, DQ3, DR15; DQ6, DR3; DQ2 (55) Rubella: HLA-A*02-C*03-B*15-A*AAACGGGC-DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04 (190), A*02-C*03-B*15-DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04 (190), HLA-DPB1, rs2064479 (188) TIV: HLA-DPB1*0401 (187), HLA-DQB1*0603 (186), HLA-DRB1*040 (187) Lower antibody production HepB: C4Ade1 (181), C4AQ0 (179–181), HLA-B8, SC01, DR3 (235), HLA-DPB*0201 (180), HLA-DRA, rs5000563 (182), HLA-DRB1*0701 (174, 176, 177, 180, 181), HLA-DQA1*0201 (180), HLA-DQB1*0102 (178), HLA-DQB1*0201 (174, 175, 179, 180), HLA-DQB1*0604 (178), HLA-DRB1*03 (177, 181), HLA-DRB1*1301 (181), HLA-DRB1*1302 (178), HLA-DR3 (extended B8, SC01) (183, 184), HLA-DR7 (extended B44, FC31) (184) Measles: HLA-DPA1*0201 (185), HLA-DRB1*03 (185) Mumps: HLA-DQB1*0303 (150), HLA-A*29-Cw*16-B*44 (569) Rubella: DRB1*13-DQA1*01-DQB1*06-DPA1*01-DPB1*04 (190), DRB1*15/16-DQB1*06-DPB1*03 (569), DRB1*04-DQB1*03-DPB1*03 (569) TIV: HLA-DRB1*07 (186)	Higher antibody production MCV-C: TRL3 (193) Lower antibody production Measles: TLR3 (192)	Variations in antibody production Diphtheria: IL-10 (196) HepB: FOXP1 (182), IL-4 (197), IL-4R (197), IL-10 promoter (198), IL-12B (196), TNF- α (196) TIV: IL-28B (199) Measles: CD46 (200, 201), CD209 (200), IL-2 (202), IL-6 (192), IL-7R (203), IL-10 (202, 203), IL-12RB (202–204), SLAM (201), TNF- α (192) MCV-C: CD44 (193) Mumps: IL-10RA, IL-12RB1 (150) PCV7/PPV23: IL-1 β (196), IL-4 (205), IL-4R (196, 205), IL-10 (196), IL-12RB1 (196), IL-13 (196, 205) Rubella: CD209/DC-SIGN (206), IL-6 (206), leukocyte specific transcript 1 (190), lymphotoxin alpha (190, 207), MOG (206), PVR (206), PVRL2 (206), RARB (206), TNF- α (190) Smallpox: IL-18 (208) Tetanus: IL-4R (196)
Cellular responses		Higher lymphoproliferative responses Measles: HLA-A*26-Cw*12-B*28 (569), DRB1*03-DQB1*02-DPB1*04 (569), DRB1*04-DQB1*03-DPB1*03 (569) Mumps: HLA-B*1302 (150), HLA-B*3701 (150), HLA-B*3801 (150), HLA-DQA1*0101 (150), HLA-DQA1*0105 (150), HLA-DQB1*0201 (150), HLA-DRB1*0101 (150), HLA-DRB1*0701 (150), HLA-DRB1*1001 (150), HLA-A*26-Cw*12-B28 (569), DRB1*03-DQB1*02-DPB1*04 (569) Rubella: DRB1-DQA1-DQB1-DPA1-DPB1*13-*01-*06-*01-*03, DRB1-DQA1-DQB1-DPA1-DPB1*03-*05-*02-*01-*04 (191), DRB1*04-DQB1*03-DPB1*03 (569), DRB1*04-DQB1*03-DPB1*03 (569) Lower lymphoproliferative responses HepB: HLA-Bw54-DR4-DRw53-SQw4 (570, 571) Mumps: HLA-DQA1*0401 (150), HLA-DQA1*0501 (150), HLA-DRB1*0301 (150), HLA-DRB1*0801 (150), HLA-DRB1*1201 (150), HLA-DRB1*1302 (150)	Lower lymphoproliferative responses Measles: TLR3 (192)	Variations in lymphoproliferative responses Measles: IL-2 (202), IL-10 (202), IL-12RB (202) Mumps: IL-10RA, IL-12RB1 (150)

(Continued on next page)

TABLE 3 (Continued)

Type of response	Vaccine (estimated degree of heritability in vaccine responses [%]) [reference(s)]	Variation in vaccine response and vaccine: MHC genes for which polymorphisms have been identified to be associated with variation in vaccine response [reference(s)]	Variation in vaccine response and vaccine: PRR genes for which polymorphisms have been identified to be associated with variation in vaccine response [reference(s)]	Variation in vaccine response and vaccine: proteins for which single-nucleotide polymorphisms in genes are associated with variations in vaccine responses [reference(s)]
Cytokine responses	BCG (39–46) (169) Measles (90) (167) Pertussis (53–65) (169) Tetanus (64) (169)			
		Higher IFN- γ production Rubella: A*02-C*07-B*07 (191), A*03-C*04-B*35 (191), DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*03 (191) Higher IL-2 production Rubella: DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*02 (191), DRB1*04-DQA1*03-DQB1*03-DPA1*01-DPB1*04 (191) Higher IL-4 production Rubella: DRB1*15-DQA1*01-DQB1*06-DPA1*01-DPB1*02 (191), DRB1*07-DQA1*02-DQB1*02-DPA1*02-DPB1*11 (191) Higher IL-5 production Rubella: A*02-C*07-B*08 (191) Higher IL-6 production Rubella: A*24-C*07-B*07 (191) Higher IL-10 production Rubella: DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*02 (191) Higher IL-12p40 production Rubella: A*03-C*03-B*40 (191), A*03-C*07-B*07 (191), DRB1*07-DQA1*02-DQB1*03-DPA1*01-DPB1*04 (191) Higher TNF- α production Rubella: A*01-C*07-B*08-DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*04 (190), A*29-C*16-B*44 (191) Lower TNF- α production Rubella: DRB1*13-DQA1*01-DQB1*06-DPA1*01-DPB1*03 (191) Lower IL-2 production Rubella: DRB1*13-DQA1*01-DQB1*06-DPA1*01-DPB1*03 (191) Lower IL-5 production Rubella: DRB1*11-DQA1*05-DQB1*03-DPA1*01-DPB1*02 (191) Lower IL-6 production Rubella: DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*04 (191), AAACGGGC-DRB1*01-DQA1*01-DQB1*05-DPA1*01-DPB1*04 (190) Lower IL-10 production Rubella: DRB1*03-DQA1*05-DQB1*02-DPA1*01-DPB1*04 (191) Lower IL-12p40 production Rubella: A*02-C*03-B*40 (191)	Higher granulocyte-macrophage colony-stimulating factor (GM-CSF) production Rubella: TLR3 (194) Higher IL-2 production BCG: TLR1, TLR6 (195) Higher IL-4 production Measles: TLR4 (192) Higher IFN- γ production BCG: TLR1, TLR6 (195) Measles: TLR5 (192), TLR6 (192) Rubella: RIG-I (194) Lower IL-10 production Rubella: RIG-I (194) Lower IFN- γ production Rubella: TLR3 (194) Lower TNF- α production Rubella: TLR3 (194) Variations in GM-CSF production Rubella: RIG-I (194), TLR3, TLR4 (194) Variations in IL-2 production Rubella: TLR3 (194), RIG-I (194) Variations in IL-2 production Rubella: RIG-I (194) Variations in TNF- α production Rubella: RIG-I (194)	Variations in GM-CSF production Rubella: CASP8 (194), RARB (194), TRIM5 (194), TRIM22 (194) Variations in IL-2 production Rubella: RARA (194), RARB (194), TRIM5 (194), TRIM22 (194) Variations in IL-4 production TIV: IL-28B (199) Variations in IL-6 production Measles: CD46 (200) Rubella: ADAR (210), PVR (210), TRIM22 (194) Variations in IL-10 production Measles: SLAM (200) Rubella: RARB (194), RXRA (194) Variations in IFN- α production Measles: CD46 (200, 201) Variations in IFN- γ production Rubella: ACO1 (211), butyrophilin (210), IL-10RB/FNAR1 (210), PTPRD (211), RARB (194), RARG (194), TRIM22 (194) Measles: IL-2 (203), IL-7R (203), IL-10 (203), IL-12RB (204), SLAM (200), DC-SIGN promoter (209) Variations in TNF- α production Measles: CD46 (200) Rubella: TRIM5 (194), VDR (194)

TABLE 4 Results with regard to comorbidities from studies investigating intrinsic host factors that influence vaccine responses

Type of response	Variation in vaccine response, vaccine, age group, measurement [reference(s)]			
	Celiac disease	Diabetes mellitus	Chronic renal failure requiring hemodialysis	Chronic liver failure
Humoral responses	Lower antibody production	Lower antibody production	Lower antibody production	Higher antibody production
	HepA Children: SPRs (225)	HepB Children: GMTs (232, 238), SPRs (232, 237–239)	Diphtheria Adults: SPRs (250)	Diphtheria Children: GMTs (260)
	HepB Infants: SPRs (221)	Adults: GMTs (232, 243–245), SPRs (242–245)	HepB Adults: SPRs (252)	IPV type 1 Children: GMTs (260)
	Children: SPRs (219, 220, 222–226, 228, 231, 233)	Measles Children: SPRs (241)	IPV type 2 Children: GMTs (260)	IPV type 3 Children: GMTs (260)
	Adults: GMTs (227), SPRs (218, 227)	Monovalent influenza vaccine Adults: SCRs (90), SPRs (90)	Tetanus Adults: GMTs (249), SPRs (249, 250)	Lower antibody production HepA Children: GMTs (265)
	No difference in antibody production	PPV23 Children: SPRs (240)	TIV Adults: GMTs (473), SPRs (473)	Adults: GMTs (102, 261, 262), SPRs (263, 264)
	HepA Children: GMTs (229), SPRs (229)	Rubella Children: GMTs (241)	No difference in antibody production	HepB Adults: GMTs, SPRs (242)
	HepB Children: GMTs (219, 232), SPRs (232)	No difference in antibody production	IPV type 1 Children: GMTs (260), SPRs (260)	Children: GMTs (265), SPRs (263, 265)
	Adults: GMTs (232), SPRs (232)	Diphtheria Children: GMTs (240, 241)	IPV type 2 Children: SPRs (260)	No difference in antibody production
	Hib Children: SPRs (219)	Hib Children: GMTs (240)	IPV type 3 Children: GMTs (260), SPRs (260)	Diphtheria Children: SPRs (260)
	Measles Children: GMTs (232), SPRs (232)	HepB Children: GMTs (572), SPRs (232, 572)	Faster weaning of antibodies	HepA Children: SPRs (265)
	Adults: GMTs (232), SPRs (232)	Adults: GMTs (572), SPRs (232, 572)	Diphtheria Adults: (254)	Adults: SPRs (102, 263)
	Rubella Children: SPRs (219)	Elderly: SPRs (248)	HepB Adults: (252, 255)	IPV type 1 Children: SPRs (260)
	Tetanus Children: SPRs (219)	Measles Children: GMTs (232, 241), SPRs (232)	Tetanus Adults: (251)	IPV type 2 Children: GMTs (260), SPRs (260)
	TIV Children: GMTs (230), SPRs (230)	Adults: GMTs (232), SPRs (232)		IPV type 3 Children: SPRs (260)
		Rubella Children: SPRs (241)		Tetanus Children: GMTs (260), SPRs (260)
		PCV7 Children: GMTs (240)		
		Pertussis Children: SPRs (241)		
		Tetanus Children: GMTs (240, 241)		
Cytokine responses	Lower cytokine production	No difference in cytokine responses		
	Tetanus Children: IL-4 (219, 573)	TIV Children: IL-2 (247), granzyme B (247)		

lower antibody responses to HepB vaccination (218–228, 231–233), with more rapid waning of antibodies (227). A meta-analysis shows that, in retrospective studies, the SCR to HepB vaccination in children with CD is 54%, and that in prospective studies is 66% (compared to 95% in healthy individuals) (234). It has been postulated that the presence of HLA-DQ2 or -DQ8, which confers a genetic predisposition to CD, may be the driver of the lower responses to HepB vaccination in CD patients. However, the presence of HLA-DQ2 is associated with higher antibody responses to HepB vaccination

(55). Nevertheless, HLA-DR3, -DR4, and -DR7, which can also be found in patients with CD (229) and patients with diabetes mellitus (DM), are associated with lower responses to HepB vaccination (183, 184, 235). Children with CD and DM have lower SPRs after HepB vaccination than those of children that have DM only (228), suggesting that gluten might be a factor in decreasing HepB vaccine efficacy, and some studies suggest that the response rate to HepB vaccination correlates with gluten intake (220, 223). Children with CD who are on a strict gluten-free diet have no difference in SPRs to HepB vaccination compared to those of healthy children (222, 226). Apart from lower antibody responses to HepB vaccination, one study also showed that CD patients are less responsive to HepA vaccination (225). However, another study did not find a difference in antibody responses to HepA vaccination in CD patients compared to healthy controls (229). There is also no difference in antibody responses to tetanus (219), measles (236), rubella (219), Hib (219), and TIV (230) vaccination between children with CD and healthy children.

Children with DM have lower antibody responses to HepB (232, 237–239) vaccination, and possibly PPV23 (240), rubella (241), and measles (241) vaccination, but not to diphtheria (240, 241), Hib (240), PCV7 (240), pertussis (241), or tetanus (240, 241) vaccination. Adults with DM also have lower antibody responses to HepB (242–245) vaccination. Adding selenium to the HepB vaccine can increase antibody responses in patients with DM (246). It is unclear whether DM influences the antibody response to TIV vaccination. Some studies report lower responses after vaccination with a monovalent influenza vaccine in adults (90), while studies of elderly people with type II DM show no difference in antibody or cytokine responses to TIV vaccination (247, 248) (Table 4).

Adults with chronic renal failure who are on hemodialysis have lower antibody responses to diphtheria (249–251), HepB (252–255), and tetanus (249–251) vaccination, with faster waning of antibodies (252–255), especially when they suffer from additional diabetes mellitus (256–259). Children on hemodialysis have lower antibody responses to poliovirus type 2 (260). SPR after HepB vaccination is inversely associated with glomerular filtration rate (253). Factors responsible for lower vaccine responses in patients with chronic renal failure include malnutrition, uremia, and a generalized immunosuppressive state. Patients with chronic renal failure benefit from an increased vaccination dose (259).

Adults with chronic liver disease have lower GMTs after HepA vaccination (102, 261, 262) (with similar SPRs [102, 262] or lower SPRs [263, 264]) and lower GMTs and SPRs after HepB vaccination (242) than those of healthy adults. Children with chronic liver disease also have lower GMTs (265) and SPRs (263, 265) after HepB vaccination (265), with no difference in SCRs. However, in contrast, they have higher antibody responses to IPV and diphtheria (260) vaccination (Table 4).

Perinatal Host Factors

Gestational age. Preterm infants are at increased risk of infections, including vaccine-preventable infections. Differences in the immune system which render preterm infants less responsive to vaccination include diminished pathogen recognition by dendritic cells and macrophages and diminished T cell activity (especially Th1 activity) and diminished B cell interaction with T cells (266). Variations in vaccine responses between term and preterm infants depend on the specific vaccine. In comparison to those of term infants, preterm infants have significantly lower antibody levels after the first dose of DTP (267). Significantly lower GMTs also persist after primary immunization with three doses for diphtheria (268), HepB (268–270), Hib (269, 271–275), PCV7 (276, 277), poliovirus type 3 (269), and pertussis (267, 268, 278–280) vaccines. However, preterm infants reach sufficient SPRs for most vaccines (Table 5), with the notable exception of responses to HepB (269), Hib (269, 271–275), pertussis (279), and poliovirus type 3 (281) vaccines. In addition to having lower GMTs and SPRs, preterm infants can also have quicker waning of antibodies, as shown for antibodies produced in response to MCV-C (282) vaccination.

TABLE 5 Results with regard to infant factors from studies investigating perinatal factors that influence vaccine responses

Type of response	Timing of response, vaccine response, vaccine, age, measurement [reference(s)]		
	Gestational age	Birth weight	Feeding
Humoral responses	After primary immunization with 3 doses (*2 doses) Higher antibody production in preterm infants than in term infants PCV7 <37 weeks: GMTs (277) for serotypes 19F, 9V, and 4 Lower antibody production in preterm infants than in term infants Diphtheria 31–35 weeks: GMTs (268) <31 weeks: GMTs (268) HepB 24–36 weeks: GMTs (269), SPRs (269) <31 weeks: GMTs (268) <35 weeks: GMTs (270) Hib 24–36 weeks: GMTs (269, 271, 272), SPRs (269, 271, 272) <32 weeks: GMTs (271, 273), SPRs (271, 273) 23–32 weeks: GMTs (274),* SPRs (274)* <30 weeks: GMTs (275), SPRs (275) PCV7 <37 weeks: GMTs (276) IPV type 3 24–36 weeks: GMTs (269) <29 weeks: SPRs (281) Pertussis AGGs 2 and 3 <37 weeks: GMTs (278) aP 28–34 weeks: GMTs (267) FHA 25–35 weeks: GMTs (279), SPRs (279) PCT 31–35 weeks: GMTs (268) <31 weeks: GMTs (268) PT <32 weeks: GMTs (280) 25–35 weeks: GMTs (279), SPRs (279) <31 weeks: GMTs (268) No difference in antibody production between preterm and term infants Diphtheria 24–36 weeks: GMTs, SPRs (269) <32 weeks: GMTs (280) 28–34 weeks: SPRs (267) <37 weeks: GMTs, SPRs (278) 25–35 weeks: SPRs (268) Hib <29 weeks: GMTs (281), SPRs (281) MCV-C <32 weeks: GMTs (273), SPRs (273) 32–36 weeks: GMTs (282) OPV <36 weeks: SPRs (574) IPV type 1 24–36 weeks: GMTs, SPRs (269) <29 weeks: GMTs (281), SPRs (281) IPV type 2 24–36 weeks: GMTs, SPRs (269) <29 weeks: GMTs (281), SPRs (281) IPV type 3 24–36 weeks: SPRs (269) <29 weeks: GMTs (281) Pertussis AGGs 2 and 3 <37 weeks: SPRs (278) aP 28–34 weeks: SPRs (267) FHA 24–36 weeks: GMTs, SPRs (269) <32 weeks: GMTs (280) <37 weeks: GMTs, SPRs (278) PCT 25–35 weeks: SPRs (268)	After primary immunization with 3 doses Lower antibody production in VLBW infants than in LBW infants Pertussis (PT): GMTs (285), SPRs (285) Hib: SPRs (285) IPV type 3: GMTs (285) Lower antibody production in LBW infants than in infants with a normal birth weight HepB: SPRs (286) Hib: SPRs (272) No difference in antibody production between VLBW and LBW infants Diphtheria: GMTs (285), SPRs (285) HepB: GMTs (285), SPRs (285) IPV type 1: GMTs (285), SPRs (285) IPV type 2: GMTs (285), SPRs (285) IPV type 3: SPRs (285) Pertussis FHA: GMTs (285), SPRs (285) PRN: GMTs (285), SPRs (285) PT: GMTs (285), SPRs (285) Tetanus: GMTs (285), SPRs (285) No difference in antibody production between VLBW and LBW/normal-birth-weight infants Pertussis FHA: GMTs (279) PT: GMTs (279) No difference in antibody production between LBW and normal-birth-weight infants PCV7: GMTs (277), SPRs (277) Measles: SCRs (287) After a booster at 18–24 months Lower antibody production in VLBW infants than in LBW infants Diphtheria: GMTs (285) HepB: GMTs (285), SPRs (285) No difference in antibody production between VLBW and LBW infants Diphtheria: SPRs (285) IPV type 1: GMTs (285), SPRs (285) IPV type 2: GMTs (285), SPRs (285) IPV type 3: SPRs (285) Pertussis FHA: GMTs (285), SPRs (285) PRN: GMTs (285), SPRs (285) PT: GMTs (285), SPRs (285) Tetanus: GMTs (285), SPRs (285)	Higher antibody production in breastfed than in formula-fed infants Diphtheria: IgA % standard plasma in saliva (292), IgG % standard plasma in serum (292) Hib: IgA median antibody titer in serum (291), IgM median antibody titer in serum (291), IgG median antibody titer in serum (291), IgG GMTs in serum (290) OPV: IgA % standard plasma in saliva (292), IgG % standard plasma in saliva (289, 292), IgM % standard plasma in stool (292) Tetanus: IgA % standard plasma in saliva (292), IgM % standard plasma in stool (292) Lower responses in breastfed infants than in formula-fed infants OPV: SCRs (295)

(Continued on next page)

TABLE 5 (Continued)

Type of response	Timing of response, vaccine response, vaccine, age, measurement [reference(s)]		
	Gestational age	Birth weight	Feeding
PRN	24–36 weeks: GMTs, SPRs (269)		
	<32 weeks: GMTs (280)		
	PT		
Tetanus	24–36 weeks: GMTs (269), SPRs (269)		
	<37 weeks: GMTs, SPRs (278)		
	24–36 weeks: GMTs (269), SPRs (269)		
	<29 weeks: GMTs (281), SPRs (281)		
	<32 weeks: GMTs (280)		
	28–34 weeks: SPRs (267)		
	<37 weeks: GMTs, SPRs (278)		

Preterm infants have lower vaccine responses not only after primary immunization but also after booster doses. At 2 to 3 years of age, they have lower antibody responses to HepB (270, 283), Hib (283), and poliovirus type 3 (283) vaccination, and at the age of 5 years, they have lower responses to HepB (283) and pertussis (284) vaccination, as well as reduced lymphoproliferation and cytokine responses in the latter case.

Birth weight. One month after the third dose of DTaP-Hib-IPV-HepB vaccination given at 2, 4, and 6 months, very-low-birth-weight (VLBW; less than 1.5 kg) infants have significantly lower GMTs to aP and poliovirus type 3 and lower SPRs to Hib than infants with a low birth weight (LBW; 1.5 to 2 kg), while both groups have similar GMTs and SPRs after diphtheria, tetanus, and HepB (285) vaccination. However, 1 month after a booster dose given at the age of 18 to 24 months, the SPR to HepB in VLBW infants is lower than that in LBW infants, and there is a trend toward lower GMTs for all other vaccine components (285) (Table 5). Similarly, 1 month after completing a 3-dose HepB schedule given at 0, 1, and 6 months, LBW infants have lower GMTs to HepB vaccine than infants with a normal birth weight (286). A decreasing birth weight is associated with a progressive reduction in antibody responses to Hib (272) vaccination. However, there is no difference in GMTs after a 3-dose schedule of PCV7 vaccine between LBW infants and infants with a normal weight (277) and no correlation between birth weight and SCRs after measles vaccination (287).

In one study, the antibody response to *Salmonella enterica* serovar Typhi vaccination (but not rabies vaccination) in adults was reported to be related to birth weight (288).

Breastfeeding. After routine vaccination, compared to formula-fed infants, breastfed infants have higher serum IgG levels after diphtheria (289), Hib (290, 291), and OPV (289, 292) vaccination, higher salivary IgA levels after tetanus, diphtheria, and OPV vaccination (289), and higher stool IgM levels after tetanus and OPV vaccination (289) (Table 5).

While one meta-analysis summarizing studies on the effect of breastfeeding on the antibody response to oral rotavirus vaccine (ORV) reports reduced SCRs in breastfed infants in all included studies (293), another meta-analysis reports decreased responses in only 3 of 16 studies (294). However, in all the included studies, only one dose of ORV was given, and infants with mixed feeding were sometimes classified as breastfed and sometimes as nonbreastfed. More recent studies show that higher levels of rotavirus-specific IgA in breast milk lead to lower SCRs in infants after ORV (a 2-fold increase is associated with a 22% decrease in SCR) (295). IgA levels in breast milk depend on geographic location: Indian women have higher levels than those in Korean and Vietnamese women and American women (296). Additionally, the neutralizing activity of IgA in breast milk from Indian women is higher than that in breast milk from American women (296). Three studies investigating withholding breastfeeding for an hour before and after ORV showed no effect on rotavirus-specific IgA SCRs in infants (297–299).

Maternal antibodies. Preexisting maternal antibodies inhibit infant antibody responses to vaccination (14) (Table 6). After primary immunization, a 2-fold higher

TABLE 6 Results with regard to maternal factors from studies investigating perinatal factors that influence vaccine responses

Type of response	Vaccine response and vaccine: measurement [reference(s)]			
	Maternal antibodies associated with lower infant responses to vaccination	Maternal high body mass index	Maternal malnutrition	Antenatal steroids
Humoral responses	Lower antibody production HepA: GMTs (305, 306) Diphtheria: GMTs (14) Measles: SCRs (49) OPV: titers (575) ORV: SCRs (295, 296, 307–310) Pertussis PRN: GMTs (14) IPV: GMTs (14) Tetanus: GMTs (14)		Lower antibody production OPV: SPRs (326) ORV: SPRs (326)	Lower antibody production Tetanus: GMTs (280)
Cytokine responses		Lower cytokine production BCG: IL-2 (325)		

maternal antibody level results in approximately one-fourth lower postvaccination GMTs in infants (28% to IPV, 24% to diphtheria, 22% to pertactin, and 13% to tetanus). Maternal antibodies also influence infant vaccine responses after booster doses in the second year of life (14).

A meta-analysis summarizing 16 studies investigating the influence of maternal antibodies on responses to measles vaccination shows that the presence of maternal antibodies decreases SCRs, on average, by 33.2% (49). However, maternal antibodies to measles virus in infants decrease quickly, and by the age of 5 months, only 12% of infants have protective levels. Maternal age is the only factor associated with maternal measles antibody levels (300, 301), while maternal weight has no influence (300). Measles-vaccinated women have significantly lower GMTs than those of women with naturally acquired immunity (301, 302).

Maternal antibodies against HepA in infants remain high during the first 6 months but then drop quickly, with only approximately 37% of infants having protective titers by the age of 12 months (303, 304). When the HepA vaccine is given to infants within the first 6 months of life, GMTs in those without maternal antibodies are significantly higher at the age of 12 to 15 months than those in infants with maternal antibodies. However, there is no difference in SPRs (305, 306). For ORV, transplacental transfer of maternal antibodies (307–309) and transfer of antibodies through breast milk (295, 296, 310) lead to decreased infant vaccine responses, in a dose-dependent matter.

The amount of maternal antibodies transferred to infants depends on several factors, including maternal antibody levels, IgG subclass, gestational age, and placental characteristics (311). The transfer of maternal antibodies can be optimized by maternal vaccination during pregnancy. This strategy is currently recommended for vaccination against tetanus, pertussis, and influenza. However, appropriate timing of vaccination during pregnancy is important. For example, Tdap given during the second trimester of pregnancy leads to significantly higher neonatal antibodies than those obtained when it is given during the third trimester (312).

Maternal infections during pregnancy. Most studies do not find an association between maternal infection with filariae, hookworm, malaria parasites, *Mansonella perstans*, or *Schistosoma mansoni* during pregnancy and infant antibody responses to diphtheria (313, 314), HepB (313–315), Hib (314), pertussis (314), and tetanus (313, 316) vaccination. However, one study shows that maternal infection with malaria parasites, filariae, or hookworm is independently associated with lower infant antibody responses to Hib vaccination (313), while another study shows that maternal infection with *S. mansoni* is associated with lower infant antibody responses to HepB vaccination (317). Maternal malaria during pregnancy is associated with lower infant SPRs after measles vaccination (318). The presence of multiple maternal infections is associated with lower

infant antibody responses to Hib, diphtheria, and tetanus (313) vaccination. In contrast, maternal infection with *Strongyloides* during pregnancy is associated with higher antibody responses to Hib, HepB, and pertussis toxin (PT) (314) vaccination.

Maternal infection with *M. perstans* during pregnancy is associated with higher infant IL-10 responses after BCG and tetanus vaccination, but there are no differences in gamma interferon (IFN- γ), IL-5, and IL-13 (319) production. Maternal infection with filariae (320), *Trypanosoma cruzi* (321), or *S. mansoni* (320) during pregnancy is associated with lower IFN- γ production in children after BCG vaccination, while other helminth infections show no effect on infant responses to BCG vaccination (319, 322, 323). Empiric treatment of mothers with albendazole or praziquantel during pregnancy does not influence infant vaccine responses to BCG (324), diphtheria (314), HepB (314), Hib (314), measles (324), pertussis (314), or tetanus (324) vaccination (Table 7).

Other maternal factors. In infants, cytokine responses to BCG vaccination correlate inversely with maternal body mass index (BMI) (325). On the other hand, maternal malnutrition is associated with lower infant antibody responses to OPV and ORV vaccination, while it does not influence responses to parenteral vaccines (326).

It has been suggested that low maternal education status is associated with higher infant GMTs to tetanus vaccination (327) and lower infant IFN- γ and IL-5 production after tetanus vaccination (319), while a lower maternal socioeconomic status is associated with lower infant IL-10 production after tetanus vaccination (319) (Table 8). However, this might be confounded by other factors, such as malnourishment and nonadherence to vaccination schedules.

Maternal tetanus immunization during pregnancy is associated with higher infant antibody responses to tetanus vaccination, while the presence of a maternal BCG scar is associated with lower infant IL-5 (319), IL-10 (323), and IL-13 (319) responses after BCG vaccination (319).

Infants who are exposed to HIV during pregnancy but remain uninfected have lower IFN- γ , IL-5, and IL-13 responses after tetanus and BCG vaccination (319). Antenatal, but not postnatal, steroids decrease infant antibody production in response to tetanus vaccination (280) (Table 6).

Extrinsic Factors

Infections. Most studies show no difference in antibody responses to MMR vaccination between children with diarrhea (287, 328), fever (287, 328), or afebrile upper respiratory tract infections (URTI) (329–332) and healthy children. However, studies have reported lower SCRs after measles (330) and varicella (331) vaccination for children with URTI (without differences in GMTs), lower GMTs after Hib vaccination in children with fever (333), and lower GMTs and SCRs for children with diarrhea after OPV vaccination (334, 335). Concurrent infection with nonpoliovirus enteroviruses at the time of vaccination with OPV reduces SCRs against poliovirus type 1 but not type 2 or 3 (334) (Table 9).

Children who are infected with Epstein-Barr virus (EBV) have reduced antibody responses to meningococcal polysaccharide (MPV) and measles vaccination. However, infants who are infected with both EBV and cytomegalovirus (CMV) have responses similar to those of uninfected infants, suggesting that the effects of EBV infection might be countered by CMV infection (336). Children who are infected with CMV also have higher GMTs after vaccination with measles vaccine (337), while results from studies investigating vaccine responses in CMV-seropositive adults are conflicting. Studies report higher antibody responses to TIV vaccination in young adults (GMTs) (338) and elderly people (SCRs) (248) who are seropositive for CMV than in seronegative individuals, while other studies show reduced antibody responses (SCRs) (339, 340), lower B and T cell activation (341), and switched memory B cells (339) in response to TIV vaccination in CMV-seropositive individuals (Table 9).

Adults who are infected with HIV have lower SPRs after vaccination with HepA vaccine. A lower viral load and higher CD4 cell count are predictors of a higher response to vaccination (104). Pregnant women who are infected with HIV have lower cytokine

TABLE 7 Results with regard to maternal infections from studies investigating perinatal factors that influence vaccine responses

Type of response	Vaccine response and vaccine: measurement [reference(s)]					
	Filariasis	Helminths	Hookworm	Malaria	<i>Mansonella perstans</i>	Schistosomiasis
Humoral responses	Lower antibody production Hib: GMTs (313) No difference in antibody production Diphtheria: GMTs (313) HepB: GMTs (313) Tetanus: GMTs (313)		Lower antibody production Hib: GMTs (313) No difference in antibody production aP: GMTs (314) Diphtheria: GMTs (313, 314) HepB: GMTs (313, 314) Hib: GMTs (314) Tetanus: GMTs (313)	Lower antibody production Hib: GMTs (313) Measles: SPRs (318) No difference in antibody production Diphtheria: GMTs (313) HepB: GMTs (313) Tetanus: GMTs (313, 316)	No difference in antibody production aP: GMTs (314) Diphtheria: GMTs (314) HepB: GMTs (314) Hib: GMTs (314)	Lower antibody production HepB: GMTs (317) No difference in antibody production aP: GMTs (314) Diphtheria: GMTs (313, 314) HepB: GMTs (313–315) Hib: GMTs (314) Tetanus: GMTs (313)
						Higher antibody production Hib: GMTs (314) HepB: GMTs (314) PT: GMTs (314)
Cytokine responses	Lower cytokine production BCG: IFN- γ (320)	No difference in cytokine production BCG (319, 322, 323)			Higher cytokine production BCG: IL-10 (319) Tetanus: IL-10 (319) Lower cytokine production BCG: IL-5 (323)	Lower cytokine production BCG: IFN- γ (320)
						Lower cytokine production BCG: IFN- γ (321)

TABLE 8 Results with regard to other maternal factors from studies investigating perinatal factors that influence vaccine responses

Type of response	Vaccine response and vaccine: measurement [reference(s)]			
	Low maternal education status	Low maternal socioeconomic status	Maternal treatment with albendazole or praziquantel during pregnancy	Maternal vaccination
Humoral responses	Higher antibody production Tetanus: GMTs (327)		No difference in antibody production aP: GMTs (314) Diphtheria: GMTs (314) HepB: GMTs (314) Hib: GMTs (314)	Maternal tetanus vaccination during pregnancy Higher antibody production (GMTs) to tetanus in infants (319)
Cytokine responses	Lower cytokine production Tetanus: IFN- γ (319), IL-5 (319)	Lower cytokine production Tetanus: IFN- γ (319)		Presence of maternal BCG scar associated with lower production in infants IL-5 (319) IL-10 (323) IL-13 (319)

responses to BCG (319, 323) and tetanus (319) vaccination. Infants who are infected with HIV have lower cytokine responses after vaccination with BCG (319, 323), measles (337), and tetanus (319) vaccines and lower antibody responses after vaccination with measles vaccine (318). Children who are infected with HIV have quicker waning of antibodies after vaccination with HepA vaccine (342).

Individuals who are chronically infected with either hepatitis B or hepatitis C virus have lower antibody responses to HepA vaccination (102, 263, 343, 344).

Parasites. Infants who are symptomatically infected with malaria parasites have lower antibody responses to Hib (333), measles (318), MCV-C (345), *Salmonella* Typhi (intradermal), and tetanus (345–347) vaccination and lower cytokine responses (IFN- γ , IL-5, and IL-13) after vaccination with tetanus (319) and BCG (319, 323) vaccines (Table 10). Children with asymptomatic malaria have lower GMTs after MCV-C (94, 348) and aP (349) vaccination but no difference in antibody responses to tetanus vaccination (350, 351). Malaria prophylaxis given to children prior to vaccination has no influence on GMTs or SCRs after diphtheria (352–355), IPV (355), measles (352, 353, 356), OCV (357), OPV (353), pertussis (352), *Salmonella* Typhi (353, 357), or tetanus (352–355, 358, 359) vaccination. Malaria prophylaxis also has no influence on the size of the tuberculin skin reaction after BCG vaccination (353). However, GMTs after vaccination with MCV-A and MCV-C are (transiently) higher in children who are on malaria prophylaxis (348, 353).

Individuals who are infected with *Onchocerca volvulus* produce fewer antibodies and have less proliferation of mononuclear cells and lower IFN- γ production (360) after tetanus vaccination, and individuals who are infected with *S. mansoni* produce less IFN- γ (361) after tetanus vaccination. In children and adults with *Ascaris lumbricoides* infection, antibody and cytokine responses (IFN- γ and IL-2) to OCV are diminished but can be partially restored by albendazole treatment prior to vaccination (362, 363). Childhood helminth infections are not associated with cytokine responses after BCG vaccination. Empiric quarterly albendazole treatment during the first 5 years of age leads to less IFN- γ and IL-13 production after vaccination with BCG (323). In contrast, albendazole treatment in individuals with proven helminth infection leads to more T cell proliferation (364) and IFN- γ (364, 365) and IL-12 (365) production after BCG vaccination but to less transforming growth factor beta (TGF- β) and concanavalin A production (365) (Table 11). Infants who are congenitally infected with *Trypanosoma cruzi* have stronger *in vitro* IFN- γ responses after vaccination with diphtheria, HepB, and tetanus vaccines (321) (Table 10).

Antibiotics, probiotics, and prebiotics. There are no studies of humans that have investigated the effects of antibiotics on vaccine responses. However, a study in mice showed that administration of clarithromycin or doxycycline leads to lower antibody responses after vaccination with a HepB, tetanus, or PPV23 vaccine, while administra-

TABLE 9 Results with regard to symptoms or infections from studies investigating extrinsic factors that influence vaccine responses

Vaccine response, vaccine, age group, measurement [reference(s)]						
Type of response	Diarrhea	Fever	URT	CMV infection	EBV infection	Hepatitis B virus infection
Humoral responses	Lower antibody production	Lower antibody production	Lower antibody production	Higher antibody production	Lower antibody production	Lower antibody production
	OPV	Hib	Measles	Influenza	Measles	HepA
	Infants: GMTs (335)	Children: GMTs (333)	Infants: SCRs (330)	Adolescents: GMTs (338)	Infants: median IgM and IgG levels (336)	Adults: GMTs (343), SPRs (102, 263, 343)
	Children: SCRs (334)	No difference in antibody production	Varicella	Elderly: SCRs (248)	MPV	HepB
Cellular responses	No difference in antibody production	Measles	No difference in antibody production	Lower antibody production	Infants: median IgM and IgG levels (336)	Adults: SPRs (263)
	Measles	Infants: SCRs (287)	Measles	Measles		
	Infants: SCRs (287)		Infants: SCRs (287)	Infants: GMTs (337)		HIV-coinfected adults: SPRs (344)
	Children: GMTs (328), SCRs (328)		Children: GMTs (329, 331), SCRs (329, 331, 332)	Influenza		HepB
			Mumps	Adults: SCRs (339, 340)		Adults: SPRs (263)
			Children: GMTs (329, 331), SCRs (329, 331)			
			Rubella			
			Children: GMTs (329, 331), SCRs (329, 331, 332)			
			Varicella			
			Children: GMTs (331)			
Lower cellular responses						
Cellular responses				TIV		
				Adults: switched memory B cells (339)		
				Adults: B and T cell activation (341)		

TABLE 10 Results with regard to parasitic infections from studies investigating extrinsic factors that influence vaccine responses

Vaccine response, vaccine, age group, measurement [reference(s)]						
Type of response	HIV infection	<i>Ascaris lumbricoides</i>	Malaria	<i>Onchocerca volvulus</i>	<i>Schistosoma mansoni</i>	<i>Trypanosoma cruzi</i>
Humoral responses	Lower antibody production HepA	Lower antibody production OCV	Lower antibody production Hib	Lower antibody production Tetanus		
	Adults: SPRs (104)	Children: GMTs (363), SCRs (363)	Children: GMTs (333)	Adults: GMTs (360)		
	Measles		MCV-C			
	Infants: SPRs (318)		Children: GMTs (94, 345, 348)			
Cellular responses			Measles			
			PT			
			Infants: GMTs (349)			
			<i>Salmonella</i> Typhi			
			Children: GMTs (345, 346)			
			Tetanus			
			Children: GMTs (346, 347)			
			No difference in antibody production			
			Tetanus			
			Children: GMTs (351)			
Cytokine responses				Lower cellular responses Tetanus		
				Adults: proliferation of mononuclear cells (360)		
	Lower cytokine production BCG	Lower cytokine production OCV	Lower cytokine production BCG	Lower cytokine production Tetanus	Lower cytokine production Tetanus	Higher cytokine production Diphtheria
	Infants: IFN- γ (319, 323), IL-5 (319, 323), IL-10 (319), IL-13 (319, 323)	Adults: IFN- γ (362), IL-2 production (362)	Women: IFN- γ (319, 323), IL-5 (319), IL-13 (319)	Adults: IFN- γ (360)	Adults: IFN- γ (361)	Women: IFN- γ (321) HepB
	Women: IFN- γ (319, 323), IL-5 (319), IL-13 (319, 323)	Tetanus			Women: IFN- γ (321) Tetanus	
	Measles		Women: IFN- γ (319), IL-5 (319), IL-13 (319)		Women: IFN- γ (321)	
	Infants: IFN- γ (337)					
	Tetanus					
	Infants: IFN- γ (319), IL-5 (319), IL-13 (320)					
	Women: IFN- γ (319), IL-5 (319), IL-13 (319)					

TABLE 11 Results with regard to antiparasitic treatment from studies investigating extrinsic factors that influence vaccine responses

Vaccine response, vaccine, age group, measurement [reference(s)]					
Type of response	Responses after treatment with albendazole	Responses on prophylaxis with amodiaquine	Responses on prophylaxis with atovaquone-proguanil	Responses on prophylaxis with chloroquine	Responses on prophylaxis with sulfadoxine-pyrimethamine
Humoral responses	Higher antibody production OCV, <i>A. lumbricoides</i> Children: GMTs (363)	No difference in antibody production Diphtheria Infants: median titers (355) Children: GMTs (352), SCRs (352)	No difference in antibody production OCV Children: GMTs (357) <i>Salmonella</i> Typhi Children: GMTs (357)	Higher antibody production MCV-A Children: GMTs (348, 353) MCV-C Children: GMTs (348, 353) No difference in antibody production	No difference in antibody production Diphtheria Infants: SCRs (354) Measles Infants: SCRs (354) Tetanus Infants: SCRs (354)
		IPV Infants: median titers (355) Measles Children: GMTs (352), SCRs (352), SPRs (356) Pertussis Children: GMTs (352), SCRs (352) Tetanus Infants: median titers (355) Children: GMTs (352), SCRs (352), titers (358, 359)		Diphtheria Children: GMTs (353) Measles Children: GMTs (353) OPV Children: GMTs (353) <i>Salmonella</i> Typhi Children: GMTs (353) Tetanus Children: GMTs (352, 353), SCRs (352)	
Cellular responses	Higher cellular response BCG, any helminth Adults: T cell proliferation (364)			No difference in cellular response BCG Children: tuberculin skin test (353)	
Cytokine responses	Higher cytokine production BCG, any helminth Adults: IFN- γ (364, 365), IL-2 (365), IL-12 (365) OCV, <i>A. lumbricoides</i> Adults: IL-2 (362) Lower cytokine production BCG, any helminth Adults: concanavalin A (365), TGF- β (365) BCG, empiric treatment Female adults: IFN- γ (323), IL-13 (323)				

TABLE 12 Results with regard to microbiota from studies investigating extrinsic factors that influence vaccine responses

Type of response	Bacterium/bacterial group, age group, affected vaccine response (reference)		
	Higher relative abundance in intestinal microbiota associated with higher vaccine responses	Higher relative abundance in intestinal microbiota associated with lower vaccine responses	Higher relative abundance in nasopharyngeal microbiota associated with higher vaccine responses
Humoral responses	Phylum <i>Actinobacteria</i> Infants: OPV (385), HepB (385) Phylum <i>Firmicutes</i> Infants: ORV (386)	Phylum <i>Proteobacteria</i> Infants: OPV (385) Phylum <i>Bacteroidetes</i> Infants: ORV (386)	<i>Bacteroides ovatus</i> Adults: LAIV (390) <i>Lactobacillus helveticus</i> Adults: LAIV (390) <i>Prevotella melaninogenica</i> Adults: LAIV (390) <i>Streptococcus infantis</i> Adults: LAIV (390) <i>Veillonella dispar</i> Adults: LAIV (390)
Cellular responses	Phylum <i>Actinobacteria</i> Infants: BCG (385), OPV (385), tetanus (385) Phylum <i>Firmicutes</i> Adults: <i>Salmonella</i> Typhi (387)	Phylum <i>Proteobacteria</i> Infants: BCG (385), HepB (385), OPV (385), tetanus (385)	

tion of ampicillin leads to higher antibody responses after vaccination with a live attenuated *Salmonella* Typhi vaccine (366). A study in calves showed that concurrent administration of oxytetracycline leads to lower antibody responses to subcutaneous vaccination with *Brucella abortus* vaccine (367).

The effects of probiotics on vaccine responses are detailed in a recent systematic review (368). A beneficial effect of probiotics has been reported for responses to diphtheria (369), HepA (370), Hib (371), IPV (372), OCV (373), ORV (374), OPV (375), and TIV (376–380) vaccination. However, the choice of probiotic strains and dose as well as the duration and timing of administration varied largely between studies.

Studies investigating the effects of nutritional supplements containing a mix of probiotics (*Lactobacillus paracasei* [381] or *Bifidobacterium longum* bv. *infantis* [341, 382]) and prebiotics (fructo-oligosaccharides [381] or gluco-oligosaccharide [341, 382]) show no effect of the supplements on antibody responses to TIV (381–383) or PPV23 (381, 383) vaccination or on B or T cell responses (341) to TIV vaccination.

Microbiota. There is an association between the intestinal microbiota and vaccine responses (384). In infants, a higher relative abundance of actinobacteria (especially the species *B. longum*) has been associated with either higher antibody or cellular vaccine responses to BCG (385), HepB (385), IPV (372), OPV (385), and tetanus (385) vaccination. In contrast, a higher relative abundance of proteobacteria (especially *Pseudomonadales*) has been associated with lower responses to these vaccines (385). Additionally, a higher relative abundance of *Firmicutes* bacteria (families *Lachnospiraceae* and *Ruminococcaceae*) has been associated with higher humoral responses to ORV (386) in infants and cellular responses to *Salmonella* Typhi (387) in adults. Additionally, in infants, one study found a higher relative abundance of *Bacteroidetes* organisms to be associated with lower humoral responses to ORV (386), while another study did not find any association between the composition of the intestinal microbiota and responses to ORV (388) (Table 12). Children with small bowel bacterial overgrowth have reduced antibody responses to OCV (389).

The one study which investigated the influence of the respiratory microbiota on vaccine responses shows a positive association between the presence of *Bacteroides ovatus*, *Lactobacillus helveticus*, *Prevotella melaninogenica*, *Streptococcus infantis*, and *Veillonella dispar* in the nasopharynx and influenza virus-specific H1 IgA levels in nasal washings after vaccination with live attenuated influenza virus (LAIV) (390).

Preexisting immunity. Individuals with higher prevaccination tetanus antibody titers have higher SPRs after booster vaccination (60), while the antibody response to diphtheria is not affected by prevaccination titers (391). Similarly, the antibody response to TIV is positively associated with prevaccination titers (93). Elderly people who have low antibody titers against influenza virus before vaccination might not seroconvert after one dose of TIV (392). Further, priming with an antigen different from that included in the TIV vaccine leads to lower SCRs and GMTs (393, 394) than those obtained after priming with similar antigens. Further evidence that preexisting immunity influences vaccine responses comes from studies showing that individuals who have antibodies against flaviviruses have higher antibody responses to dengue fever vaccination (95). Previous exposure to Hib-like environmental bacteria increases antibody responses to Hib vaccination (327). In contrast, there is evidence that lower cytokine production after BCG vaccination can be explained partly by previous exposure to other mycobacteria (395–397). However, this is not the case in all studies (398). The evidence for antibody responses to HepB vaccination is also conflicting, with one study showing higher antibody responses in those who are anti-HBc positive (242) and another showing lower responses (72). For OCV, SCRs have been observed to be lower for individuals with preexisting immunity (399).

Behavioral Factors

Smoking. Smoking leads to lower antibody responses to HepB vaccination in some (66, 68, 69, 74, 75, 78, 80, 400) but not all studies (81, 100, 401, 402) and to increased antibody responses to YF vaccination (157). Smoking has no influence on GMTs after human papillomavirus (HPV) vaccination, but it increases the risk of having low-avidity antibodies after vaccination (403). Smokers have higher SCRs after vaccination with LAIV, but waning of antibodies is quicker in smokers than in nonsmokers after vaccination with LAIV and TIV (404) (Table 13).

Alcohol consumption. Alcohol intake has been found not to influence antibody responses to HepA (405) or HepB (68, 69, 81, 402, 406) vaccination but might influence responses to pneumococcus vaccination (142). After vaccination with PPV23, alcoholics have lower SCRs to serotypes 3, 4, 7F, 8, and 19F (however, this is significant only for serotypes 3 and 19F) (142) (Table 13).

Exercise. A small study showed that antibody responses to tetanus vaccination were higher in runners vaccinated after they completed a marathon than in a nonrunner control group (407). However, a larger study found no differences in antibody responses to diphtheria, tetanus, and PPV23 vaccines given to triathletes after they completed a race compared to the responses in triathletes vaccinated when they had not been exercising or in vaccinated sedentary controls (408). A further study reports higher GMTs to TIV (only to A/Panama [H3N2]) in females who used an ergometer in the 45 min before vaccination (409), and one study showed that active participants over the age of 62 years (defined as more than 20 min of vigorous exercise three or more times per week) had higher antibody responses to TIV than those of sedentary participants (410), while other studies with interventions to increase physical activity in adults do not show an association between increasing exercise and antibody responses to TIV (411) or PPV23 (412) vaccination (Table 13).

One study showed that eccentric exercise of the arm before administration of TIV leads to increased interferon gamma production (with the increase in cytokine production correlating with the increase in arm circumference) in males and antibody production in females (124). The increase in antibody response to TIV vaccination through exercise varies among different vaccine strains, with low-immunogenicity strains being particularly responsive to augmentation through exercise (127). However, a follow-up study could not confirm an association between eccentric exercise of the arm and the humoral or cellular vaccine response to TIV (413) (Table 13).

Acute psychological stress. In elderly people, positive mood on the day of vaccination is associated with higher antibody responses to TIV (414). In contrast, mental stress before vaccination leads to higher GMTs after TIV vaccination in females (only to

TABLE 13 Results from studies investigating behavioral factors that influence vaccine responses

Vaccine response, vaccine, age group, task or characteristic, measurement [reference(s)]					
Type of response	Smoking	Alcohol consumption	Exercise	Acute psychological stress	Chronic psychological stress
Humoral responses	Higher antibody production LAIV Adults: SPRs (404)	Lower antibody production PPV23 Adults: GMTs (142), SPRs (142)	Higher antibody production Tetanus Male adults, run: % standard plasma (407)	Higher antibody production MCV-A Male adults, mental task: GMTs (139)	Higher antibody production HepB Adolescents, chronic stress: GMTs (435)
	Lower antibody production YF Adults: SPRs (157)	No difference in antibody production HepA Adults: GMTs (66, 68, 69, 74, 75, 78, 80, 400), HepB Adults: GMTs (69, 81, 406), SCRs (406), SPRs (68, 69, 406)	TIV Female adults, eccentric arm exercise: GMTs (124) Female adults, ergometer: GMTs (409) Elderly, vigorous exercise: GMTs (410)	TIV Female adults, mental task: GMTs (409) Elderly, good mood on day of vaccination: GMTs (414)	Lower antibody production HepB Adolescents, stressful life events: SCRs (431) Adolescents, chronic stress: GMTs (432, 433), SPRs (430) MCV-C Adolescents, perceived stress: GMTs (434) MPV-C Adolescents, stressful life events: GMTs (423)
Humoral responses	Quicker weaning of antibodies LAIV Adults: SPRs (404)	Pregnant women: SCRs (402)	No difference in antibody production Diphtheria Adult males, triathlon: GMTs (408)	PPV23 Children, kindergarten entry (441): GMTs Elderly, chronic stress: GMTs (420) Rubella Adults, low self-esteem: GMTs (438)	Adult males: GMTs 7 nights after vaccination (445) No difference in antibody production
	Lower avidity of antibodies HPV Female adults (403) No difference in antibody production HepA Adults: SPRs (405)	Adults: SPRs (404)	Tetanus Adult males, triathlon: GMTs (408)	TIV Elderly: GMTs (414) Adults with obstructive sleep apnea: GMTs (446), SCRs (446)	Adult males, night after vaccination: GMTs (443) Adult males, night after vaccination: GMTs HepB Adults, 7 nights around vaccination: GMTs (442), SPRs (442)
Humoral responses	HPV Female adults: GMTs (403)	Adults: GMTs (81, 100) Pregnant women: SCRs (402)	Adult males, eccentric arm exercise: GMTs (413) Adults, increased exercise: GMTs (411)	Adolescents, stressful life events: GMTs (423) Adolescents, loneliness: GMTs (424) Adults, perceived stress: GMTs (411, 421, 422) Elderly, chronic stress: GMTs (419), SCRs (416–418) Elderly, perceived stress: GMTs (410) No difference in antibody production HepB Adolescents, chronic stress: GMTs (437), SPRs (437), titers (436, 437)	Adult males, night after vaccination: GMTs (443) Adult males, night after vaccination: GMTs HepB Adults, 7 nights around vaccination: GMTs (442), SPRs (442)
	HPV Female adults: GMTs (403)	Adults: GMTs (81, 100) Pregnant women: SCRs (402)	Adult males, eccentric arm exercise: GMTs (413) Adults, increased exercise: GMTs (411)	Adolescents, stressful life events: GMTs (423) Adolescents, loneliness: GMTs (424) Adults, perceived stress: GMTs (411, 421, 422) Elderly, chronic stress: GMTs (419), SCRs (416–418) Elderly, perceived stress: GMTs (410) No difference in antibody production HepB Adolescents, chronic stress: GMTs (437), SPRs (437), titers (436, 437)	Adult males, night after vaccination: GMTs (443) Adult males, night after vaccination: GMTs HepB Adults, 7 nights around vaccination: GMTs (442), SPRs (442)

(Continued on next page)

TABLE 13 (Continued)

Vaccine response, vaccine, age group, task or characteristic, measurement [reference(s)]					
Type of response	Smoking	Alcohol consumption	Exercise	Acute psychological stress	Chronic psychological stress
Cellular responses					
				Lower cellular responses HepB Adolescents, stressful life events: blastogenic response (431) TIV Adults, chronic stress: specific CD8 T cells (425)	Sleep deprivation Lower cellular responses HepA Specific Th cells (444)
Cytokine responses					
				Higher cytokine production TIV Elderly, chronic stress: IL-6 production (419) Lower cytokine production TIV Elderly, chronic stress: IL-1 β (416, 417) Elderly, chronic stress: IL-2 (416, 417) Elderly, perceived stress: IL-2 (410) No difference in cytokine production TIV Adults, chronic stress: IFN- γ (426) Adults, chronic stress: IL-4 (426) Elderly, chronic stress: IL-6 (416)	

A/Panama [H3N2]) (409) and to higher GMTs to MCV-A in males (139). Individuals who have greater blood pressure reactions (with evidence of delayed diastolic blood pressure recovery) toward the end of a mental arithmetic stress task that causes aversive stimuli have higher SCRs after vaccination with MPV-A (415) and TIV (to A/Panama [H3N2] and B/Shandong) (Table 13).

Chronic psychological stress. Many studies report (mostly negative) associations between chronic psychological stress and vaccine responses. For example, elderly people who suffer from stress by being caregivers of relatives with dementia have lower antibody responses (416–419), less IL-1 β and IL-2 production (410, 416, 417), and more IL-6 production (419) after vaccination with TIV, as well as lower antibody responses after vaccination with PPV23 (420). In contrast, greater optimism in elderly people is associated with higher antibody responses (411) and more IL-10 production (410) after vaccination with TIV. Adults with high perceived stress, stressful life events, or loneliness also have lower antibody (410, 421–424) and cellular (425) responses after vaccination with TIV. This is not the case for adults who care for patients with multiple sclerosis (426). Responses to influenza A/H1N1 and B viruses appear to be more sensitive to the influence of psychological stress than those to A/H3N2 viruses (427). Having better social support or being married is associated with higher antibody responses to HepB (417) and TIV (423, 428) vaccination, while bereavement is associated with lower antibody responses to TIV (428) (however, one study reports lower antibody responses to TIV vaccination in patients with better social support [429]). Mindfulness-based stress reduction exercises do not influence antibody responses to TIV vaccination (411).

Young adults with stressful life events, chronic stress, and a low level of psychological well-being can have lower antibody responses to HepB (430–433) and MCV-C (434) vaccination. However, in contrast, one study shows higher antibody responses to HepB vaccination in young adults with chronic stress (435), and some studies do not find any associations between psychological stress and antibody responses to HepB vaccination (436, 437). Antibody responses might also be influenced by coping mechanisms. For example, individuals who accept the reality of stressful situations have higher antibody responses to HepB vaccination, while individuals who cope by substance use (430) or have high trait negative affect (436) have lower responses. High internalizing behavior, neuroticism, and low self-esteem are associated with lower antibody responses to rubella vaccination (438), while children with internalizing mood symptoms (depressive or anxious symptoms) have higher antibody responses to MCV-4 (439). One study found no association between coping mechanisms and antibody responses to HepB vaccination (432).

Observed negative/conflict behaviors in an interaction task between parents and children predicts lower antibody responses to serotype C after MCV-4 vaccination in children (440). Children who have higher salivary cortisol levels after starting kindergarten have lower antibody responses to PPV23 (441) (Table 13).

Sleep. Short sleep duration, but not subjective sleep quality, in the week around vaccination is associated with lower antibody responses to HepB vaccination (442). Deliberate sleep deprivation during the night after HepA vaccination is associated with lower antibody levels (443, 444) and specific Th cell responses (444), while high sleep slow-wave activity is associated with higher antibody responses (444). Deliberate sleep deprivation 1 week after vaccination with TIV is also associated with lower antibody responses (445), while no association is found between sleep duration (414) or obstructive sleep apnea (446) and antibody responses to TIV vaccination (Table 13).

Nutritional Factors

Body mass index. Many studies in adults show that an increase in body mass index (BMI) is inversely correlated with antibody responses to HepA (61, 447) and HepB (61, 66, 68, 77, 78, 80, 100, 259, 401, 402, 448–454) vaccination. After vaccination with TIV, an increase in BMI is initially correlated with higher antibody responses. However, 12 months after vaccination, a higher BMI is associated with a greater decline in

antibodies, and obese individuals also have fewer specific CD8 T cells and less IFN- γ production (449) (Table 14).

Nutritional status. Many vaccine responses are not influenced by malnourishment. However, malnourished children are reported to have lower antibody responses to HepB (455), MPVS (456), measles (318, 457–459), OPV (335), pertussis (460), *Salmonella* Typhi (461), and tetanus (462) vaccination. Additionally, malnourished children have smaller tuberculin skin reactions after BCG vaccination (463–465) (Table 14).

Micronutrients (vitamins A, D, and E and zinc). Vitamin D plays an important role in innate, humoral, and cellular immune responses (466). However, its role in influencing vaccine responses is not clear (466). Most studies reporting on the effects of vitamin D on vaccine responses have investigated responses to TIV. The results of these studies are conflicting (Table 14). In adults, there is no association between vitamin D levels or administration of vitamin D and antibody responses to TIV (467–469). In children, some studies find no association between vitamin D levels or administration of vitamin D and antibody responses to TIV (470, 471), while others show a trend toward decreased SPRs against TIV in children with vitamin D deficiency (472). In contrast, after vaccination with LAIV, higher antibody responses against two influenza B virus strains were observed in children with low vitamin D levels, while there was no association between vitamin D levels and GMTs against the A strain of the LAIV vaccine (471). In adult dialysis patients, parenteral calcitriol treatment leads to higher antibody responses to TIV (473). Additionally, there is also a clear association between vitamin D deficiency in hemodialysis patients and diminished antibody responses to HepB vaccine (474). In children with idiopathic nephrotic syndrome, there is no correlation between vitamin D levels and antibody responses to PPV23 (475). In asplenic patients vaccinated against Hib, MCV-C, and PCV7, there is no correlation between vitamin D levels and vaccine antibody levels (476). Adults receiving vitamin D supplementation before a booster dose of tetanus have higher antibody levels against tetanus (477). Infants receiving supplementation with vitamins A and D have stronger tuberculin skin reactions (478) and lower IFN- γ responses after BCG vaccination.

Studies investigating coadministration of vitamin A and measles vaccine also report conflicting results. Vitamin A given simultaneously with a measles vaccine at 6 months of age leads to lower SCRs (154), but only in infants with maternal antibodies. Vitamin A given simultaneously with measles vaccination at 9 months of age does not lead to a difference in GMTs and SCRs at the age of 12 months (479) but does lead to higher GMTs at the ages of 18 months (35) and 6 to 8 years (480), especially in boys. Vitamin A given simultaneously with measles vaccination at 9 months of age to malnourished infants leads to significantly higher GMTs (479). In children with and without vitamin A deficiency, there is no difference in antibody responses to diphtheria and tetanus vaccination (481). In elderly people who are not vitamin deficient, there is no association between levels of vitamin A, vitamin E, or zinc and antibody responses to TIV (482). Polymorphisms of vitamin A and D receptor are associated with lower antibody responses to HepB vaccination (483) and with variations in cytokine responses after rubella and measles vaccination (194, 484).

Enteropathy. Enteropathy is defined as intestinal inflammation not necessarily associated with diarrhea. It occurs more frequently in individuals exposed to poor sanitary conditions. It is often proposed that enteropathy is one of the mechanisms behind the lower effectiveness of oral vaccines in developing countries. However, only one study has investigated the effect of enteropathy on vaccine responses. That study found that infants with enteropathy have lower SPRs against OPV and ORV but not against parenteral vaccines (326).

Environmental Factors

Rural versus urban environment. Children living in rural areas have higher antibody responses to tetanus (351) and an experimental malaria vaccine (485, 486). They have a Th1-skewed response (IL-5 production) to tetanus and TIV vaccination, while children living in semiurban areas have a Th2-skewed response (IFN- γ production) (351, 487).

TABLE 14 Results from studies investigating nutritional factors that influence vaccine responses

Type of response	Vaccine response, vaccine, age group, measurement [reference(s)]			
	Higher body mass index	Malnourishment	Low vitamin D levels	Enteropathy
Humoral responses	Higher antibody production	Lower antibody production	Higher antibody production	Lower antibody production
	TIV Adults: GMTs (449) HepB Adults: GMTs (101) Lower antibody production HepA Adults: GMTs (447), SCRs (447) Elderly: GMTs (61), SPRs (61) HepB Children: GMTs (448) Adolescents: SPRs (401), titers (453) Adults: GMTs (77, 100, 449), SCRs (80, 450), SPRs (66, 68, 77, 78, 450, 454) Women: SPRs (451) Elderly: GMTs (61), SPRs (61) Pregnant women: SCRs (402) Dialysis patients: SPRs (259) TIV Adults: GMTs (449) No difference in antibody production HepA (61, 447) Adults: SPRs (405)	HepB Children: GMTs (455), SPRs (455) MPVs A and C Children: GMTs (456) Measles Children: GMTs (457, 458), SCRs (458, 459), SPRs (318) OPV Infants: GMTs (335) Pertussis (PT) Infants: GMTs (460) <i>Salmonella</i> Typhi Children: GMTs (461), SPRs (461) Tetanus Children: GMTs (462) No difference in antibody production Diphtheria Infants: GMTs (335) Children: GMTs (462, 576), SPRs (576) HepB Infants: GMTs (162) Children: GMTs (577), SPRs (577) Hib Infants: GMTs (162) Measles Infants: GMTs (335) Children: GMTs (576, 578), SCRs (287, 578–580), SPRs (576) MCV-C Children: GMTs (94) MPVs A and C Children: GMTs (576), SPRs (576) OPV Children: GMTs (576), SPRs (576) PPV23 Children: SPRs (122) Rabies Children: SPRs (122) <i>Salmonella</i> Typhi Children: GMTs (576), SPRs (576) Smallpox Children: GMTs (578), SCRs (578) Tetanus Infants: GMTs (335) Children: GMTs (457, 462, 576, 581), SPRs (576), titers (359)	LAIV B strain Children: GMTs (471) Lower antibody responses TIV Children: SPRs (472) No difference in antibody production HepB Adults with chronic kidney disease: GMTs (474), SPRs (474) Hib Asplenic adults: GMTs (476) LAIV A strain Children: GMTs (471) MCV-C Asplenic adults: GMTs (476) PCV7 Asplenic adults: GMTs (476) PPV23 Children with nephrotic syndrome: GMTs (475) TIV Children: GMTs (470, 471), SCRs (470), SPRs (470) Adults: SCRs (467), SPRs (467) HIV-infected adults: SCRs (469), SPRs (469)	OPV Infants: SPRs (326) ORV Infants: SPRs (326) No difference in antibody production Diphtheria Infants: SPRs (326) Hib Infants: SPRs (326) Measles Infants: SPRs (326) Tetanus Infants: SPRs (326)
Cellular responses	Lower cellular responses TIV Adults: specific CD8 T cells (449)	Lower cellular response BCG Children: size of tuberculin skin reaction (463–465) No difference in cellular responses Tetanus Children: lymphoproliferation (582)		
Cytokine responses	Lower cytokine production TIV Adults: IFN-γ (449)			

In contrast, humoral and cellular responses to TIV are lower in children living in rural areas than in those living in semiurban areas (487). Similarly, antibody responses to HepB vaccination (161, 486, 488) and cytokine responses after vaccination with BCG (323) are lower in children and adults living in rural areas.

Geographic location. Children living in developing countries have higher antibody responses to Hib (489), diphtheria (489), PCV7 (490), and pertussis (489) vaccination but lower antibody responses to measles (491–493), OCV (494), OPV (495, 496), and *Salmonella* Typhi (497) vaccination. Adults in developing countries have lower antibody responses to HepB vaccination (498). Children living in developed countries have a Th2-skewed response to BCG vaccination, with more IFN- γ production (396, 398, 499, 500), while children in developing countries have a Th1-skewed response (499).

Season. There is an association between month of administration and antibody responses to pertussis (460), PPV23 (146), rabies (146), and *Salmonella* Typhi (146) vaccination but no association between month of vaccine administration and antibody responses to diphtheria (146), HepB (146), and tetanus (146) vaccination (Table 15). African infants born in the wet season have stronger CD154 vaccine responses to BCG than those of infants born in the dry season (325). In adolescents, antibody responses (GMTs) to HepB vaccination are lower in individuals who receive their first and second doses in summer than in those who receive them in winter. However, after the third dose, no statistically significant difference in GMTs is found. It has been suggested that these variations in vaccine responses may be explained through differences in exposure to UV irradiation (501). Nevertheless, exposing healthy volunteers to UVB on five consecutive days before HepB vaccination does not lead to a difference in GMTs or cellular vaccine responses (in a lymphocyte stimulation test) between UVB- and non-UVB-exposed individuals (502).

Family size. A larger number of people living in the household is associated with superior antibody responses to Hib vaccine (327).

Toxins. One study compared vaccine responses in lead-exposed children with metabolic impairment to those in healthy children and did not find a difference in antibody responses to tetanus (503). Another study showed that early-life arsenic exposure leads to decreased antibody levels to mumps virus after vaccination with MMR (504). It has also been suggested that pre- and postnatal (breast milk) exposure to polychlorinated biphenyls and dioxins leads to lower antibody responses to measles and mumps viruses (505).

Vaccine Factors

Vaccine type, product, and strain. Immune responses vary widely with different vaccine types and products. For example, live vaccines usually induce high vaccine responses leading to life-long protection, often after just one dose, while inactivated, subunit, or toxoid vaccines usually require several doses, including booster doses, to achieve similar protection. Responses to different subunit vaccines also vary. Polysaccharide vaccines induce a T cell-independent vaccine response which does not induce immune memory and is therefore short-lived. Such vaccines are not protective in children under 2 years of age and do not decrease nasopharyngeal carriage. In contrast, polysaccharide-protein-conjugated vaccines have superior immunogenicity, protect infants under 2 years of age, and reduce nasopharyngeal carriage. The responses to similar vaccines against the same disease can also vary according to specific product or strain. This has been shown, for example, for BCG (323, 506, 507), HepB (107, 508), TIV (86), PCV7 (490), rabies (509), and measles (49) vaccines. However, detailed discussion of this topic is beyond the scope of this review.

Adjuvants. Adjuvants are added to vaccines to elicit stronger immune responses. There is great variation in the magnitude and quality of vaccine responses depending on which adjuvants are added to a vaccine (510). For example, the new adjuvant MF59 increases antibody affinity and cross-protection against TIV (511, 512), and compared to those obtained with the standard HepB vaccine, a vaccine containing the new adjuvant AS04 induces higher SPRs and GMTs (513).

TABLE 15 Results from studies investigating environmental factors that influence vaccine responses

Vaccine response, vaccine, age group, measurement [reference(s)]						
Type of response	Living in rural areas	Living in developing countries	Season	Larger family size	Arsenic exposure	Polychlorinated biphenyls and dioxins exposure
Humoral responses	Higher antibody production	Higher antibody production	Association between month of administration and antibody production	Higher antibody production	Lower antibody levels	Lower antibody levels
	Tetanus	Hib	Pertussis (PT)	Hib	Mumps	Measles
	Children: GMTs (351)	Infants: GMTs (489), SPRs (489)	Infants: GMTs (460)	Infants: GMTs (327)	Infants: GMTs (504)	Children: GMTs (505)
	Malaria (PfAMAI, PfRh5)	Diphtheria	Pertussis (PT)			Mumps
	Children: GMTs (485)	Infants: GMTs (489)	Children: GMTs (146)			Children: GMTs (505)
	Lower antibody production	PCV7	Rabies			
	HepB	Pertussis (FHA)	Adults: GMTs (146)			
	Adolescents: SPRs (161)	Infants: GMTs (489)	<i>Salmonella</i> Typhi			
	Children: SPRs (486, 488)	Pertussis (PT)	Adults: GMTs (146)			
	TIV	Infants: GMTs (489)	No association between month of administration and antibody production			
Cellular responses	Children: GMTs (487)	Tetanus	Diphtheria			
		Infants: GMTs (489)	HepB			
		Lower antibody production	Measles			
		HepB	Adults: SPRs (498)			
		Measles	Children: GMTs (491–493), SCR (491–493)			
		OCV	Infants: GMTs (146)			
		Children: GMTs (494)	HepB			
		OPV	Tetanus			
		Children: SCR (495, 496)	Infants: GMTs (146)			
		<i>Salmonella</i> Typhi: SCR (497), SPR (497)	Infants: GMTs (146)			
Cytokine responses	No difference in antibody production	No difference in antibody production				
	Diphtheria	Diphtheria				
	Infants: SPRs (489)	Infants: SPRs (489)				
	Pertussis (FHA)	Pertussis (FHA)				
	Infants: SPRs (489)	Infants: SPRs (489)				
	Pertussis (PT)	Pertussis (PT)				
	Infants: SPRs (489)	Infants: SPRs (489)				
	Tetanus	Tetanus				
	Infants: SPRs (489)	Infants: SPRs (489)				
Cellular responses	Differences in cellular responses	Lower cellular response	Higher cellular response			
	Tetanus	BCG	BCG			
	Skewed towards Th1	Smaller tuberculin skin reaction (396), skewed towards Th1 (499)	CD154 (325)			
	(351)					
	TIV					
	Skewed towards Th1					
	(487)					
Cytokine responses	Higher cytokine production	Lower cytokine production				
	Tetanus	BCG				
	IL-5 (351)	IFN- γ (396, 398, 500)				
	TIV					
	IL-5 (487)					
	Lower cytokine production					
	Tetanus					
	IFN- γ (351)					
	TIV					
	IFN- γ (487)					

Vaccine dose. A study investigating IPV showed that there is a linear relationship between the dose of administered antigen and antibody responses (514). With ORV, the inhibitory effect of transplacental or breast milk-transferred maternal antibodies can be overcome by increasing the vaccine dose (309).

In adolescents receiving HepB vaccination, 10 μ g instead of the more commonly used 20- μ g dose is sufficient to induce seroprotection (454). However, it leads to lower GMTs (71, 515) and SCRs (71). In patients with end-stage kidney disease, 80 μ g of HepB vaccine increases the likelihood of persistent protective antibodies (259).

For the Hib vaccine, it has been shown that even one-eighth the usually given dose leads to adequate antibody titers associated with long-term immunity (516).

For TIV, it has been shown for elderly people that higher doses of antigens are associated with higher antibody responses (130, 517), while in previously immunized participants of 18 to 49 years of age, half the usual vaccine dose leads to comparable SCRs and GMTs, especially in females (126).

Administration Factors

Vaccination schedule. A further factor influencing vaccine responses is the spacing of vaccine doses. Schedules that have longer intervals between vaccine doses usually lead to higher immune responses. For example, antibody responses to aP are significantly higher after a 2-month to 4- to 6-month schedule than after an accelerated 2-month to 3- to 4-month schedule (349). Similarly, antibody responses to DTP vaccination are higher after a 3-month to 5- to 9-month schedule than after an accelerated 2-month to 3- to 4-month schedule (518). For HepB vaccination, increased time between the first and second doses or the second and third doses also correlates with increasing GMTs and SPRs (117, 401). However, one study showed lower GMTs after HepB vaccination on a 0-month to 12- to 24-month schedule than after a 0-month to 1- to 6-month schedule (448), and similarly, another study also showed that individuals who have an interval of more than 1 month between the first and second doses have lower SPRs (79).

In contrast, GMTs after HepA vaccination are higher after a 0-month to 1- to 12-month schedule than after a 0-month to 6- to 12-month schedule (99) or a 0-month to 1- to 2-month schedule (64).

In infants receiving two doses of measles, mumps, rubella, and varicella virus vaccination (MMRV), GMTs are higher to all components of the vaccine when the doses are given 12 months apart instead of 4 weeks apart (519). When influenza vaccination is given to children below the age of 24 months, there is no difference in antibody responses if one priming dose is given in spring followed by the second dose in fall or if both doses are given in fall (520).

Vaccination site. In adults, HepB vaccination given in the buttock area leads to lower responses than those obtained when it is given in the upper arm (521–524). However, this is not the case for infants (525). In children receiving Hib vaccination, there is also no difference in GMTs between children who receive the vaccination in the vastus lateralis and those who receive it in the deltoid muscle (526). Similarly, there is no difference in GMTs after HepB vaccination in infants who receive the vaccine in the anterolateral thigh compared to those who receive it in the ventrogluteal region (8).

Vaccination route. Intramuscular administration of TIV leads to higher antibody responses than those obtained by subcutaneous administration (125). However, there is no difference in antibody responses to diphtheria (137), PPV23 (143), or tetanus (137) vaccination after intramuscular or subcutaneous administration. For HepB and rabies vaccines, a lower dose given intradermally induces an antibody response similar to that induced by a larger intramuscular dose (148, 527–529). Intramuscular vaccination relies on a T cell-mediated response, while intradermal vaccination activates a dendritic cell-mediated response, which requires lower antigen doses (530). Individuals who do not respond to intramuscular HepB vaccination might respond to intradermal administration (531, 532). While 5 μ g given intradermally leads to higher SCRs than those obtained with 40 μ g given intramuscularly (533), 2 μ g given intradermally leads to

lower SPRs (74) and GMTs (75) than those obtained with 20 μ g given intramuscularly (75). There is no difference in time required to seroconvert or time to peak antibody titer (75).

Needle size. The size of the needle used to administer vaccines has not been found to influence vaccine responses (534, 535).

Time of day. Studies investigating diurnal variations in antibody responses to TIV in adults show conflicting results. One study showed that individuals receiving the vaccine in the morning have significantly higher antibody responses to the H1N1 A strain and a trend toward higher responses to the B strain, while the time of vaccine administration has no influence on responses to the H3N2 A strain (536). A second study indicated that diurnal variations in antibody responses after TIV are strain specific (537). Additionally, a third study showed higher GMTs to TIV after morning (compared to afternoon) vaccination, but only in men (538). The same has been shown for GMTs after HepA vaccination, but again only in men (538).

Coadministered vaccines. A vast number of studies have investigated the influence of concurrent administration of live vaccines on vaccine responses. Two meta-analyses summarized RCTs comparing vaccine responses in infants receiving either one dose of MMRV or MMR and V as separate vaccines (539, 540). The first meta-analysis, which included 10 RCTs, did not find any difference in GMTs to any of the vaccine components (540). However, the second meta-analysis, which included 24 RCTs, showed that after a single vaccination in children of 9 to 24 months of age, GMTs against mumps and varicella viruses are comparable between infants receiving MMRV and those receiving MMR and V (MMR+V) or MMR. In contrast, individuals receiving MMRV achieve significantly higher GMTs to measles virus than those in individuals receiving MMR+V or MMR. GMTs to rubella virus are reduced in those receiving MMRV compared to those in individuals receiving MMR+V or MMR (539). MMRV also leads to lower SCRs than those with MMR+V or MMR, but this is likely confounded by lower virus antigen doses in early vaccines (539). In investigations of immune responses after two vaccine doses, similar GMTs to most vaccine viruses are observed (541–545). However, there is a tendency toward higher varicella (541, 542, 544, 545) and mumps (541, 543–545) GMTs and lower measles (542–544) and rubella (541, 544, 545) GMTs in groups receiving MMRV as a second dose than in those receiving MMR+V. Concurrent administration of LAIV with MMR+V does not influence GMTs or SPRs against any of the vaccine components (546). YF vaccine given simultaneously with the MMR vaccine leads to lower SCRs than those obtained when the vaccines are given 1 month apart (61% versus 71% for mumps, 90% versus 97% for rubella, and 70% versus 87% for YF), while SCRs for measles are not influenced by simultaneous vaccination (547). One study suggests that a live attenuated Japanese encephalitis (JE) vaccine given 30 days before a YF vaccine might interfere with SCRs to YF vaccination (548). However, a subsequent study did not find a difference in SCRs to YF vaccine whether JE was given 30 days before, simultaneously with, or after the vaccine. For JE, even though there were also no significant differences in SCRs between individuals given the two vaccinations at the same time and those receiving them 30 days apart, GMTs were significantly higher in participants who receive JE 30 days before YF rather than the other way around or at the same time (549).

Studies show that simultaneous administration of nonlive vaccines with MMR or V vaccine does not influence the response to any of the vaccine components. This includes 7-valent conjugated pneumococcal (Pn) (550–552), 10-valent Pn-Hib (553), meningococcal C (MenC) (554), DTaP-HBV-IPV-Hib (555), and HepA (551, 552) vaccines.

An additional dose of acellular pertussis (aP) vaccine at birth might lead to subsequently lower HepB (52, 53), Hib (52, 53), and diphtheria (556) GMTs.

Studies investigating the influence of coadministering BCG vaccine show that it leads to significantly higher levels of antibodies against HepB, OPV, PCV7, and TIV but not against DTaP-Hib or *Salmonella* Typhi (557).

There are several studies which show that concomitant administration of OPV reduces vaccine responses to ORV (558, 559). Infants who receive the two vaccines

concomitantly are less likely to seroconvert than those who receive both vaccines in a staggered manner (558). The interference is greater after the first dose of OPV, presumably because the first dose is associated with the greatest intestinal replication of vaccine poliovirus strains (559). However, when the vaccines are given concomitantly after the age of 3 months, neither OPV nor ORV influences vaccine responses (560).

There is less interference reported with coadministration of nonlive vaccines. Co-administration of PCV7 vaccine with either acellular pertussis or whole-cell pertussis vaccine has no effect on the immunogenicity of the PCV7 vaccine, except for that against serotype 14, for which the specific antibody response is lower when the vaccine is given with the acellular pertussis vaccine (490). One RCT showed that when DPT-IPV and Hib are given together as a single dose, the antibody response to tetanus is significantly lower than that obtained when DPT-IPV is given at an injection site different from that used for Hib or given 6 months apart (561). A Cochrane review summarizing studies that compared the immunogenicities of the combined DTP-HBV-Hib vaccine and the DTP-HBV and Hib vaccines given at separate sites did not find conclusive results, as only one study reported significantly lower immunological responses to Hib and tetanus when the vaccine components were given in a combined vaccine (562).

Coadministered drugs. Several studies have investigated the effect of concurrent administration of paracetamol around the time of vaccination. A review summarizing 13 RCTs which investigated the influence of prophylactic antipyretic administration after vaccination shows that infants receiving paracetamol after each of 3 doses of routine vaccination have lower GMTs to all Pn serotypes, Hib, diphtheria, tetanus, and pertactin but not to pertussis toxin, filamentous hemagglutinin (FHA), HepB, or IPV. After a booster dose, lower GMTs persisted in the prophylactic paracetamol group for all Pn serotypes, diphtheria, and tetanus (563). The one study that investigated the effect of ibuprofen administration around the time of vaccination shows that GMTs to FHA and tetanus are diminished after primary administration but not after a booster dose, while responses to conjugated Pn vaccine are not affected (564). Further, a recent large study in elderly individuals showed that the intake of statins diminishes GMTs to TIV (565). Similarly, preterm infants who receive dexamethasone for chronic lung disease have significantly lower GMTs against Hib after basic immunization with 3 doses (566).

CONCLUDING REMARKS

This review summarizes many important (and often unrecognized or underappreciated) factors that might affect how individuals respond to vaccines (Fig. 1). There is solid evidence that intrinsic factors, such as genetics, sex, age at time of vaccination, and comorbidities, as well as vaccine-related factors, such as choice of vaccine products, adjuvants, and vaccination schedule, strongly influence vaccine responses. Good evidence also exists for the interaction between maternal antibodies and vaccine responses in infants. In contrast, the available data on the influence of other perinatal factors, such as birth weight or feeding method, or on the influence of infections, antibiotics, the microbiota, and nutrition are less robust. For smoking, alcohol consumption, psychological stress, and exercise, the data from different studies are inconsistent. Many studies report differences in vaccine responses depending on geographic region. However, many other factors, such as preexisting immunity, nutritional status, and other behavioral factors, as well as genetics and the microbiota, might confound this observation. The potential for confounding also exists for many of the other factors discussed in this review, as the response to vaccination is complex, likely involving the interplay of multiple different factors. It is therefore important not to overinterpret findings from single studies.

There are many different methods for quantifying vaccine responses (Fig. 2). However, most studies investigating vaccine responses quantify antibodies. The antibody concentration defined as a protective correlate varies depending on whether it relates to protection against colonization, mucosal disease, or invasive disease. However,




FIG 2 Methods for quantifying vaccine responses.

vaccine responses are far more complex than just measurable antibody concentrations. Other parts of the immune system, such as innate, cellular, and cytokine responses, also play a crucial role in vaccine efficacy. The complex interplay between these different components of the immune system in vaccine responses is not fully understood, and surrogate markers of vaccine-induced protection are imperfect. As most vaccines induce very high antibody responses, small differences in antibody concentrations between groups of individuals may not be clinically significant in terms of protective efficacy, may be relevant only in individuals with poor responses, or may impact only the duration of protection. Moreover, the quality of antibody response is an important consideration, as only a subset of total detectable antibody can neutralize pathogens. SPRs or GMCs do not take this into account and are therefore imperfect correlates of protection. Further, the level of antibody response *in vitro* does not necessarily correlate with health outcomes. For example, seroconversion does not mean full protection against a disease, and nonseroconversion is not necessarily associated with susceptibility (567). Moreover, antibody levels wane with time, but seronegative individuals can still be protected through other immune mechanisms, as shown, for example, after HepB vaccination (568).

This review provides an overview of the current evidence for factors that might influence vaccine responses and identifies factors that require further investigation. Important topics for future studies include the influences of the microbiota (intestinal and respiratory), concurrent infections, and antibiotics on vaccine responses. Further important lines of investigation include the association between preexisting immunity and vaccine responses, as well as the influence of behavioral factors. Understanding

these interactions in more depth will open new avenues for improving vaccine immunogenicity and effectiveness as well as designing vaccine schedules that optimize the benefits of vaccination.

ACKNOWLEDGMENTS

P.Z. is supported by a Fellowship from the European Society of Pediatric Infectious Diseases and an International Research Scholarship from the University of Melbourne.

We declare that we have no competing interests.

P.Z. drafted the initial manuscript and approved the final manuscript as submitted. N.C. critically reviewed and revised the manuscript and approved the final manuscript as submitted.

REFERENCES

- World Health Organization. 2009. State of the world's vaccines and immunization. WHO. Geneva, Switzerland.
- Anonymous. 1999. Impact of vaccines universally recommended for children—United States, 1990–1998. *MMWR Morb Mortal Wkly Rep* 48:243–248.
- Pulendran B, Ahmed R. 2011. Immunological mechanisms of vaccination. *Nat Immunol* 12:509–517. <https://doi.org/10.1038/ni.2039>.
- Sallusto F, Lanzavecchia A, Araki K, Ahmed R. 2010. From vaccines to memory and back. *Immunity* 33:451–463. <https://doi.org/10.1016/j.immuni.2010.10.008>.
- Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. *Nat Immunol* 10:116–125. <https://doi.org/10.1038/ni.1688>.
- Ritz N, Mui M, Balloch A, Curtis N. 2013. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations. *Vaccine* 31:3098–3103. <https://doi.org/10.1016/j.vaccine.2013.03.059>.
- Nakaya HI, Hagan T, Duraisingham SS, Lee EK, Kwissa M, Roupheal N, Frasca D, Gersten M, Mehta AK, Gaujoux R, Li GM, Gupta S, Ahmed R, Mulligan MJ, Shen-Orr S, Blomberg BB, Subramaniam S, Pulendran B. 2015. Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. *Immunity* 43:1186–1198. <https://doi.org/10.1016/j.immuni.2015.11.012>.
- Junqueira AL, Tavares VR, Martins RM, Frauzino KV, da Costa e Silva AM, Minamisava R, Teles SA. 2010. Safety and immunogenicity of hepatitis B vaccine administered into ventrogluteal vs. anterolateral thigh sites in infants: a randomised controlled trial. *Int J Nurs Stud* 47:1074–1079. <https://doi.org/10.1016/j.nurstu.2010.01.009>.
- Finan C, Ota MO, Marchant A, Newport MJ. 2008. Natural variation in immune responses to neonatal *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) vaccination in a cohort of Gambian infants. *PLoS One* 3:e3485. <https://doi.org/10.1371/journal.pone.0003485>.
- Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. 2007. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. *J Infect Dis* 196:1339–1345. <https://doi.org/10.1086/522519>.
- Siegrist CA. 2007. The challenges of vaccine responses in early life: selected examples. *J Comp Pathol* 137(Suppl 1):S4–S9. <https://doi.org/10.1016/j.jcpa.2007.04.004>.
- Poland GA, Jacobson RM. 1994. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. *Arch Intern Med* 154:1815–1820. <https://doi.org/10.1001/archinte.1994.00420160048006>.
- Grassly NC, Kang G, Kampmann B. 2015. Biological challenges to effective vaccines in the developing world. *Philos Trans R Soc Lond B Biol Sci* 370:20140138. <https://doi.org/10.1098/rstb.2014.0138>.
- Voysey M, Kelly DF, Fanshawe TR, Sadarangani M, O'Brien KL, Perera R, Pollard AJ. 2017. The influence of maternally derived antibody and infant age at vaccination on infant vaccine responses: an individual participant meta-analysis. *JAMA Pediatr* 171:637–646. <https://doi.org/10.1001/jamapediatrics.2017.0638>.
- Halsey N, Galazka A. 1985. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. *Bull World Health Organ* 63:1151–1169.
- di Sant'Agnese PA. 1950. Simultaneous immunization of newborn infants against diphtheria, tetanus, and pertussis; production of antibodies and duration of antibody levels in an eastern metropolitan area. *Am J Public Health Nations Health* 40:674–680. <https://doi.org/10.2105/AJPH.40.6.674>.
- Kagina BM, Abel B, Bowmaker M, Scriba TJ, Gelderbloem S, Smit E, Erasmus M, Nene N, Walzl G, Black G, Hussey GD, Hesselning AC, Hanekom WA. 2009. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. *Vaccine* 27:5488–5495. <https://doi.org/10.1016/j.vaccine.2009.06.103>.
- Burl S, Adetifa UJ, Cox M, Touray E, Ota MO, Marchant A, Whittle H, McShane H, Rowland-Jones SL, Flanagan KL. 2010. Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. *J Immunol* 185:2620–2628. <https://doi.org/10.4049/jimmunol.1000552>.
- Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, Bell BP. 2008. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. *Pediatr Infect Dis J* 27:881–885. <https://doi.org/10.1097/INF.0b013e31817702ba>.
- Hammit LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. 2007. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. *Vaccine* 25:6958–6964. <https://doi.org/10.1016/j.vaccine.2007.06.059>.
- West DJ, Calandra GB. 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. *Vaccine* 14:1019–1027. [https://doi.org/10.1016/0264-410X\(96\)00062-X](https://doi.org/10.1016/0264-410X(96)00062-X).
- Abanamy A, Khalil M, Salman H, Abdel Azeem M. 1992. Vaccination of Saudi children against measles with Edmonston-Zagreb. *Ann Saudi Med* 12:110–111. <https://doi.org/10.5144/0256-4947.1992.110a>.
- Anonymous. 1977. Measles immunity in the first year after birth and the optimum age for vaccination in Kenyan children. Collaborative study by the Ministry of Health of Kenya and the World Health Organization. *Bull World Health Organ* 55:21–31.
- Bolotovskii VM, Grabowsky M, Clements CJ, Albrecht P, Brenner ER, Zargaryantz AI, Litvinov SK, Mikheyeva IV. 1994. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. *Int J Epidemiol* 23:1069–1077. <https://doi.org/10.1093/ije/23.5.1069>.
- Carson MM, Spady DW, Albrecht P, Beeler JA, Thipphawong J, Barreto L, Grimsrud KM, Pabst HF. 1995. Measles vaccination of infants in a well-vaccinated population. *Pediatr Infect Dis J* 14:17–22. <https://doi.org/10.1097/00006454-199501000-00003>.
- Cutts FT, Nyandu B, Markowitz LE, Forsey T, Zell ER, Othepa O, Wilkins K. 1994. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. *Vaccine* 12:1311–1316. [https://doi.org/10.1016/S0264-410X\(94\)80057-7](https://doi.org/10.1016/S0264-410X(94)80057-7).
- Díaz-Ortega JL, Zárate-Aquino ML, Valdespino-Gómez JL, Cardenas-Ayala VM, Ruiz-Matus C. 1986. Seroconversion with measles vaccine in children 8–18 months old. *Bol Med Hosp Infant Mex* 43:526–531.

28. Ekunwe EO. 1985. Separating the factors in measles vaccine failure. *Ann Trop Paediatr* 5:103–106. <https://doi.org/10.1080/02724936.1985.11748371>.
29. de Castro JF, Gomez JLV, Ortega JLD, Aquino MLZ. 1986. Diploid cell measles vaccine. *JAMA* 256:714. <https://doi.org/10.1001/jama.1986.03380060040014>.
30. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. 1998. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. *JAMA* 280:527–532. <https://doi.org/10.1001/jama.280.6.527>.
31. He H, Chen E, Chen H, Wang Z, Li Q, Yan R, Guo J, Zhou Y, Pan J, Xie S. 2014. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administered at 8 months versus 12 months age in children. *Vaccine* 32:4001–4005. <https://doi.org/10.1016/j.vaccine.2014.04.044>.
32. Job JS, John TJ, Joseph A. 1984. Antibody response to measles immunization in India. *Bull World Health Organ* 62:737–741.
33. Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML. 1994. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. *Pediatrics* 93:939–944.
34. Katiyar GP, Kaur G, Agarwal DK, Gulati AK, Kalra A, Agarwal KN. 1985. Sero-conversion response to Mevlin-L measles vaccine at age 6–15 months. *Indian Pediatr* 22:653–659.
35. Benn CS, Aaby P, Bale C, Olsen J, Michaelsen KF, George E, Whittle H. 1997. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, West Africa. *Lancet* 350:101–105. [https://doi.org/10.1016/S0140-6736\(96\)12019-5](https://doi.org/10.1016/S0140-6736(96)12019-5).
36. Berry S, Hernandez H, Kanashiro R, Campos M, Azabache V, Gomez G, Gutierrez M, Weirs B, De Quadros C, Halsey N. 1992. Comparison of high titer Edmonston-Zagreb, Biken-CAM and Schwarz measles vaccines in Peruvian infants. *Pediatr Infect Dis J* 11:822–827. <https://doi.org/10.1097/00006454-199210000-00003>.
37. Gans HA, Maldonado Y, Yasukawa LL, Beeler J, Audet S, Rinki MM, DeHovitz R, Arvin AM. 1999. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. *J Immunol* 162:5569–5575.
38. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, Audet S, Maldonado Y, Arvin AM. 2001. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. *J Infect Dis* 184:817–826. <https://doi.org/10.1086/323346>.
39. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM. 2004. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. *J Infect Dis* 190:83–90. <https://doi.org/10.1086/421032>.
40. Garly ML, Bale C, Martins CL, Monteiro M, George E, Kidd M, Dias F, Aaby P, Whittle HC. 2001. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. *Vaccine* 19:1951–1959. [https://doi.org/10.1016/S0264-410X\(00\)00431-X](https://doi.org/10.1016/S0264-410X(00)00431-X).
41. Hussey GD, Goddard EA, Hughes J, Ryon JJ, Kerran M, Carelse E, Strebel PM, Markowitz LE, Moodie J, Barron P, Latief Z, Sayed R, Beatty D, Griffin DE. 1996. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. *J Infect Dis* 173:1320–1326. <https://doi.org/10.1093/infdis/173.6.1320>.
42. Jensen TG, Whittle H, Mordhorst CH, Pedersen IR, Thaarup J, Poulsen A, Sodemann M, Jakobsen M, Brink L, Gansted U, Permin A, Clotilde da Silva M, Aaby P. 1994. Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4–8 months versus vaccination with Schwarz strain at 9–12 months of age. *Vaccine* 12:1026–1031. [https://doi.org/10.1016/0264-410X\(94\)90340-9](https://doi.org/10.1016/0264-410X(94)90340-9).
43. Kiepiela P, Coovadia HM, Loening WE, Coward P, Botha G, Hugo J, Becker PJ. 1991. Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants. *Bull World Health Organ* 69:221–227.
44. Ko B, Roberts D, Begg N, Rao M, Teare L, Cohen B. 1999. Neutralising antibody responses to two doses of measles vaccine at 5 and 13 months of age in the United Kingdom. *Commun Dis Public Health* 2:203–206.
45. Lee YL, Black FL, Chen CL, Wu CL, Berman LL. 1983. The optimal age for vaccination against measles in an Asiatic city, Taipei, Taiwan: reduction of vaccine induced titre by residual transplacental antibody. *Int J Epidemiol* 12:340–343. <https://doi.org/10.1093/ije/12.3.340>.
46. Anonymous. 1982. Seroconversion rates and measles antibody titers induced by measles vaccine in Latin American children 6–12 months of age. Collaborative study by the Ministries of Health of Brazil, Chile, Costa Rica, Ecuador, and the Pan American Health Organization. *Bull Pan Am Health Organ* 16:272–285.
47. Rogers S, Sanders RC, Alpers MP. 1991. Immunogenicity of standard dose Edmonston-Zagreb measles vaccine in highland Papua New Guinean children from four months of age. *J Trop Med Hyg* 94:88–91.
48. Tidjani O, Grunitsky B, Guerin N, Levy-Bruhl D, Lecam N, Xuereff C, Tatagan K. 1989. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4–5 or 8–10 months. *Lancet* ii:1357–1360.
49. Lochlainn LN, de Gier B, van der Maas N, Rots N, van Binnendijk R, de Melker H, Hahné S. 2015. Measles vaccination below 9 months of age: systematic literature review and meta-analyses of effects and safety. Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM). Bilthoven, the Netherlands.
50. Carazo Perez S, De Serres G, Bureau A, Skowronski DM. 2017. Reduced antibody response to infant measles vaccination: effects based on type and timing of the first vaccine dose persist after the second dose. *Clin Infect Dis* 65:1094–1102. <https://doi.org/10.1093/cid/cix510>.
51. Njie-Jobe J, Nyamweya S, Miles DJ, van der Sande M, Zaman S, Touray E, Hossin S, Adetifa J, Palmero M, Burl S, Jeffries D, Rowland-Jones S, Flanagan K, Jaye A, Whittle H. 2012. Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. *Vaccine* 30:2543–2550. <https://doi.org/10.1016/j.vaccine.2012.01.083>.
52. Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, Siegrist CA, Zepp F. 2008. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. *J Pediatr* 152:655–660. <https://doi.org/10.1016/j.jpeds.2007.09.034>.
53. Wood N, McIntyre P, Marshall H, Robertson D. 2010. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. *Pediatr Infect Dis J* 29:209–215. <https://doi.org/10.1097/INF.0b013e3181bc98d5>.
54. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. *Pediatrics* 96:29–35.
55. Belloni C, Orsolini P, Martinetti M, Chirico G, Cerbo RM, Comolli G, Maccarini U, Barlassina C, Togni C, Polatti F. 1993. Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers. *New Microbiol* 16:237–244.
56. Wood N, Siegrist CA. 2011. Neonatal immunization: where do we stand? *Curr Opin Infect Dis* 24:190–195. <https://doi.org/10.1097/QCO.0b013e328345d563>.
57. Levy O. 2007. Innate immunity of the newborn: basic mechanisms and clinical correlates. *Nat Rev Immunol* 7:379–390. <https://doi.org/10.1038/nri2075>.
58. Siegrist CA, Aspinall R. 2009. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol* 9:185–194. <https://doi.org/10.1038/nri2508>.
59. Siegrist CA. 2001. Neonatal and early life vaccinology. *Vaccine* 19:3331–3346. [https://doi.org/10.1016/S0264-410X\(01\)00028-7](https://doi.org/10.1016/S0264-410X(01)00028-7).
60. Bayas JM, Vilella A, Bertran MJ, Vidal J, Batalla J, Asenjo MA, Salleras LL. 2001. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary? *Epidemiol Infect* 127:451–460.
61. Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. 2006. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. *Vaccine* 24:5509–5515. <https://doi.org/10.1016/j.vaccine.2006.04.016>.
62. Wolters B, Junge U, Dziuba S, Roggendorf M. 2003. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. *Vaccine* 21:3623–3628. [https://doi.org/10.1016/S0264-410X\(03\)00399-2](https://doi.org/10.1016/S0264-410X(03)00399-2).
63. Tanaka E, Sata M, Nakano H, Suzuki H, Tanikawa K. 1997. Antibody response to inactivated hepatitis A vaccine. *Hepatol Res* 9:103–112. [https://doi.org/10.1016/S1386-6346\(97\)00079-X](https://doi.org/10.1016/S1386-6346(97)00079-X).
64. McMahon BJ, Williams J, Bulkow L, Snowball M, Wainwright R, Kennedy M, Krause D. 1995. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. *J Infect Dis* 171:676–679. <https://doi.org/10.1093/infdis/171.3.676>.
65. D'Acremont V, Herzog C, Genton B. 2006. Immunogenicity and safety of

- a virosomal hepatitis A vaccine (Epaxal) in the elderly. *J Travel Med* 13:78–83. <https://doi.org/10.1111/j.1708-8305.2006.00001.x>.
66. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, Xu K, Ren J, Yao J, Li Y, Cao Q, Chen P, Xie T, Wang C, Wang B, Mao C, Ruan B, Jiang T, Li L. 2016. Factors influencing immunologic response to hepatitis B vaccine in adults. *Sci Rep* 6:27251. <https://doi.org/10.1038/srep27251>.
 67. Westmoreland D, Player V, Heap DC, Hammond A. 1990. Immunization against hepatitis B—what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B. *Epidemiol Infect* 104:499–509. <https://doi.org/10.1017/S0950268800047506>.
 68. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. 1993. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. *JAMA* 270:2931–2934. <https://doi.org/10.1001/jama.1993.03510240043029>.
 69. Bock HL, Kruppenbacher J, Sanger R, Hobel W, Clemens R, Jilg W. 1996. Immunogenicity of a recombinant hepatitis B vaccine in adults. *Arch Intern Med* 156:2226–2231. <https://doi.org/10.1001/archinte.1996.00440180088011>.
 70. Morris CA, Oliver PR, Reynolds F, Selkon JB. 1989. Intradermal hepatitis B immunization with yeast-derived vaccine: serological response by sex and age. *Epidemiol Infect* 103:387–394. <https://doi.org/10.1017/S0950268800030740>.
 71. Denticio P, Buongiorno R, Volpe A, Zavoiani A, Pastore G, Schiraldi O. 1992. Long-term immunogenicity safety and efficacy of a recombinant hepatitis B vaccine in healthy adults. *Eur J Epidemiol* 8:650–655. <https://doi.org/10.1007/BF00145379>.
 72. Yen YH, Chen CH, Wang JH, Lee CM, Changchien CS, Lu SN. 2005. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). *Liver Int* 25:1162–1168. <https://doi.org/10.1111/j.1478-3231.2005.01157.x>.
 73. Hess G, Hingst V, Cseke J, Bock HL, Clemens R. 1992. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. *Eur J Clin Microbiol Infect Dis* 11:334–340. <https://doi.org/10.1007/BF01962073>.
 74. Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O. 1992. Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. *Scand J Infect Dis* 24:423–429. <https://doi.org/10.3109/00365549209052627>.
 75. Coleman PJ, Shaw FE, Jr, Serovich J, Hadler SC, Margolis HS. 1991. Intradermal hepatitis B vaccination in a large hospital employee population. *Vaccine* 9:723–727. [https://doi.org/10.1016/0264-410X\(91\)90287-G](https://doi.org/10.1016/0264-410X(91)90287-G).
 76. Cleveland JL, Siew C, Lockwood SA, Gruninger SE, Chang SB, Neidle EA, Russell CM. 1994. Factors associated with hepatitis B vaccine response among dentists. *J Dent Res* 73:1029–1035. <https://doi.org/10.1177/00220345940730050301>.
 77. Estévez ZC, Betancourt AA, Muzio González V, Baile NF, Silva CV, Bernal FH, Arias EP, Delhanty Fernández A, Olazábal NM, del Río Martín A, Batista LL, Véliz Ríos G, Hernández HH, Hernández AB, Lugo EP, de la Torre Cruz J, Batista Marchec BL, Falcón LA, Brito JT, León DO, Saura PL. 2007. Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. *Biologicals* 35:115–122. <https://doi.org/10.1016/j.biologicals.2006.06.001>.
 78. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. 1998. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. *Am J Prev Med* 15:1–8. [https://doi.org/10.1016/S0749-3797\(98\)00003-8](https://doi.org/10.1016/S0749-3797(98)00003-8).
 79. Sabido M, Gavalda L, Olona N, Ramon JM. 2007. Timing of hepatitis B vaccination: its effect on vaccine response in health care workers. *Vaccine* 25:7568–7572. <https://doi.org/10.1016/j.vaccine.2007.08.025>.
 80. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. 1993. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. *JAMA* 270:2935–2939. <https://doi.org/10.1001/jama.1993.03510240047030>.
 81. Tohme RA, Awosika-Olumo D, Nielsen C, Khuwaja S, Scott J, Xing J, Drobeniuc J, Hu DJ, Turner C, Wafeeg T, Sharapov U, Spradling PR. 2011. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. *Vaccine* 29:9316–9320. <https://doi.org/10.1016/j.vaccine.2011.10.011>.
 82. Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, Janoff EN. 1998. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. *J Infect Dis* 178:431–440. <https://doi.org/10.1086/515644>.
 83. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. 1996. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. *J Infect Dis* 173:387–393. <https://doi.org/10.1093/infdis/173.2.387>.
 84. Konradsen H, Henrichsen J. 1991. Antibody response to pneumococcal vaccination in the elderly. *Zentralbl Bakteriell* 275:94–99. [https://doi.org/10.1016/S0934-8840\(11\)80772-3](https://doi.org/10.1016/S0934-8840(11)80772-3).
 85. McElhaney JE, Meneilly GS, Beattie BL, Helgason CD, Lee SF, Devine RD, Bleackley RC. 1992. The effect of influenza vaccination on IL2 production in healthy elderly: implications for current vaccination practices. *J Gerontol* 47:M3–M8. <https://doi.org/10.1093/geronj/47.1.M3>.
 86. McElhaney JE, Upshaw CM, Hooton JW, Lechelt KE, Meneilly GS. 1998. Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults. *Vaccine* 16:1742–1747. [https://doi.org/10.1016/S0264-410X\(98\)00133-9](https://doi.org/10.1016/S0264-410X(98)00133-9).
 87. Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM. 1998. Cytokine production after influenza vaccination in a healthy elderly population. *Vaccine* 16:1722–1731. [https://doi.org/10.1016/S0264-410X\(98\)00140-6](https://doi.org/10.1016/S0264-410X(98)00140-6).
 88. Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. 2005. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. *Vaccine* 23:3232–3235. <https://doi.org/10.1016/j.vaccine.2005.01.085>.
 89. Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. 1995. A population-based serologic survey of immunity to tetanus in the United States. *N Engl J Med* 332:761–766. <https://doi.org/10.1056/NEJM199503233321201>.
 90. Kao TM, Hsieh SM, Kung HC, Lee YC, Huang KC, Huang LM, Chang FY, Wang NC, Liu YC, Lee WS, Liu HE, Chen CI, Chen CH. 2010. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. *Vaccine* 28:6159–6163. <https://doi.org/10.1016/j.vaccine.2010.07.026>.
 91. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. 2012. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. *J Infect Dis* 205:610–620. <https://doi.org/10.1093/infdis/jir791>.
 92. McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, Pawelec G. 2012. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. *Vaccine* 30:2060–2067. <https://doi.org/10.1016/j.vaccine.2012.01.015>.
 93. Mugitani A, Ito K, Irie S, Eto T, Ishibashi M, Ohfuiji S, Fukushima W, Maeda A, Hirota Y. 2014. Immunogenicity of the trivalent inactivated influenza vaccine in young children less than 4 years of age, with a focus on age and baseline antibodies. *Clin Vaccine Immunol* 21:1253–1260. <https://doi.org/10.1128/CVI.00200-14>.
 94. Greenwood BM, Bradley AK, Blakebrough IS, Whittle HC, Marshall TF, Gilles HM. 1980. The immune response to a meningococcal polysaccharide vaccine in an African village. *Trans R Soc Trop Med Hyg* 74:340–346. [https://doi.org/10.1016/0035-9203\(80\)90095-4](https://doi.org/10.1016/0035-9203(80)90095-4).
 95. Kanasa-Thanan N, Sun W, Ludwig GV, Rossi C, Putnak JR, Mangiafico JA, Innis BL, Edelman R. 2003. Atypical antibody responses in dengue vaccine recipients. *Am J Trop Med Hyg* 69:32–38. <https://doi.org/10.4269/ajtmh.2003.69.32>.
 96. Wagner G, Lavanchy D, Darioli R, Pecoud A, Brulein V, Safary A, Frei PC. 1993. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers. *Vaccine* 11:1027–1032. [https://doi.org/10.1016/0264-410X\(93\)90128-K](https://doi.org/10.1016/0264-410X(93)90128-K).
 97. Chen XQ, Bulbul M, de Gast GC, van Loon AM, Nalin DR, van Hattum J. 1997. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. *J Hepatol* 26:260–264. [https://doi.org/10.1016/S0168-8278\(97\)80039-6](https://doi.org/10.1016/S0168-8278(97)80039-6).
 98. Goubau P, Van Gerven V, Safary A, Delem A, Knops J, D'Hondt E, Andre FE, Desmyter J. 1992. Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. *Vaccine* 10:S114–S118. [https://doi.org/10.1016/0264-410X\(92\)90561-W](https://doi.org/10.1016/0264-410X(92)90561-W).
 99. Sandman L, Davidson M, Krugman S. 1995. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. *J Infect Dis* 171:S50–S52. https://doi.org/10.1093/infdis/171.Supplement_1.S50.
 100. Hohler T, Groeger-Bicanic G, Hoet B, Stoffel M. 2007. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. *Vaccine* 25:1503–1508. <https://doi.org/10.1016/j.vaccine.2006.10.024>.
 101. Reutter J, Bart PA, Francioli P, Safary A, Frei PC. 1998. Production of

- antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/hepatitis B vaccination in 242 adult volunteers. *J Viral Hepat* 5:205–211. <https://doi.org/10.1046/j.1365-2893.1998.00101.x>.
102. Keefe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, Baumgarten R, Wiese M, Fournneau M, Safary A, Clemens R, Krause DS. 1998. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. *Hepatology* 27:881–886. <https://doi.org/10.1002/hep.510270336>.
 103. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. 2002. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. *J Med Virol* 68:489–493. <https://doi.org/10.1002/jmv.10244>.
 104. Weissman S, Feucht C, Moore BA. 2006. Response to hepatitis A vaccine in HIV-positive patients. *J Viral Hepat* 13:81–86. <https://doi.org/10.1111/j.1365-2893.2005.00658.x>.
 105. Jilg W, Lorbeer B, Schmidt M, Wilske B, Zoulek G, Deinhardt F. 1984. Clinical evaluation of a recombinant hepatitis B vaccine. *Lancet* ii: 1174–1175.
 106. Zeeshan M, Jabeen K, Ali AN, Ali AW, Farooqui SZ, Mehraj V, Zafar A. 2007. Evaluation of immune response to hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study. *BMC Infect Dis* 7:120. <https://doi.org/10.1186/1471-2334-7-120>.
 107. Rendi-Wagner P, Kundi M, Stemberger H, Wiedermann G, Holzmann H, Hofer M, Wiesinger K, Kollaritsch H. 2001. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multi-center travel-clinic based experience. *Vaccine* 19:2055–2060. [https://doi.org/10.1016/S0264-410X\(00\)00410-2](https://doi.org/10.1016/S0264-410X(00)00410-2).
 108. Halota W, Muszyńska M, Pawłowska M. 2002. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. *Med Sci Monit* 8:Cr516–Cr519.
 109. Douvin C, Simon D, Charles MA, Deforges L, Bierling P, Lehner V, Budkowska A, Dhumeaux D. 1997. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. *Diabetes Care* 20:148–151. <https://doi.org/10.2337/diacare.20.2.148>.
 110. Das K, Gupta RK, Kumar V, Kar P. 2003. Immunogenicity and reactogenicity of a recombinant hepatitis B vaccine in subjects over age of forty years and response of a booster dose among nonresponders. *World J Gastroenterol* 9:1132–1134. <https://doi.org/10.3748/wjg.v9.i5.1132>.
 111. West DJ, Snively DB, Zajac BA, Brown GW, Babb CJ. 1990. Development and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine. *Vaccine* 8:111–114. [https://doi.org/10.1016/0264-410X\(90\)90132-6](https://doi.org/10.1016/0264-410X(90)90132-6).
 112. Stevens CE, Szmunn W, Goodman AI, Weseley SA, Fotino M. 1980. Hepatitis B vaccine: immune responses in haemodialysis patients. *Lancet* ii:1211–1213.
 113. Rogan PD, Duguid JK. 1991. Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine. *J Infect* 22:5–9. [https://doi.org/10.1016/0163-4453\(91\)90786-R](https://doi.org/10.1016/0163-4453(91)90786-R).
 114. Fang JW, Lai CL, Chung HT, Wu PC, Lau JY. 1994. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. *J Trop Pediatr* 40:104–107. <https://doi.org/10.1093/tropej/40.2.104>.
 115. Gold Y, Somech R, Mandel D, Peled Y, Reif S. 2003. Decreased immune response to hepatitis B eight years after routine vaccination in Israel. *Acta Paediatr* 92:1158–1162.
 116. Cook IF, Murtagh J. 2002. Comparative immunogenicity of hepatitis B vaccine administered into the ventrogluteal area and anterolateral thigh in infants. *J Paediatr Child Health* 38:393–396. <https://doi.org/10.1046/j.1440-1754.2002.00013.x>.
 117. Keyserling HL, West DJ, Hesley TM, Bosley C, Wiens BL, Calandra GB. 1994. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve or fifteen months of age. *J Pediatr* 125:67–69. [https://doi.org/10.1016/S0022-3476\(94\)70123-7](https://doi.org/10.1016/S0022-3476(94)70123-7).
 118. Nissen TN, Birk NM, Smits G, Jeppesen DL, Stensballe LG, Netea MG, van der Klis F, Benn CS, Pryds O. 2017. Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial. *Vaccine* 35:2084–2091. <https://doi.org/10.1016/j.vaccine.2017.02.048>.
 119. Stark K, Schonfeld C, Barg J, Molz B, Vornwald A, Bienzle U. 1999. Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. *Vaccine* 17:844–850. [https://doi.org/10.1016/S0264-410X\(98\)00269-2](https://doi.org/10.1016/S0264-410X(98)00269-2).
 120. Shaw MM, Leggat PA, Williams ML. 2006. Intradermal pre-exposure rabies immunisation in New Zealand. *Travel Med Infect Dis* 4:29–33. <https://doi.org/10.1016/j.tmaid.2004.11.005>.
 121. Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, Wasi C. 2000. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. *Bull World Health Organ* 78:693–698.
 122. Moore SE, Goldblatt D, Bates CJ, Prentice AM. 2003. Impact of nutritional status on antibody responses to different vaccines in undernourished Gambian children. *Acta Paediatr* 92:170–176.
 123. Kennedy RB, Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Ryan MA, Poland GA. 2009. Gender effects on humoral immune responses to smallpox vaccine. *Vaccine* 27:3319–3323. <https://doi.org/10.1016/j.vaccine.2009.01.086>.
 124. Edwards KM, Burns VE, Allen LM, McPhee JS, Bosch JA, Carroll D, Drayson M, Ring C. 2007. Eccentric exercise as an adjuvant to influenza vaccination in humans. *Brain Behav Immun* 21:209–217. <https://doi.org/10.1016/j.bbi.2006.04.158>.
 125. Cook IF, Barr I, Hartel G, Pond D, Hampson AW. 2006. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. *Vaccine* 24:2395–2402. <https://doi.org/10.1016/j.vaccine.2005.11.057>.
 126. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ. 2008. Half- vs full-dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. *Arch Intern Med* 168:2405–2414. <https://doi.org/10.1001/archinternmed.2008.513>.
 127. Edwards KM, Campbell JP, Ring C, Drayson MT, Bosch JA, Downes C, Long JE, Lumb JA, Merry A, Paine NJ, Burns VE. 2010. Exercise intensity does not influence the efficacy of eccentric exercise as a behavioural adjuvant to vaccination. *Brain Behav Immun* 24:623–630. <https://doi.org/10.1016/j.bbi.2010.01.009>.
 128. Booy R, Khandaker G, Heron LG, Yin J, Doyle B, Tundo KK, Hueston L, Gilbert GL, Macintyre CR, Dwyer DE. 2011. Cross-reacting antibodies against the pandemic (H1N1) 2009 influenza virus in older Australians. *Med J Aust* 194:19–23.
 129. Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, Jeanfreau RJ, Ghosh MR, Kabongo ML, Gittleman C, Karron RA. 2010. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. *J Infect Dis* 202: 1327–1337. <https://doi.org/10.1086/656601>.
 130. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. 2009. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *J Infect Dis* 200:172–180. <https://doi.org/10.1086/599790>.
 131. Furman D, Hejblum BP, Simon N, Jovic V, Dekker CL, Thiebaut R, Tibshirani RJ, Davis MM. 2014. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. *Proc Natl Acad Sci U S A* 111:869–874. <https://doi.org/10.1073/pnas.1321060111>.
 132. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. 2001. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. *J Virol* 75: 12182–12187. <https://doi.org/10.1128/JVI.75.24.12182-12187.2001>.
 133. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdar-dottir B, Hooper A, Graham IL, Edelman R, He F, Nino D, Capellan J, Ruben FL. 2007. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. *Vaccine* 25:7656–7663. <https://doi.org/10.1016/j.vaccine.2007.08.042>.
 134. Hui SL, Chu LW, Peiris JS, Chan KH, Chu D, Tsui W. 2006. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. *Vaccine* 24:5371–5380. <https://doi.org/10.1016/j.vaccine.2006.04.032>.
 135. Miller E, Rush M, Morgan-Capner P, Hutchinson D, Hindle L. 1994. Immunity to diphtheria in adults in England. *BMJ* 308:598. <https://doi.org/10.1136/bmj.308.6928.598b>.
 136. Cohen D, Katzenelson E, Green M, Slepion R, Bercovier H, Danon Y. 1991. Prevalence and correlates of diphtheria toxin antibodies among young adults in Israel. *J Infect* 23:117–121. [https://doi.org/10.1016/0163-4453\(91\)91929-R](https://doi.org/10.1016/0163-4453(91)91929-R).
 137. Mark A, Carlsson RM, Granstrom M. 1999. Subcutaneous versus intra-

- muscular injection for booster DT vaccination of adolescents. *Vaccine* 17:2067–2072. [https://doi.org/10.1016/S0264-410X\(98\)00410-1](https://doi.org/10.1016/S0264-410X(98)00410-1).
138. Björkholm B, Hagberg L, Sundbeck G, Granström M. 2000. Booster effect of low doses of tetanus toxoid in elderly vaccinees. *Eur J Clin Microbiol Infect Dis* 19:195–199.
 139. Edwards KM, Burns VE, Adkins AE, Carroll D, Drayson M, Ring C. 2008. Meningococcal A vaccination response is enhanced by acute stress in men. *Psychosom Med* 70:147–151. <https://doi.org/10.1097/PSY.0b013e318164232e>.
 140. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. 2009. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years. *Clin Infect Dis* 49:1318–1325. <https://doi.org/10.1086/606046>.
 141. Brandão AP, de Oliveira TC, de Cunto Brandileone MC, Gonçalves JE, Yara TI, Simonsen V. 2004. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long-term-care residents in Brazil. *Vaccine* 23:762–768. <https://doi.org/10.1016/j.vaccine.2004.07.024>.
 142. McMahon BJ, Parkinson AJ, Bulkow L, Davidson M, Wainwright K, Wolfe P, Schiffman GS. 1993. Immunogenicity of the 23-valent pneumococcal polysaccharide vaccine in Alaska Native chronic alcoholics compared with nonalcoholic Native and non-Native controls. *Am J Med* 95: 589–594. [https://doi.org/10.1016/0002-9343\(93\)90354-R](https://doi.org/10.1016/0002-9343(93)90354-R).
 143. Cook IF, Pond D, Hartel G. 2007. Comparative reactogenicity and immunogenicity of 23 valent pneumococcal vaccine administered by intramuscular or subcutaneous injection in elderly adults. *Vaccine* 25: 4767–4774. <https://doi.org/10.1016/j.vaccine.2007.04.017>.
 144. Roghmann KJ, Tabloski PA, Bentley DW, Schiffman G. 1987. Immune response of elderly adults to pneumococcus: variation by age, sex, and functional impairment. *J Gerontol* 42:265–270. <https://doi.org/10.1093/geronj/42.3.265>.
 145. Zhang X, Castelli FA, Zhu X, Wu M, Maillere B, BenMohamed L. 2008. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. *Clin Vaccine Immunol* 15: 1436–1449. <https://doi.org/10.1128/CI.00123-08>.
 146. Moore SE, Collinson AC, Fulford AJ, Jilil F, Siegrist CA, Goldblatt D, Hanson LA, Prentice AM. 2006. Effect of month of vaccine administration on antibody responses in The Gambia and Pakistan. *Trop Med Int Health* 11:1529–1541. <https://doi.org/10.1111/j.1365-3156.2006.01700.x>.
 147. Marvell DM, Parish HJ. 1940. Tetanus prophylaxis and circulating antitoxin in men and women. *Br Med J* 2:891–895. <https://doi.org/10.1136/bmj.2.4173.891>.
 148. Lau C, Sisson J. 2002. The effectiveness of intradermal pre-exposure rabies vaccination in an Australian travel medicine clinic. *J Travel Med* 9:285–288.
 149. Green MS, Shohat T, Lerman Y, Cohen D, Slepon R, Duvdevani P, Varsano N, Dagan R, Mendelson E. 1994. Sex differences in the humoral antibody response to live measles vaccine in young adults. *Int J Epidemiol* 23:1078–1081. <https://doi.org/10.1093/ije/23.5.1078>.
 150. Ovsyannikova IG, Jacobson RM, Dhiman N, Vierkant RA, Pankratz VS, Poland GA. 2008. Human leukocyte antigen and cytokine receptor gene polymorphisms associated with heterogeneous immune responses to mumps viral vaccine. *Pediatrics* 121:e1091–e1099. <https://doi.org/10.1542/peds.2007-1575>.
 151. Dominguez A, Plans P, Costa J, Torner N, Cardenas N, Batalla J, Plasencia A, Salleras L. 2006. Seroprevalence of measles, rubella, and mumps antibodies in Catalonia, Spain: results of a cross-sectional study. *Eur J Clin Microbiol Infect Dis* 25:310–317. <https://doi.org/10.1007/s10096-006-0133-z>.
 152. Umlauf BJ, Haralambieva IH, Ovsyannikova IG, Kennedy RB, Pankratz VS, Jacobson RM, Poland GA. 2012. Associations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination. *Viral Immunol* 25:29–36. <https://doi.org/10.1089/vim.2011.0051>.
 153. Mitchell LA. 1999. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation. *J Med Microbiol* 48: 1075–1080. <https://doi.org/10.1099/00222615-48-12-1075>.
 154. Semba RD, Munasir Z, Beeler J, Akib A, Muhilal AS, Sommer A. 1995. Reduced seroconversion to measles in infants given vitamin A with measles vaccination. *Lancet* 345:1330–1332.
 155. Davidkin I, Valle M, Julkunen I. 1995. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. *Vaccine* 13:1617–1622. [https://doi.org/10.1016/0264-410X\(95\)00064-8](https://doi.org/10.1016/0264-410X(95)00064-8).
 156. Ovsyannikova IG, Jacobson RM, Ryan JE, Dhiman N, Vierkant RA, Poland GA. 2007. Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination. *Clin Vaccine Immunol* 14:115–122. <https://doi.org/10.1128/CI.00247-06>.
 157. Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P. 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. *Am J Trop Med Hyg* 66:533–541. <https://doi.org/10.4269/ajtmh.2002.66.533>.
 158. Pfister M, Kursteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L'Age-Stehr J, Kaufhold A, Herzog C. 2005. Immunogenicity and safety of BERNAL-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. *Am J Trop Med Hyg* 72:339–346. <https://doi.org/10.4269/ajtmh.2005.72.339>.
 159. Camacho LAB, Freire MDS, Leal MDL, Aguiar SG, Nascimento JP, Iguchi T, Lozana JDA, Farias RH. 2004. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. *Rev Saude Publica* 38: 671–678. <https://doi.org/10.1590/S0034-89102004000500009>.
 160. Klein SL, Jedlicka A, Pekosz A. 2010. The Xs and Y of immune responses to viral vaccines. *Lancet Infect Dis* 10:338–349. [https://doi.org/10.1016/S1473-3099\(10\)70049-9](https://doi.org/10.1016/S1473-3099(10)70049-9).
 161. Wang LY, Hu CT, Ho TY, Lin HH. 2006. Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area. *Vaccine* 24:4427–4432. <https://doi.org/10.1016/j.vaccine.2005.12.069>.
 162. Asturias EJ, Mayorga C, Caffaro C, Ramirez P, Ram M, Verstraeten T, Clemens R, Halsey NA. 2009. Differences in the immune response to hepatitis B and Haemophilus influenzae type b vaccines in Guatemalan infants by ethnic group and nutritional status. *Vaccine* 27:3650–3654. <https://doi.org/10.1016/j.vaccine.2009.03.035>.
 163. Haralambieva IH, Ovsyannikova IG, Umlauf BJ, Vierkant RA, Shane Pankratz V, Jacobson RM, Poland GA. 2011. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. *Vaccine* 29:8988–8997. <https://doi.org/10.1016/j.vaccine.2011.09.043>.
 164. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Shane Pankratz V, Poland GA. 2013. Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. *Hum Immunol* 74:1263–1266. <https://doi.org/10.1016/j.humimm.2013.06.031>.
 165. Haralambieva IH, Salk HM, Lambert ND, Ovsyannikova IG, Kennedy RB, Warner ND, Pankratz VS, Poland GA. 2014. Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. *Vaccine* 32:1946–1953. <https://doi.org/10.1016/j.vaccine.2014.01.090>.
 166. Hsu LC, Lin SR, Hsu HM, Chao WH, Hsieh JT, Wang MC, Lu CF, Chang YH, Ho MS. 1996. Ethnic differences in immune responses to hepatitis B vaccine. *Am J Epidemiol* 143:718–724. <https://doi.org/10.1093/oxfordjournals.aje.a008805>.
 167. Kennedy RB, Ovsyannikova IG, Haralambieva IH, O'Byrne MM, Jacobson RM, Pankratz VS, Poland GA. 2012. Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes. *Vaccine* 30:2159–2167. <https://doi.org/10.1016/j.vaccine.2012.01.025>.
 168. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz VS. 2001. Twin studies of immunogenicity—determining the genetic contribution to vaccine failure. *Vaccine* 19:2434–2439. [https://doi.org/10.1016/S0264-410X\(00\)00468-0](https://doi.org/10.1016/S0264-410X(00)00468-0).
 169. Newport MJ, Goetghebuer T, Weiss HA, Whittle H, Siegrist CA, Marchant A. 2004. Genetic regulation of immune responses to vaccines in early life. *Genes Immun* 5:122–129. <https://doi.org/10.1038/sj.gene.6364051>.
 170. Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, Vollmar J, Schneider PM, Fimmers R. 2002. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. *Lancet* 360:991–995. [https://doi.org/10.1016/S0140-6736\(02\)11083-X](https://doi.org/10.1016/S0140-6736(02)11083-X).
 171. Yan K, Cai W, Cao F, Sun H, Chen S, Xu R, Wei X, Shi X, Yan W. 2013. Genetic effects have a dominant role on poor responses to infant vaccination to hepatitis B virus. *J Hum Genet* 58:293–297. <https://doi.org/10.1038/jhg.2013.18>.

172. Lee YC, Newport MJ, Goetghebuer T, Siegrist CA, Weiss HA, Pollard AJ, Marchant A. 2006. Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins. *Vaccine* 24: 5335–5340. <https://doi.org/10.1016/j.vaccine.2006.04.021>.
173. Klein NP, Fireman B, Enright A, Ray P, Black S, Dekker CL. 2007. A role for genetics in the immune response to the varicella vaccine. *Pediatr Infect Dis J* 26:300–305. <https://doi.org/10.1097/01.inf.0000257454.74513.07>.
174. McDermott AB, Zuckerman JN, Sabin CA, Marsh SG, Madrigal JA. 1997. Contribution of human leukocyte antigens to the antibody response to hepatitis B vaccination. *Tissue Antigens* 50:8–14. <https://doi.org/10.1111/j.1399-0039.1997.tb02827.x>.
175. Amirzargar AA, Mohseni N, Shokrgozar MA, Arjang Z, Ahmadi N, Yousefi Behzadi M, Amanzadeh A, Shokri F. 2008. HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine. *Iran J Immunol* 5:92–99. <https://doi.org/10.1111/j.1399-0039.1997.tb02827.x>.
176. Qian Y, Zhang L, Liang XM, Hou JL, Luo KX. 2002. Association of immune response to hepatitis B vaccine with HLA-DRB1*02, 07, 09 genes in the population of Han nationality in Guangdong Province. *Di Yi Jun Yi Da Xue Xue Bao* 22:67–69.
177. Höhler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, Starke R, Zepp F, Sängler R, Clemens R, Meyer Zum Büschenfelde KH, Rittner C. 1998. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. *Hum Immunol* 59:212–218. [https://doi.org/10.1016/S0198-8859\(98\)00014-7](https://doi.org/10.1016/S0198-8859(98)00014-7).
178. Lango-Warensjo A, Cardell K, Lindblom B. 1998. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. *Tissue Antigens* 52: 374–380. <https://doi.org/10.1111/j.1399-0039.1998.tb03058.x>.
179. Martinetti M, De Silvestri A, Belloni C, Pasi A, Tinelli C, Pistorio A, Salvaneschi L, Rondini G, Avanzini MA, Cuccia M. 2000. Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond. *Clin Immunol* 97:234–240. <https://doi.org/10.1006/clin.2000.4933>.
180. Martinetti M, Cuccia M, Daielli C, Ambroselli F, Gatti C, Pizzochero C, Belloni C, Orsolini P, Salvaneschi L. 1995. Anti-HBV neonatal immunization with recombinant vaccine. Part II. Molecular basis of the impaired alloreactivity. *Vaccine* 13:555–560. [https://doi.org/10.1016/0264-410X\(94\)00044-N](https://doi.org/10.1016/0264-410X(94)00044-N).
181. Hohler T, Stradmann-Bellinghausen B, Starke R, Sanger R, Victor A, Rittner C, Schneider PM. 2002. C4A deficiency and nonresponse to hepatitis B vaccination. *J Hepatol* 37:387–392. [https://doi.org/10.1016/S0168-8278\(02\)00205-2](https://doi.org/10.1016/S0168-8278(02)00205-2).
182. Davila S, Froeling FE, Tan A, Bonnard C, Boland GJ, Snippe H, Hibberd ML, Seielstad M. 2010. New genetic associations detected in a host response study to hepatitis B vaccine. *Genes Immun* 11:232–238. <https://doi.org/10.1038/gene.2010.1>.
183. Varla-Leftherioti M, Papanicolaou M, Spyropoulou M, Vallindra H, Tsiroyianni P, Tassopoulos N, Kapasouri H, Stavropoulos-Giokas C. 1990. HLA-associated non-responsiveness to hepatitis B vaccine. *Tissue Antigens* 35:60–63. <https://doi.org/10.1111/j.1399-0039.1990.tb01757.x>.
184. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG, Polk BF, Syndman DR, Platt R, Crumpacker CS. 1986. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. *Ann Intern Med* 105:356–360. <https://doi.org/10.7326/0003-4819-105-3-356>.
185. Poland GA, Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Schaid DJ. 2001. Identification of an association between HLA class II alleles and low antibody levels after measles immunization. *Vaccine* 20:430–438. [https://doi.org/10.1016/S0264-410X\(01\)00346-2](https://doi.org/10.1016/S0264-410X(01)00346-2).
186. Gelder CM, Lambkin R, Hart KW, Fleming D, Williams OM, Bunce M, Welsh KI, Marshall SE, Oxford J. 2002. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. *J Infect Dis* 185:114–117. <https://doi.org/10.1086/338014>.
187. Moss AJ, Gaughran FP, Karasu A, Gilbert AS, Mann AJ, Gelder CM, Oxford JS, Stephens HA, Lambkin-Williams R. 2013. Correlation between human leukocyte antigen class II alleles and HAI titers detected post-influenza vaccination. *PLoS One* 8:e71376. <https://doi.org/10.1371/journal.pone.0071376>.
188. Lambert ND, Haralambieva IH, Kennedy RB, Ovsyannikova IG, Pankratz VS, Poland GA. 2015. Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination. *J Infect Dis* 211:898–905. <https://doi.org/10.1093/infdis/jiu553>.
189. Haralambieva IH, Oberg AL, Ovsyannikova IG, Kennedy RB, Grill DE, Middha S, Bot BM, Wang VW, Smith DI, Jacobson RM, Poland GA. 2013. Genome-wide characterization of transcriptional patterns in high and low antibody responders to rubella vaccination. *PLoS One* 8:e62149. <https://doi.org/10.1371/journal.pone.0062149>.
190. Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. 2010. Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity. *PLoS One* 5:e11806. <https://doi.org/10.1371/journal.pone.0011806>.
191. Ovsyannikova IG, Vierkant RA, Pankratz VS, O'Byrne MM, Jacobson RM, Poland GA. 2009. HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. *Vaccine* 27:3349–3358. <https://doi.org/10.1016/j.vaccine.2009.01.080>.
192. Dhiman N, Ovsyannikova IG, Vierkant RA, Ryan JE, Pankratz VS, Jacobson RM, Poland GA. 2008. Associations between SNPs in Toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. *Vaccine* 26: 1731–1736. <https://doi.org/10.1016/j.vaccine.2008.01.017>.
193. Moore CE, Hennig BJ, Perrett KP, Hoe JC, Lee SJ, Fletcher H, Brocklebank D, O'Connor D, Snape MD, Hall AJ, Segal S, Hill AV, Pollard AJ. 2012. Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine. *Clin Vaccine Immunol* 19:295–303. <https://doi.org/10.1128/CVI.05379-11>.
194. Ovsyannikova IG, Dhiman N, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. 2010. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. *Hum Genet* 127:207–221. <https://doi.org/10.1007/s00439-009-0763-1>.
195. Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, Lerumo L, Hughes J, Hussey G, Hawkrigde A, Kaplan G, Hanekom WA, Hawn TR. 2011. Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. *PLoS Pathog* 7:e1002174. <https://doi.org/10.1371/journal.ppat.1002174>.
196. Yucesoy B, Johnson VJ, Fluharty K, Kashon ML, Slaven JE, Wilson NW, Weissman DN, Biagini RE, Germolec DR, Luster MI. 2009. Influence of cytokine gene variations on immunization to childhood vaccines. *Vaccine* 27:6991–6997. <https://doi.org/10.1016/j.vaccine.2009.09.076>.
197. Lin YJ, Lan YC, Huang YC, Lin TH, Huang SM, Lai CC, Liu CS, Lin CW, Chen SY, Tsai FJ. 2012. Effects of cytokine and cytokine receptor gene variation on high anti-HB titers: following up on Taiwan's neonatal hepatitis B immunization program. *Clin Chim Acta* 413:1194–1198. <https://doi.org/10.1016/j.cca.2012.03.004>.
198. Hohler T, Reuss E, Freitag CM, Schneider PM. 2005. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. *Hepatology* 42:72–76. <https://doi.org/10.1002/hep.20740>.
199. Egli A, Santer DM, O'Shea D, Barakat K, Syedbashah M, Vollmer M, Baluch A, Bhat R, Groenendyk J, Joyce MA, Lisboa LF, Thomas BS, Battegay M, Khanna N, Mueller T, Tyrrell DL, Houghton M, Humar A, Kumar D. 2014. IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. *PLoS Pathog* 10:e1004556. <https://doi.org/10.1371/journal.ppat.1004556>.
200. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. 2011. The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms. *Hum Hered* 72:206–223. <https://doi.org/10.1159/000331585>.
201. Dhiman N, Poland GA, Cunningham JM, Jacobson RM, Ovsyannikova IG, Vierkant RA, Wu Y, Pankratz VS. 2007. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. *J Allergy Clin Immunol* 120:666–672. <https://doi.org/10.1016/j.jaci.2007.04.036>.
202. Dhiman N, Ovsyannikova IG, Cunningham JM, Vierkant RA, Kennedy RB, Pankratz VS, Poland GA, Jacobson RM. 2007. Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. *J Infect Dis* 195:21–29. <https://doi.org/10.1086/510596>.
203. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. 2011. Associations between single nucle-

- otide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. *Vaccine* 29:7883–7895. <https://doi.org/10.1016/j.vaccine.2011.08.083>.
204. White SJ, Haralambieva IH, Ovsyannikova IG, Vierkant RA, O'Byrne MM, Poland GA. 2012. Replication of associations between cytokine and cytokine receptor single nucleotide polymorphisms and measles-specific adaptive immunophenotypic extremes. *Hum Immunol* 73:636–640. <https://doi.org/10.1016/j.humimm.2012.03.015>.
 205. Wiertsema SP, Baynam G, Khoo SK, Veenhoven RH, van Heerbeek N, Zhang G, Laing IA, Rijkers GT, Goldblatt J, Sanders EA, Le Souëf PN. 2007. Impact of genetic variants in IL-4, IL-4 RA and IL-13 on the anti-pneumococcal antibody response. *Vaccine* 25:306–313. <https://doi.org/10.1016/j.vaccine.2006.07.024>.
 206. Haralambieva IH, Lambert ND, Ovsyannikova IG, Kennedy RB, Larrabee BR, Pankratz VS, Poland GA. 2014. Associations between single nucleotide polymorphisms in cellular viral receptors and attachment factor-related genes and humoral immunity to rubella vaccination. *PLoS One* 9:e99997. <https://doi.org/10.1371/journal.pone.0099997>.
 207. Pankratz VS, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Poland GA. 2010. Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. *BMC Immunol* 11:48. <https://doi.org/10.1186/1471-2172-11-48>.
 208. Haralambieva IH, Ovsyannikova IG, Dhiman N, Kennedy RB, O'Byrne M, Pankratz VS, Jacobson RM, Poland GA. 2011. Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans. *J Infect Dis* 204:433–441. <https://doi.org/10.1093/infdis/jir268>.
 209. Clifford HD, Richmond P, Khoo SK, Zhang G, Yerkovich ST, Le Souëf PN, Hayden CM. 2011. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. *Vaccine* 29:5407–5413. <https://doi.org/10.1016/j.vaccine.2011.05.068>.
 210. Kennedy RB, Ovsyannikova IG, Haralambieva IH, Lambert ND, Pankratz VS, Poland GA. 2014. Genetic polymorphisms associated with rubella virus-specific cellular immunity following MMR vaccination. *Hum Genet* 133:1407–1417. <https://doi.org/10.1007/s00439-014-1471-z>.
 211. Kennedy RB, Ovsyannikova IG, Haralambieva IH, Lambert ND, Pankratz VS, Poland GA. 2014. Genome-wide SNP associations with rubella-specific cytokine responses in measles-mumps-rubella vaccine recipients. *Immunogenetics* 66:493–499. <https://doi.org/10.1007/s00251-014-0776-3>.
 212. Bucacas KL, Franco LM, Shaw CA, Bray MS, Wells JM, Nino D, Arden N, Quarles JM, Couch RB, Belmont JW. 2011. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. *J Infect Dis* 203:921–929. <https://doi.org/10.1093/infdis/jiq156>.
 213. Cooling L. 2015. Blood groups in infection and host susceptibility. *Clin Microbiol Rev* 28:801–870. <https://doi.org/10.1128/CMR.00109-14>.
 214. Clemens JD, Sack DA, Harris JR, Chakraborty J, Khan MR, Huda S, Ahmed F, Gomes J, Rao MR, Svennerholm AM. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. *J Infect Dis* 159:770–773. <https://doi.org/10.1093/infdis/159.4.770>.
 215. Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, Lesmana MM, Wangsasaputra FF, Pandam SS, Levine MM, O'Hanley PP, Cryz SJ, Simanjuntak CH. 2000. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. *Vaccine* 18:2399–2410. [https://doi.org/10.1016/S0264-410X\(00\)00006-2](https://doi.org/10.1016/S0264-410X(00)00006-2).
 216. Lagos R, Avendano A, Prado V, Horwitz I, Wasserman S, Losonsky G, Cryz S, Jr, Kaper JB, Levine MM. 1995. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. *Infect Immun* 63:707–709.
 217. Ramamurthy T, Wagener D, Chowdhury G, Majumder PP. 2010. A large study on immunological response to a whole-cell killed oral cholera vaccine reveals that there are significant geographical differences in response and that O blood group individuals do not elicit a higher response. *Clin Vaccine Immunol* 17:1232–1237. <https://doi.org/10.1128/CI.00123-10>.
 218. Ahishali E, Boztas G, Akyuz F, Ibrisim D, Poturoglu S, Pinarbasi B, Ozdil S, Mungan Z. 2008. Response to hepatitis B vaccination in patients with celiac disease. *Dig Dis Sci* 53:2156–2159. <https://doi.org/10.1007/s10620-007-0128-3>.
 219. Park SD, Markowitz J, Pettei M, Weinstein T, Sison CP, Swiss SR, Levine J. 2007. Failure to respond to hepatitis B vaccine in children with celiac disease. *J Pediatr Gastroenterol Nutr* 44:431–435. <https://doi.org/10.1097/MPG.0b013e3180320654>.
 220. Nemes E, Lefler E, Szegedi L, Kapitany A, Kovacs JB, Balogh M, Szabados K, Tumpek J, Sipka S, Korponay SIR. 2008. Gluten intake interferes with the humoral immune response to recombinant hepatitis B vaccine in patients with celiac disease. *Pediatrics* 121:e1570–e1576. <https://doi.org/10.1542/peds.2007-2446>.
 221. Balamtekin N, Uslu N, Baysoy G, Saltik-Temizel I, Demir H, Yüce A. 2011. Responsiveness of children with celiac disease to different hepatitis B vaccination protocols. *Turk J Gastroenterol* 22:27–31. <https://doi.org/10.4318/tjg.2011.0152>.
 222. Ertem D, Gonen I, Tanidir C, Ugras M, Yildiz A, Pehlivanoglu E, Eksioğlu-Demiralp E. 2010. The response to hepatitis B vaccine: does it differ in celiac disease? *Eur J Gastroenterol Hepatol* 22:787–793. <https://doi.org/10.1097/MEG.0b013e31832832e9d41>.
 223. Ertekin V, Tosun MS, Selimoglu MA. 2011. Is there need for a new hepatitis B vaccine schedule for children with celiac disease? *Hepat Mon* 11:634–637. <https://doi.org/10.5812/kowsar.1735143X.1129>.
 224. Leonardi S, Spina M, Spicuzza L, Rotolo N, La Rosa M. 2009. Hepatitis B vaccination failure in celiac disease: is there a need to reassess current immunization strategies? *Vaccine* 27:6030–6033. <https://doi.org/10.1016/j.vaccine.2009.07.099>.
 225. Urganci N, Kalyoncu D. 2013. Response to hepatitis A and B vaccination in pediatric patients with celiac disease. *J Pediatr Gastroenterol Nutr* 56:408–411. <https://doi.org/10.1097/MPG.0b013e31827af200>.
 226. Zingone F, Capone P, Tortora R, Rispo A, Morisco F, Caporaso N, Imperatore N, De Stefano G, Iovino P, Ciacci C. 2013. Role of gluten intake at the time of hepatitis B virus vaccination in the immune response of celiac patients. *Clin Vaccine Immunol* 20:660–662. <https://doi.org/10.1128/CI.00729-12>.
 227. Zingone F, Morisco F, Zanetti A, Romano L, Portella G, Capone P, Andreozzi S, Tortora R, Ciacci C. 2011. Long-term antibody persistence and immune memory to hepatitis B virus in adult celiac patients vaccinated as adolescents. *Vaccine* 29:1005–1008. <https://doi.org/10.1016/j.vaccine.2010.11.060>.
 228. Leonardi S, Filippelli M, Manti S, Cuppari C, Salpietro C. 2015. Extending the debate on poor response to hepatitis B virus vaccination in children with celiac disease: which question remains? *Hepat Mon* 15:e30888. <https://doi.org/10.5812/hepatmon.30888>.
 229. Sari S, Dalgic B, Basturk B, Gonen S, Soylemezoglu O. 2011. Immunogenicity of hepatitis A vaccine in children with celiac disease. *J Pediatr Gastroenterol Nutr* 53:532–535. <https://doi.org/10.1097/MPG.0b013e318223b3ed>.
 230. Schappi MG, Meier S, Bel M, Siegrist CA, Posfay-Barbe KM. 2012. Protective antibody responses to influenza A/H1N1/09 vaccination in children with celiac disease. *J Pediatr Gastroenterol Nutr* 54:817–819. <https://doi.org/10.1097/MPG.0b013e318248e7be>.
 231. Filippelli M, Garozzo MT, Capizzi A, Spina M, Manti S, Tardino L, Salpietro C, Leonardi S. 2016. Immune response to hepatitis B virus vaccine in celiac subjects at diagnosis. *World J Hepatol* 8:1105–1109. <https://doi.org/10.4254/wjh.v8.i26.1105>.
 232. Zononi G, Contreas G, Valletta E, Gabrielli O, Mengoli C, Veneri D. 2015. Normal or defective immune response to hepatitis B vaccine in patients with diabetes and celiac disease. *Hum Vaccin Immunother* 11:58–62. <https://doi.org/10.4161/hv.34309>.
 233. Walkiewicz-Jedrzejczak D, Egberg M, Nelson C, Eickoff J. 2014. Evaluation of the response to vaccination with hepatitis B vaccine in pediatric patients diagnosed with celiac disease. *SAGE Open Med* 2:2050312114563346. <https://doi.org/10.1177/2050312114563346>.
 234. Opri R, Veneri D, Mengoli C, Zononi G. 2015. Immune response to hepatitis B vaccine in patients with celiac disease: a systematic review and meta-analysis. *Hum Vaccin Immunother* 11:2800–2805. <https://doi.org/10.1080/21645515.2015.1069448>.
 235. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of nonresponse to hepatitis B vaccine. *N Engl J Med* 321:708–712. <https://doi.org/10.1056/NEJM198909143211103>.
 236. Leonardi S, Longo R, Cotugno M, Tardino L, Spina M, Lionetti E, La Rosa M. 2011. Vaccination and celiac disease: results of a retrospective study. *Minerva Pediatr* 63:363–367.
 237. Elrashidy H, Elbahrawy A, El-Didamony G, Mostafa M, George NM, Elwassief A, Saeid Mohamed AG, Elmestikawy A, Morsy MH, Hashim A, Abdelbasseer MA. 2013. Antibody levels against hepatitis B virus after

- hepatitis B vaccination in Egyptian diabetic children and adolescents. *Hum Vaccin Immunother* 9:2002–2006. <https://doi.org/10.4161/hv.25426>.
238. Leonardi S, Vitaliti G, Garozzo MT, Miraglia del Giudice M, Marseglia G, La Rosa M. 2012. Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. *Hum Vaccin Immunother* 8:448–452. <https://doi.org/10.4161/hv.19107>.
 239. Arslanoğlu I, Cetin B, Işgüven P, Karavuş M. 2002. Anti-HBs response to standard hepatitis B vaccination in children and adolescents with diabetes mellitus. *J Pediatr Endocrinol Metab* 15:389–395.
 240. Eisenhut M, Chesover A, Misquith R, Nathwani N, Walters A. 2016. Antibody responses to immunizations in children with type 1 diabetes mellitus: a case-control study. *Clin Vaccine Immunol* 23:873–877. <https://doi.org/10.1128/CVI.00400-16>.
 241. Dashti AS, Alaei MR, Musavi Z, Faramarzi R, Mansouri F, Nasimfar A. 2015. Serological response to vaccines in children with diabetes. *Roum Arch Microbiol Immunol* 74:112–117.
 242. Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A, Ramos Cuadra A, Ferrer Rios MT, Sousa Martin JM, Sayago Mota M, Giraldez Gallego A, Suárez Artacho G. 2012. Response to vaccination against hepatitis B virus with a schedule of four 40-µg doses in cirrhotic patients evaluated for liver transplantation: factors associated with a response. *Transplant Proc* 44:1499–1501. <https://doi.org/10.1016/j.transproceed.2012.05.071>.
 243. Pozzilli P, Arduini P, Visalli N, Sutherland J, Pezzella M, Galli C, Corradini SG, Biasio L, Gale EA, Andreani D. 1987. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. *Diabetologia* 30:817–819.
 244. Wismans PJ, van Hattum J, de Gast GC, Bouter KP, Diepersloot RJ, Maikoe T, Mudde GC. 1991. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. *J Med Virol* 35:216–222. <https://doi.org/10.1002/jmv.1890350313>.
 245. Bouter KP, Diepersloot RJ, Wismans PJ, Gmelig Meyling FH, Hoekstra JB, Heijntink RA, van Hattum J. 1992. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type 1 diabetes mellitus. *Diabet Med* 9:66–69. <https://doi.org/10.1111/j.1464-5491.1992.tb01717.x>.
 246. Janbakhsh A, Mansouri F, Vaziri S, Sayad B, Afsharian M, Rahimi M, Shahebrahimi K, Salari F. 2013. Effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients. *Caspian J Intern Med* 4:603–606.
 247. McElhaney JE, Pinkoski MJ, Au D, Lechelt KE, Bleackley RC, Meneilly GS. 1996. Helper and cytotoxic T lymphocyte responses to influenza vaccination in healthy compared to diabetic elderly. *Vaccine* 14:539–544. [https://doi.org/10.1016/0264-410X\(95\)00219-Q](https://doi.org/10.1016/0264-410X(95)00219-Q).
 248. McElhaney JE, Garneau H, Camous X, Dupuis G, Pawelec G, Baehl S, Tessier D, Frost EH, Frasca D, Larbi A, Fulop T. 2015. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. *BMJ Open Diabetes Res Care* 3:e000140. <https://doi.org/10.1136/bmjdr-2015-000140>.
 249. Girndt M, Pietsch M, Kohler H. 1995. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. *Am J Kidney Dis* 26:454–460. [https://doi.org/10.1016/0272-6386\(95\)90491-3](https://doi.org/10.1016/0272-6386(95)90491-3).
 250. Kruger S, Seyfarth M, Sack K, Kreft B. 1999. Defective immune response to tetanus toxoid in hemodialysis patients and its association with diphtheria vaccination. *Vaccine* 17:1145–1150. [https://doi.org/10.1016/S0264-410X\(98\)00334-X](https://doi.org/10.1016/S0264-410X(98)00334-X).
 251. Guerin A, Buisson Y, Nutini MT, Saliou P, London G, Marchais S. 1992. Response to vaccination against tetanus in chronic haemodialysed patients. *Nephrol Dial Transplant* 7:323–326. <https://doi.org/10.1093/oxfordjournals.ndt.a092136>.
 252. Buti M, Viladomiu L, Jardi R, Olmos A, Rodriguez JA, Bartolome J, Esteban R, Guardia J. 1992. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. *Am J Nephrol* 12:144–147. <https://doi.org/10.1159/000168436>.
 253. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, Kiai M, Taylor PA, Levin A. 2003. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. *Am J Kidney Dis* 42:1184–1192. <https://doi.org/10.1053/j.ajkd.2003.08.019>.
 254. Kruger S, Muller-Steinhardt M, Kirchner H, Kreft B. 2001. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. *Am J Kidney Dis* 38:1264–1270. <https://doi.org/10.1053/ajkd.2001.29223>.
 255. Ramezani A, Eslamifard A, Banifazl M, Ahmadi F, Maziar S, Razeghi E, Kalantar E, Amirkhani A, Aghakhani A. 2009. Efficacy and long-term immunogenicity of hepatitis B vaccine in haemodialysis patients. *Int J Clin Pract* 63:394–397. <https://doi.org/10.1111/j.1742-1241.2007.01470.x>.
 256. Alavian SM, Tabatabaei SV. 2010. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. *Vaccine* 28:3773–3777. <https://doi.org/10.1016/j.vaccine.2010.03.038>.
 257. Fabrizi F, Dixit V, Martin P, Messa P. 2011. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. *Aliment Pharmacol Ther* 33:815–821. <https://doi.org/10.1111/j.1365-2036.2011.04589.x>.
 258. Ocak S, Eskioçak AF. 2008. The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid. *Nephrology (Carlton)* 13: 487–491. <https://doi.org/10.1111/j.1440-1797.2008.00936.x>.
 259. Chow KM, Law MC, Leung CB, Szeto CC, Li PK. 2006. Antibody response to hepatitis B vaccine in end-stage renal disease patients. *Nephron Clin Pract* 103:c89–c93. <https://doi.org/10.1159/000092016>.
 260. Balloni A, Assael BM, Ghio L, Pedrazzi C, Nebbia G, Gridelli B, Melada E, Panuccio A, Foti M, Barbi M, Luraschi C. 1999. Immunity to poliomyelitis, diphtheria and tetanus in pediatric patients before and after renal or liver transplantation. *Vaccine* 17:2507–2511. [https://doi.org/10.1016/S0264-410X\(99\)00064-X](https://doi.org/10.1016/S0264-410X(99)00064-X).
 261. Lee S. 2000. Hepatitis A vaccination in patients with chronic liver disease in Taiwan. *J Viral Hepat* 7:19–21. <https://doi.org/10.1046/j.1365-2893.2000.00015.x>.
 262. Tsang SW, Sung JJ. 1999. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. *Aliment Pharmacol Ther* 13:1445–1449. <https://doi.org/10.1046/j.1365-2036.1999.00628.x>.
 263. Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S. 2003. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. *Z Gastroenterol* 41:983–990. <https://doi.org/10.1055/s-2003-42929>.
 264. Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, Henderson JM, Carey WD. 1999. Immunogenicity of hepatitis A vaccine in decompensated liver disease. *Am J Gastroenterol* 94:1601–1604. <https://doi.org/10.1111/j.1572-0241.1999.01150.x>.
 265. Ferreira CT, da Silveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. 2003. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. *J Pediatr Gastroenterol Nutr* 37:258–261. <https://doi.org/10.1097/00005176-200309000-00011>.
 266. Baxter D. 2010. Impaired functioning of immune defenses to infection in premature and term infants and their implications for vaccination. *Hum Vaccin* 6:494–505. <https://doi.org/10.4161/hv.6.6.12008>.
 267. Bernbaum JC, Daft A, Anolik R, Samuelson J, Barkin R, Douglas S, Polin R. 1985. Response of preterm infants to diphtheria-tetanus-pertussis immunizations. *J Pediatr* 107:184–188. [https://doi.org/10.1016/S0022-3476\(85\)80122-0](https://doi.org/10.1016/S0022-3476(85)80122-0).
 268. Faldella G, Alessandrini R, Magini GM, Perrone A, Sabatini MR, Vancini A, Salvioli GP. 1998. The preterm infant's antibody response to a combined diphtheria, tetanus, acellular pertussis and hepatitis B vaccine. *Vaccine* 16:1646–1649. [https://doi.org/10.1016/S0264-410X\(98\)00060-7](https://doi.org/10.1016/S0264-410X(98)00060-7).
 269. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, Boceta R, Romero A, Lopez G, Dal-Re R. 2005. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. *Pediatrics* 116:1292–1298. <https://doi.org/10.1542/peds.2004-2336>.
 270. Linder N, Vishne TH, Levin E, Handscher R, Fink-Kremer I, Waldman D, Levine A, Ashkenazi S, Sirota L. 2002. Hepatitis B vaccination: long-term follow-up of the immune response of preterm infants and comparison of two vaccination protocols. *Infection* 30:136–139. <https://doi.org/10.1007/s15010-002-2068-3>.
 271. Berrington JE, Cant AJ, Matthews JN, O'Keeffe M, Spickett GP, Fenton AC. 2006. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. *Pediatrics* 117:e717–e724. <https://doi.org/10.1542/peds.2005-0348>.
 272. Omenaca F, Garcia-Sicilia J, Garcia-Corbeira P, Boceta R, Torres V. 2007.

- Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine. *Pediatrics* 119:e179–e185. <https://doi.org/10.1542/peds.2005-2907>.
273. Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Andrews N, Borrow R, Goldblatt D, Miller E. 2001. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. *J Infect Dis* 184:1617–1620. <https://doi.org/10.1086/324666>.
 274. Munoz A, Salvador A, Brodsky NL, Arbeter AM, Porat R. 1995. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. *Pediatrics* 96:216–219.
 275. Kristensen K, Gyhrs A, Lausen B, Barington T, Heilmann C. 1996. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. *Pediatr Infect Dis J* 15:525–529. <https://doi.org/10.1097/00006454-199606000-00010>.
 276. Ruggeberg JU, Collins C, Clarke P, Johnson N, Sinha R, Everest N, Chang J, Stanford E, Balmer P, Borrow R, Martin S, Robinson MJ, Moxon ER, Pollard AJ, Heath PT. 2007. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. *Vaccine* 25:264–271. <https://doi.org/10.1016/j.vaccine.2006.07.036>.
 277. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. 2002. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. *Pediatr Infect Dis J* 21:182–186. <https://doi.org/10.1097/00006454-200203000-00003>.
 278. Ramsay ME, Miller E, Ashworth LA, Coleman TJ, Rush M, Waight PA. 1995. Adverse events and antibody response to accelerated immunisation in term and preterm infants. *Arch Dis Child* 72:230–232. <https://doi.org/10.1136/adc.72.3.230>.
 279. Schloesser RL, Fischer D, Otto W, Rettwitz-Volk W, Herden P, Zielen S. 1999. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. *Pediatrics* 103:e60. <https://doi.org/10.1542/peds.103.5.e60>.
 280. Slack MH, Schapira D, Thwaites RJ, Schapira C, Bamber J, Burrage M, Southern J, Andrews N, Miller E. 2004. Acellular pertussis vaccine given by accelerated schedule: response of preterm infants. *Arch Dis Child Fetal Neonatal Ed* 89:F57–F60. <https://doi.org/10.1136/fn.89.1.F57>.
 281. D'Angio CT, Maniscalco WM, Pichichero ME. 1995. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. *Pediatrics* 96:18–22.
 282. Esposito S, Corbellini B, Bosis S, Pugni L, Tremolati E, Tagliabue C, Toneatto D, Mosca F, Principi N. 2007. Immunogenicity, safety and tolerability of meningococcal C CRM197 conjugate vaccine administered 3, 5 and 11 months post-natally to pre- and full-term infants. *Vaccine* 25:4889–4894. <https://doi.org/10.1016/j.vaccine.2007.04.018>.
 283. Omeñaca F, García-Sicilia J, Boceta R, Sistiaga-Hernando A, García-Corbeira P. 2007. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely. *Pediatr Infect Dis J* 26:824–829. <https://doi.org/10.1097/INF.0b013e318124a9c8>.
 284. Esposito S, Faldella G, Giammanco A, Bosis S, Friscia O, Clerici M, Principi N. 2002. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. *Vaccine* 20:2928–2932. [https://doi.org/10.1016/S0264-410X\(02\)00230-X](https://doi.org/10.1016/S0264-410X(02)00230-X).
 285. Vazquez L, Garcia F, Ruttimann R, Coconier G, Jacquet JM, Schuerman L. 2008. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants. *Acta Paediatr* 97:1243–1249. <https://doi.org/10.1111/j.1651-2227.2008.00884.x>.
 286. Han K, Shao X, Zheng H, Wu C, Zhu J, Zheng X, Zhang Y. 2012. Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. *Hum Vaccin Immunother* 8:1845–1849. <https://doi.org/10.4161/hv.21818>.
 287. Halsey NA, Boulos R, Mode F, Andre J, Bowman L, Yaeger RG, Toureau S, Rohde J, Boulos C. 1985. Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses. *N Engl J Med* 313:544–549. <https://doi.org/10.1056/NEJM198508293130904>.
 288. Moore SE, Jalil F, Ashraf R, Szu SC, Prentice AM, Hanson LA. 2004. Birth weight predicts response to vaccination in adults born in an urban slum in Lahore, Pakistan. *Am J Clin Nutr* 80:453–459. <https://doi.org/10.1093/ajcn/80.2.453>.
 289. Pickering LK, Granoff DM, Erickson JR, Masor ML, Cordle CT, Schaller JP, Winship TR, Paule CL, Hilty MD. 1998. Modulation of the immune system by human milk and infant formula containing nucleotides. *Pediatrics* 101:242–249. <https://doi.org/10.1542/peds.101.2.242>.
 290. Pabst HF, Spady DW. 1990. Effect of breast-feeding on antibody response to conjugate vaccine. *Lancet* 336:269–270. [https://doi.org/10.1016/0140-6736\(90\)91802-H](https://doi.org/10.1016/0140-6736(90)91802-H).
 291. Silfverdal SA, Bodin L, Ulanova M, Hahn-Zoric M, Hanson LA, Olcen P. 2002. Long term enhancement of the IgG2 antibody response to Haemophilus influenzae type b by breast-feeding. *Pediatr Infect Dis J* 21:816–821. <https://doi.org/10.1097/01.inf.0000027668.74570.96>.
 292. Hahn-Zoric M, Fulconis F, Minoli I, Moro G, Carlsson B, Böttiger M, Räihä N, Hanson LA. 1990. Antibody responses to parenteral and oral vaccines are impaired by conventional and low protein formulas as compared to breast-feeding. *Acta Paediatr Scand* 79:1137–1142.
 293. Pichichero ME. 1990. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. *J Infect Dis* 162:753–755. <https://doi.org/10.1093/infdis/162.3.753>.
 294. Glass RI, Ing DJ, Stoll BJ, Ing RT. 1991. Immune response to rotavirus vaccines among breast-fed and nonbreast-fed children. *Adv Exp Med Biol* 310:249–254. https://doi.org/10.1007/978-1-4615-3838-7_33.
 295. Chilengi R, Simuyandi M, Beach L, Mwila K, Becker-Dreps S, Emperador DM, Velasquez DE, Bosomprah S, Jiang B. 2016. Association of maternal immunity with rotavirus vaccine immunogenicity in Zambian infants. *PLoS One* 11:e0150100. <https://doi.org/10.1371/journal.pone.0150100>.
 296. Moon SS, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, Baek LJ, Parashar U, Glass RI, Jiang B. 2010. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. *Pediatr Infect Dis J* 29:919–923. <https://doi.org/10.1097/INF.0b013e3181e232ea>.
 297. Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, Jiang B, McNeal MM, Steele D, Bhutta Z, Zaidi AK. 2015. Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial. *PLoS One* 10:e0127622. <https://doi.org/10.1371/journal.pone.0127622>.
 298. Rongsen-Chandola T, Strand TA, Goyal N, Flem E, Rathore SS, Arya A, Winje BA, Lazarus R, Shanmugasundaram E, Babji S, Sommerfelt H, Vainio K, Kang G, Bhandari N. 2014. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. *Vaccine* 32:A134–A139. <https://doi.org/10.1016/j.vaccine.2014.04.078>.
 299. Groome MJ, Moon SS, Velasquez D, Jones S, Koen A, van Niekerk N, Jiang B, Parashar UD, Madhi SA. 2014. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. *Bull World Health Organ* 92:238–245. <https://doi.org/10.2471/BLT.13.128066>.
 300. de Francisco A, Hall AJ, Unicomb L, Chakraborty J, Yunus M, Sack RB. 1998. Maternal measles antibody decay in rural Bangladeshi infants—implications for vaccination schedules. *Vaccine* 16:564–568. [https://doi.org/10.1016/S0264-410X\(97\)00245-4](https://doi.org/10.1016/S0264-410X(97)00245-4).
 301. Markowitz LE, Albrecht P, Rhodes P, Demonteverde R, Swint E, Maes EF, Powell C, Patriarca PA. 1996. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. *Pediatrics* 97:53–58.
 302. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. 2010. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. *BMJ* 340:c1626. <https://doi.org/10.1136/bmj.c1626>.
 303. Derya A, Necmi A, Emre A, Akgun Y. 2005. Decline of maternal hepatitis A antibodies during the first 2 years of life in infants born in Turkey. *Am J Trop Med Hyg* 73:457–459. <https://doi.org/10.4269/ajtmh.2005.73.457>.
 304. Lieberman JM, Chang SJ, Partridge S, Hollister JC, Kaplan KM, Jensen EH, Kuter B, Ward JI. 2002. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. *Pediatr Infect Dis J* 21:347–348. <https://doi.org/10.1097/00006454-200204000-00017>.
 305. Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, Lambert SB, Margolis HS. 2004. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. *J Pediatr* 144:327–332. <https://doi.org/10.1016/j.jpeds.2003.11.030>.
 306. Lieberman JM, Marcy M, Partridge S, Ward JI. 1998. Evaluation of a HA vaccine in infants: effect of maternal antibodies on antibody response,

- [abstract]. In Program and abstracts of the 36th annual meeting of the Infectious Diseases Society of America, Denver, CO. Infectious Diseases Society of America, Alexandria, VA.
307. Moon SS, Groome MJ, Velasquez DE, Parashar UD, Jones S, Koen A, van Niekerk N, Jiang B, Madhi SA. 2016. Pre vaccination rotavirus serum IgG and IgA are associated with lower immunogenicity of live, oral human rotavirus vaccine in South African infants. *Clin Infect Dis* 62:157–165. <https://doi.org/10.1093/cid/civ828>.
 308. Becker-Dreps S, Vilchez S, Velasquez D, Moon SS, Hudgens MG, Zambrana LE, Jiang B. 2015. Rotavirus-specific IgG antibodies from mothers' serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. *Pediatr Infect Dis J* 34:115–116. <https://doi.org/10.1097/INF.0000000000000481>.
 309. Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vratil S. 2014. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. *Vaccine* 32:651–656. <https://doi.org/10.1016/j.vaccine.2013.12.017>.
 310. Moon SS, Tate JE, Ray P, Dennehy PH, Archary D, Coutoudis A, Bland R, Newell ML, Glass RI, Parashar U, Jiang B. 2013. Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. *Pediatr Infect Dis J* 32:863–870. <https://doi.org/10.1097/INF.0b013e318290646d>.
 311. de Voer RM, van der Klis FR, Nootgedaght JE, Versteegh FG, van Huisseling JC, van Rooijen DM, Sanders EA, Berbers GA. 2009. Seroprevalence and placental transportation of maternal antibodies specific for *Neisseria meningitidis* serogroup C, *Haemophilus influenzae* type B, diphtheria, tetanus, and pertussis. *Clin Infect Dis* 49:58–64. <https://doi.org/10.1086/599347>.
 312. Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combesure C, Othenin-Girard V, Chilin A, Petre J, de Tejada BM, Siegrist CA. 2016. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. *Clin Infect Dis* 62:829–836. <https://doi.org/10.1093/cid/ciw027>.
 313. Malhotra I, McKibben M, Mungai P, McKibben E, Wang X, Sutherland LJ, Muchiri EM, King CH, King CL, LaBeaud AD. 2015. Effect of antenatal parasitic infections on anti-vaccine IgG levels in children: a prospective birth cohort study in Kenya. *PLoS Negl Trop Dis* 9:e0003466. <https://doi.org/10.1371/journal.pntd.0003466>.
 314. Nash S, Mentzer AJ, Lule SA, Kizito D, Smits G, van der Klis FR, Elliott AM. 2017. The impact of prenatal exposure to parasitic infections and to anthelmintic treatment on antibody responses to routine immunisations given in infancy: secondary analysis of a randomised controlled trial. *PLoS Negl Trop Dis* 11:e0005213. <https://doi.org/10.1371/journal.pntd.0005213>.
 315. Bassily S, Kotkat A, Hyams KC, Youssef FG, El-Masry NA, Arthur R, Imam IZ, Brown FM. 1997. Immunogenicity of recombinant hepatitis B vaccine among infants of mothers with active schistosomiasis. *Am J Trop Med Hyg* 57:197–199. <https://doi.org/10.4269/ajtmh.1997.57.197>.
 316. Brabin BJ, Nagel J, Hagenaars AM, Ruitenberg E, van Tilborgh AM. 1984. The influence of malaria and gestation on the immune response to one and two doses of adsorbed tetanus toxoid in pregnancy. *Bull World Health Organ* 62:919–930.
 317. Ghaffar YA, Kamel M, el-Sobky M, Bahnasy R, Strickland GT. 1989. Response to hepatitis B vaccine in infants born to mothers with schistosomiasis. *Lancet* ii:272.
 318. Kizito D, Twayongyere R, Namatovu A, Webb EL, Muhangi L, Lule SA, Bukenya H, Cose S, Elliott AM. 2013. Factors affecting the infant antibody response to measles immunisation in Entebbe-Uganda. *BMC Public Health* 13:619. <https://doi.org/10.1186/1471-2458-13-619>.
 319. Elliott AM, Mawa PA, Webb EL, Nampijja M, Lyadda N, Bukusuba J, Kizza M, Namujju PB, Nabulime J, Ndibazza J, Muwanga M, Whitworth JA. 2010. Effects of maternal and infant co-infections, and of maternal immunisation, on the infant response to BCG and tetanus immunisation. *Vaccine* 29:247–255. <https://doi.org/10.1016/j.vaccine.2010.10.047>.
 320. Malhotra I, Mungai P, Wamachi A, Kioko J, Ouma JH, Kazura JW, King CL. 1999. Helminth- and bacillus Calmette-Guérin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. *J Immunol* 162:6843–6848.
 321. Dauby N, Alonso-Vega C, Suarez E, Flores A, Hermann E, Cordova M, Tellez T, Torrico F, Truysens C, Carlier Y. 2009. Maternal infection with *Trypanosoma cruzi* and congenital Chagas disease induce a trend to a type 1 polarization of infant immune responses to vaccines. *PLoS Negl Trop Dis* 3:e571. <https://doi.org/10.1371/journal.pntd.0000571>.
 322. Djuardi Y, Sartono E, Wibowo H, Supali T, Yazdanbakhsh M. 2010. A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses. *PLoS One* 5:e14066. <https://doi.org/10.1371/journal.pone.0014066>.
 323. Lule SA, Mawa PA, Nkurunungi G, Nampijja M, Kizito D, Akello F, Muhangi L, Elliott AM, Webb EL. 2015. Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five year olds BCG-immunised at birth in Entebbe, Uganda. *Vaccine* 33:796–804. <https://doi.org/10.1016/j.vaccine.2014.12.015>.
 324. Webb EL, Mawa PA, Ndibazza J, Kizito D, Namatovu A, Kyosiimire-Lugemwa J, Nanteza B, Nampijja M, Muhangi L, Woodburn PW, Akurut H, Mpairwe H, Akello M, Lyadda N, Bukusuba J, Kihembo M, Kizza M, Kizindo R, Nabulime J, Ameke C, Namujju PB, Twayongyere R, Muwanga M, Whitworth JA, Elliott AM. 2011. Effect of single-dose antenatal treatment during pregnancy on an infant's response to immunisation and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial. *Lancet* 377:52–62. [https://doi.org/10.1016/S0140-6736\(10\)61457-2](https://doi.org/10.1016/S0140-6736(10)61457-2).
 325. Miles DJ, van der Sande M, Crozier S, Ojuola O, Palmero MS, Sanneh M, Touray ES, Rowland-Jones S, Whittle H, Ota M, Marchant A. 2008. Effects of antenatal and postnatal environments on CD4 T-cell responses to *Mycobacterium bovis* BCG in healthy infants in the Gambia. *Clin Vaccine Immunol* 15:995–1002. <https://doi.org/10.1128/CVI.00037-08>.
 326. Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, Dickson D, van der Klis F, Weldon W, Steven Oberste M, Ma JZ, Petri WA, Jr. 2015. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. *EBioMedicine* 2:1759–1766. <https://doi.org/10.1016/j.ebiom.2015.09.036>.
 327. Levine OS, Granoff DM, Lagos R, Fritzell B, Levine MM. 1997. Factors associated with superior antibody responses to a single dose of *Haemophilus influenzae* type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. *Vaccine* 15:325–328. [https://doi.org/10.1016/S0264-410X\(96\)00161-2](https://doi.org/10.1016/S0264-410X(96)00161-2).
 328. Ndikuyezu A, Munoz A, Stewart J, Modlin J, Heymann D, Herrmann KL, Polk BF. 1988. Immunogenicity and safety of measles vaccine in ill African children. *Int J Epidemiol* 17:448–455. <https://doi.org/10.1093/ije/17.2.448>.
 329. Cilla G, Pena B, Marimon JM, Perez-Trallero E. 1996. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. *Vaccine* 14:492–494. [https://doi.org/10.1016/0264-410X\(95\)00234-R](https://doi.org/10.1016/0264-410X(95)00234-R).
 330. Krober MS, Stracener CE, Bass JW. 1991. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds. *JAMA* 265:2095–2096. <https://doi.org/10.1001/jama.1991.03460160073032>.
 331. Dennehy PH, Saracen CL, Peter G. 1994. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. *Pediatrics* 94:514–516.
 332. Ratnam S, West R, Gadag V. 1995. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. *J Pediatr* 127:432–434. [https://doi.org/10.1016/S0022-3476\(95\)70077-3](https://doi.org/10.1016/S0022-3476(95)70077-3).
 333. Usen S, Milligan P, Etchevenaux C, Greenwood B, Mulholland K. 2000. Effect of fever on the serum antibody response of Gambian children to *Haemophilus influenzae* type b conjugate vaccine. *Pediatr Infect Dis J* 19:444–449. <https://doi.org/10.1097/00006454-200005000-00010>.
 334. Parker EP, Kampmann B, Kang G, Grassly NC. 2014. Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. *J Infect Dis* 210:853–864. <https://doi.org/10.1093/infdis/jiu182>.
 335. Haque R, Snider C, Liu Y, Ma JZ, Liu L, Nayak U, Mychaleckyj JC, Korpe P, Mondal D, Kabir M, Alam M, Pallansch M, Oberste MS, Weldon W, Kirkpatrick BD, Petri WA, Jr. 2014. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. *Vaccine* 32:478–482. <https://doi.org/10.1016/j.vaccine.2013.11.056>.
 336. Holder B, Miles DJ, Kaye S, Crozier S, Mohammed NI, Duah NO, Roberts E, Ojuola O, Palmero MS, Touray ES, Waight P, Cotten M, Rowland-Jones S, van der Sande M, Whittle H. 2010. Epstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infants. *PLoS One* 5:e14013. <https://doi.org/10.1371/journal.pone.0014013>.
 337. Miles DJ, Sanneh M, Holder B, Crozier S, Nyamweya S, Touray ES,

- Palmero MS, Zaman SM, Rowland-Jones S, van der Sande M, Whittle H. 2008. Cytomegalovirus infection induces T-cell differentiation without impairing antigen-specific responses in Gambian infants. *Immunology* 124:388–400. <https://doi.org/10.1111/j.1365-2567.2007.02787.x>.
338. Furman D, Jojic V, Sharma S, Shen-Orr SS, Angel CJ, Onengut-Gumuscu S, Kidd BA, Maecker HT, Concannon P, Dekker CL, Thomas PG, Davis MM. 2015. Cytomegalovirus infection enhances the immune response to influenza. *Sci Transl Med* 7:281ra243.
339. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. 2015. Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine. *Vaccine* 33:1433–1439. <https://doi.org/10.1016/j.vaccine.2015.01.071>.
340. Trzonkowski P, Myśliwski J, Szmit E, Wieckiewicz J, Lukaszuk K, Brydak LB, Machala M, Myśliwski A. 2003. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination—an impact of immunosenescence. *Vaccine* 21:3826–3836. [https://doi.org/10.1016/S0264-610X\(03\)00309-8](https://doi.org/10.1016/S0264-610X(03)00309-8).
341. Enani S, Przemska-Kosicka A, Childs CE, Maidens C, Dong H, Conterno L, Tuohy K, Todd S, Gosney M, Yaqoob P. 2018. Impact of ageing and a synbiotic on the immune response to seasonal influenza vaccination; a randomised controlled trial. *Clin Nutr* 37:443–451. <https://doi.org/10.1016/j.clnu.2017.01.011>.
342. Gouvêa ADFB, Pinto MIDM, Miyamoto M, Machado DM, Pessoa SD, Carmo FBD, Beltrão SCDV, Succu RCDM. 2015. Persistence of hepatitis A virus antibodies after primary immunization and response to revaccination in children and adolescents with perinatal HIV exposure. *Rev Paul Pediatr* 33:142–149. <https://doi.org/10.1016/j.rpped.2014.09.005>.
343. Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, Safary A. 1997. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. *J Med Virol* 52:215–218. [https://doi.org/10.1002/\(SICI\)1096-9071\(199706\)52:2<215::AID-JMV16>3.0.CO;2-J](https://doi.org/10.1002/(SICI)1096-9071(199706)52:2<215::AID-JMV16>3.0.CO;2-J).
344. Jabłonowska E, Kuydowicz J. 2014. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. *Int J STD AIDS* 25:745–750. <https://doi.org/10.1177/0956462413518902>.
345. Williamson WA, Greenwood BM. 1978. Impairment of the immune response to vaccination after acute malaria. *Lancet* i:1328–1329.
346. Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. 1972. Immunosuppression in children with malaria. *Lancet* i:169–172.
347. McGregor IA, Barr M. 1962. Antibody response to tetanus toxoid inoculation in malarious and non-malarious Gambian children. *Trans R Soc Trop Med Hyg* 56:364–367. [https://doi.org/10.1016/0035-9203\(62\)90005-6](https://doi.org/10.1016/0035-9203(62)90005-6).
348. Greenwood AM, Greenwood BM, Bradley AK, Ball PAJ, Gilles HM. 1981. Enhancement of the immune response to meningococcal polysaccharide vaccine in a malaria endemic area by administration of chloroquine. *Ann Trop Med Parasitol* 75:261–263. <https://doi.org/10.1080/00034983.1981.11687439>.
349. Simondon F, Preziosi MP, Pinchinat S, Yam A, Chabirand L, Wassilak S, Pines E, Trape JF, Salomon H, Hoffenbach A. 1999. Randomised study of the possible adjuvant effect of BCG vaccine on the immunogenicity of diphtheria-tetanus-acellular pertussis vaccine in Senegalese infants. *Eur J Clin Microbiol Infect Dis* 18:23–29. <https://doi.org/10.1007/s100960050221>.
350. Corrigan RJ. 1988. Asymptomatic malaria parasitaemia and the antibody response to tetanus toxoid vaccination. *Trans R Soc Trop Med Hyg* 82:540–541. [https://doi.org/10.1016/0035-9203\(88\)90497-X](https://doi.org/10.1016/0035-9203(88)90497-X).
351. van Riet E, Retra K, Adegnik AA, Jol-van der Zijde CM, Uh HW, Lell B, Issifou S, Kremsner PG, Yazdanbakhsh M, van Tol MJ, Hartgers FC. 2008. Cellular and humoral responses to tetanus vaccination in Gabonese children. *Vaccine* 26:3690–3695. <https://doi.org/10.1016/j.vaccine.2008.04.067>.
352. Rosen JB, Breman JG, Manclark CR, Meade BD, Collins WE, Lobel HO, Saliou P, Roberts JM, Campaore P, Miller MA. 2005. Malaria chemoprophylaxis and the serologic response to measles and diphtheria-tetanus-whole-cell pertussis vaccines. *Malar J* 4:53. <https://doi.org/10.1186/1475-2875-4-53>.
353. Bradley-Moore AM, Greenwood BM, Bradley AK, Bartlett A, Bidwell DE, Voller A, Craske J, Kirkwood BR, Gilles HM. 1985. Malaria chemoprophylaxis with chloroquine in young Nigerian children. II. Effect on the immune response to vaccination. *Ann Trop Med Parasitol* 79:563–573. <https://doi.org/10.1080/00034983.1985.11811963>.
354. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P. 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. *Lancet* 357:1471–1477. [https://doi.org/10.1016/S0140-6736\(00\)04643-2](https://doi.org/10.1016/S0140-6736(00)04643-2).
355. Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Ronn AM, Theander TG, Bygbjerg IC. 2003. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: a randomised placebo-controlled trial. *Lancet* 361:1853–1860. [https://doi.org/10.1016/S0140-6736\(03\)13504-0](https://doi.org/10.1016/S0140-6736(03)13504-0).
356. Monjour L, Bourdillon F, Froment A, Daniel-Ribeiro C, Tirard S, Datry A, Chastang C, Tselentis Y, Gentilini M. 1985. Measles vaccination in the Sudan-Sahel region of Africa. Absence of the immunodepressive effect of malaria. *Pathol Biol (Paris)* 33:232–235.
357. Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, Lell B, Que JU, Miller GB, Kremsner PG. 2002. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. *Clin Infect Dis* 35:1147–1154. <https://doi.org/10.1086/342908>.
358. Monjour L, Bourdillon F, Korinek AM, Aubonet-Laignel A, Brousse G, Gentilini M, Bayard P, Ballet JJ. 1988. Humoral immunity, 5 years after anti-tetanus vaccination, in a group of malaria-infected and malnourished African children. *Pathol Biol (Paris)* 36:235–239.
359. Monjour L, Bourdillon F, Schlumberger M, Fayet MT, Michon C, Ballet JJ, Gouba E, Gentilini M. 1982. Humoral and cellular immunity following antitetanus vaccination in malnourished and malaria-induced African children. 1. Study of the antitetanus antibody response. *Bull World Health Organ* 60:589–596.
360. Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. 1998. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. *J Infect Dis* 178:1133–1138. <https://doi.org/10.1086/515661>.
361. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. 1996. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with *Schistosoma mansoni*. *J Infect Dis* 173:269–272. <https://doi.org/10.1093/infdis/173.1.269>.
362. Cooper PJ, Chico M, Sandoval C, Espinel I, Guevara A, Levine MM, Griffin GE, Nutman TB. 2001. Human infection with *Ascaris lumbricoides* is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. *Infect Immun* 69:1574–1580. <https://doi.org/10.1128/IAI.69.3.1574-1580.2001>.
363. Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, Sridhara R, Aguilar M, Guevara A, Guderian RH, Levine MM, Griffin GE, Nutman TB. 2000. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. *J Infect Dis* 182:1199–1206. <https://doi.org/10.1086/315837>.
364. Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. 2001. Effect of deworming on human T cell responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-Guérin (BCG) vaccination. *Clin Exp Immunol* 123:219–225. <https://doi.org/10.1046/j.1365-2249.2001.01446.x>.
365. Elias D, Britton S, Aseffa A, Engers H, Akuffo H. 2008. Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF- β production. *Vaccine* 26:3897–3902. <https://doi.org/10.1016/j.vaccine.2008.04.083>.
366. Woo PC, Tsoi HW, Wong LP, Leung HC, Yuen KY. 1999. Antibiotics modulate vaccine-induced humoral immune response. *Clin Diagn Lab Immunol* 6:832–837.
367. Smith RA, Thedford TR, Espe BH, Woodson PD, Burrows GE. 1983. Effect of oxytetracycline administration on antibody response to *Brucella abortus* vaccination in calves. *J Am Vet Med Assoc* 183:70–71.
368. Zimmermann P, Curtis N. 2018. The influence of probiotics on vaccine responses—a systematic review. *Vaccine* 36:207–213. <https://doi.org/10.1016/j.vaccine.2017.08.069>.
369. West CE, Gothefors L, Granstrom M, Kayhty H, Hammarstrom ML, Hernell O. 2007. Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. *Pediatr Allergy Immunol* 19:53–60. <https://doi.org/10.1111/j.1399-3038.2007.00583.x>.
370. Redondo N, Nova E, Gheorghe A, Diaz LE, Hernandez A, Marcos A. 2017. Evaluation of *Lactobacillus coryniformis* CECT5711 strain as a coadju-

- vant in a vaccination process: a randomised clinical trial in healthy adults. *Nutr Metab (Lond)* 14:2. <https://doi.org/10.1186/s12986-016-0154-2>.
371. Kukkonen K, Nieminen T, Poussa T, Savilahti E, Kuitunen M. 2006. Effect of probiotics on vaccine antibody responses in infancy—a randomized placebo-controlled double-blind trial. *Pediatr Allergy Immunol* 17: 416–421. <https://doi.org/10.1111/j.1399-3038.2006.00420.x>.
 372. Mullie C, Yazourh A, Thibault H, Odou MF, Singer E, Kalach N, Kremp O, Romond MB. 2004. Increased poliovirus-specific intestinal antibody response coincides with promotion of *Bifidobacterium longum*-infantis and *Bifidobacterium breve* in infants: a randomized, double-blind, placebo-controlled trial. *Pediatr Res* 56:791–795. <https://doi.org/10.1203/01.PDR.0000141955.47550.A0>.
 373. Paineau D, Carcano D, Leyer G, Darquy S, Alyanakian MA, Simoneau G, Bergmann JF, Brassart D, Bornet F, Ouwehand AC. 2008. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. *FEMS Immunol Med Microbiol* 53:107–113. <https://doi.org/10.1111/j.1574-695X.2008.00413.x>.
 374. Isolauri E, Joensuu J, Suomalainen H, Luomala M, Vesikari T. 1995. Improved immunogenicity of oral D × RRV reassortant rotavirus vaccine by *Lactobacillus casei* GG. *Vaccine* 13:310–312. [https://doi.org/10.1016/0264-410X\(95\)93319-5](https://doi.org/10.1016/0264-410X(95)93319-5).
 375. de Vrese M, Rautenberg P, Laue C, Koopmans M, Herremans T, Schrezenmeier J. 2005. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. *Eur J Nutr* 44:406–413. <https://doi.org/10.1007/s00394-004-0541-8>.
 376. Bosch M, Mendez M, Perez M, Farran A, Fuentes MC, Cune J. 2012. *Lactobacillus plantarum* CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. *Nutr Hosp* 27:504–509. <https://doi.org/10.1590/S0212-16112012000200023>.
 377. Rizzardini G, Eskesen D, Calder PC, Capetti A, Jespersen L, Clerici M. 2012. Evaluation of the immune benefits of two probiotic strains *Bifidobacterium animalis* ssp. *lactis*, BB-12(R) and *Lactobacillus paracasei* ssp. *paracasei*, L. *casei* 431(R) in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. *Br J Nutr* 107: 876–884. <https://doi.org/10.1017/S000711451100420X>.
 378. Davidson LE, Fiorino AM, Snyderman DR, Hibberd PL. 2011. *Lactobacillus* GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. *Eur J Clin Nutr* 65:501–507. <https://doi.org/10.1038/ejcn.2010.289>.
 379. Boge T, Remigy M, Vaudaine S, Tanguy J, Bourdet-Sicard R, van der Werf S. 2009. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. *Vaccine* 27:5677–5684. <https://doi.org/10.1016/j.vaccine.2009.06.094>.
 380. Olivares M, Díaz-Ropero MP, Sierra S, Lara-Villoslada F, Fonollá J, Navas M, Rodríguez JM, Xaus J. 2007. Oral intake of *Lactobacillus fermentum* CECT5716 enhances the effects of influenza vaccination. *Nutrition* 23: 254–260. <https://doi.org/10.1016/j.nut.2007.01.004>.
 381. Bunout D, Barrera G, Hirsch S, Gattas V, de la Maza MP, Haschke F, Steenhout P, Klassen P, Hager C, Avendaño M, Petermann M, Muñoz C. 2004. Effects of a nutritional supplement on the immune response and cytokine production in free-living Chilean elderly. *JPEN J Parenter Enteral Nutr* 28:348–354. <https://doi.org/10.1177/0148607104028005348>.
 382. Przemska-Kosicka A, Childs CE, Enani S, Maidens C, Dong H, Dayel IB, Tuohy K, Todd S, Gosney MA, Yaqoob P. 2016. Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence. *Immun Ageing* 13:6. <https://doi.org/10.1186/s12979-016-0061-4>.
 383. Bunout D, Hirsch S, Pia de la Maza M, Muñoz C, Haschke F, Steenhout P, Klassen P, Barrera G, Gattas V, Petermann M. 2002. Effects of prebiotics on the immune response to vaccination in the elderly. *JPEN J Parenter Enteral Nutr* 26:372–376. <https://doi.org/10.1177/0148607102026006372>.
 384. Zimmermann P, Curtis N. 2018. The influence of the intestinal microbiome on vaccine responses. *Vaccine* 36:4433–4439. <https://doi.org/10.1016/j.vaccine.2018.04.066>.
 385. Huda MN, Lewis Z, Kalanetra KM, Rashid M, Ahmad SM, Raqib R, Qadri F, Underwood MA, Mills DA, Stephensen CB. 2014. Stool microbiota and vaccine responses of infants. *Pediatrics* 134:e362–e372. <https://doi.org/10.1542/peds.2013-3937>.
 386. Harris VC, Armah G, Fuentes S, Korpela KE, Parashar U, Victor JC, Tate J, de Weerth C, Giaquinto C, Wiersinga WJ, Lewis KD, de Vos WM. 2017. Significant correlation between the infant gut microbiome and rotavirus vaccine response in rural Ghana. *J Infect Dis* 215:34–41. <https://doi.org/10.1093/infdis/jiw518>.
 387. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, Sztein MB, Fraser CM. 2013. Impact of oral typhoid vaccination on the human gut microbiota and correlations with *S. Typhi*-specific immunological responses. *PLoS One* 8:e62026. <https://doi.org/10.1371/journal.pone.0062026>.
 388. Parker EPK, Praharaj I, Zekavati A, Lazarus RP, Giri S, Operario DJ, Liu J, Hout E, Iturriza-Gomara M, Kampmann B, John J, Kang G, Grassly NC. 2018. Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. *Vaccine* 36: 264–272. <https://doi.org/10.1016/j.vaccine.2017.11.031>.
 389. Donowitz JR, Petri WA, Jr. 2015. Pediatric small intestine bacterial overgrowth in low-income countries. *Trends Mol Med* 21:6–15. <https://doi.org/10.1016/j.molmed.2014.11.001>.
 390. Salk HM, Simon WL, Lambert ND, Kennedy RB, Grill DE, Kabat BF, Poland GA. 2016. Taxa of the nasal microbiome are associated with influenza-specific IgA response to live attenuated influenza vaccine. *PLoS One* 11:e0162803. <https://doi.org/10.1371/journal.pone.0162803>.
 391. Pedrazzi C, Ghio L, Balloni A, Panuccio A, Foti M, Edefonti A, Assael BM. 1999. Duration of immunity to diphtheria and tetanus in young kidney transplant patients. *Pediatr Transplant* 3:109–114. <https://doi.org/10.1034/j.1399-3046.1999.00013.x>.
 392. Matsushita M, Takeuchi S, Kumagai N, Uehara Y, Matsushita C, Arise K, Seo H, Awatani T. 2012. Prevalence of antibody titers can estimate the immune response to influenza vaccine in a rural community-dwelling elderly population. *Vaccine* 30:1101–1107. <https://doi.org/10.1016/j.vaccine.2011.12.024>.
 393. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. 2006. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? *Pediatrics* 118:e570–e578. <https://doi.org/10.1542/peds.2006-0198>.
 394. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. 2006. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. *Pediatrics* 118:e579–e585. <https://doi.org/10.1542/peds.2006-0201>.
 395. Fine PE. 1995. Variation in protection by BCG: implications of and for heterologous immunity. *Lancet* 346:1339–1345. [https://doi.org/10.1016/S0140-6736\(95\)92348-9](https://doi.org/10.1016/S0140-6736(95)92348-9).
 396. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, Ngwira B, Sichali L, Nazareth B, Blackwell JM, Branson K, Chagulukula SD, Donovan L, Jarman E, King E, Fine PE, Dockrell HM. 2002. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. *Lancet* 359:1393–1401. [https://doi.org/10.1016/S0140-6736\(02\)08353-8](https://doi.org/10.1016/S0140-6736(02)08353-8).
 397. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, Fine PE, Smith PG, Lipman M, Elliman D, Watson JM, Drumright LN, Whiting PF, Vynnycky E, Rodrigues LC. 2013. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. *Health Technol Assess* 17:1–372. <https://doi.org/10.3310/hta17370>.
 398. Weir RE, Black GF, Nazareth B, Floyd S, Stenson S, Stanley C, Branson K, Sichali L, Chagulukula SD, Donovan L, Crampin AC, Fine PE, Dockrell HM. 2006. The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi. *Clin Exp Immunol* 146:390–399. <https://doi.org/10.1111/j.1365-2249.2006.03222.x>.
 399. Anh DD, Canh DG, Lopez AL, Thiem VD, Long PT, Son NH, Deen J, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Holmgren J, Clemens J. 2007. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. *Vaccine* 25: 1149–1155. <https://doi.org/10.1016/j.vaccine.2006.09.049>.
 400. Winter AP, Flottet EA, McIntyre J, Stewart J, Symington IS. 1994. Influence of smoking on immunological responses to hepatitis B vaccine. *Vaccine* 12:771–772. [https://doi.org/10.1016/0264-410X\(94\)90283-6](https://doi.org/10.1016/0264-410X(94)90283-6).
 401. Middleman AB, Kozinetz CA, Robertson LM, DuRant RH, Emans SJ. 2001. The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis B immunization among adolescents. *Pediatrics* 107:1065–1069. <https://doi.org/10.1542/peds.107.5.1065>.
 402. Sheffield JS, Hickman A, Tang J, Moss K, Kourosh A, Crawford NM, Wendel GD, Jr. 2011. Efficacy of an accelerated hepatitis B vaccination

- program during pregnancy. *Obstet Gynecol* 117:1130–1135. <https://doi.org/10.1097/AOG.0b013e3182148efe>.
403. Namujju PB, Pajunen E, Simen-Kapeu A, Hedman L, Merikukka M, Surcel HM, Kirnbauer R, Apter D, Paavonen J, Hedman K, Lehtinen M. 2014. Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine—a pilot study. *BMC Res Notes* 7:445. <https://doi.org/10.1186/1756-0500-7-445>.
 404. MacKenzie JS, MacKenzie IH, Holt PG. 1976. The effect of cigarette smoking on susceptibility to epidemic influenza and on serological responses to live attenuated and killed subunit influenza vaccines. *J Hyg (Lond)* 77:409–417. <https://doi.org/10.1017/S0022172400055790>.
 405. Lim J, Song YJ, Park WS, Sohn H, Lee MS, Shin DH, Kim CB, Kim H, Oh GJ, Ki M. 2014. The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix(R) and Epaxal(R)) in Korean young adults. *Yonsei Med J* 55:126–131. <https://doi.org/10.3349/ymj.2014.55.1.126>.
 406. Oliveira LC, Silva TE, Alves MH. 2007. Response to hepatitis B vaccine in alcoholics without clinically evident liver cirrhosis. *Arq Gastroenterol* 44:195–200. <https://doi.org/10.1590/S0004-28032007000300003>.
 407. Eskola J, Ruuskanen O, Soppi E, Viljanen MK, Jarvinen M, Toivonen H, Kouvalainen K. 1978. Effect of sport stress on lymphocyte transformation and antibody formation. *Clin Exp Immunol* 32:339–345.
 408. Bruunsgaard H, Hartkopp A, Mohr T, Konradsen H, Heron I, Mordhorst CH, Pedersen BK. 1997. In vivo cell-mediated immunity and vaccination response following prolonged, intense exercise. *Med Sci Sports Exerc* 29:1176–1181. <https://doi.org/10.1097/00005768-199709000-00009>.
 409. Edwards KM, Burns VE, Reynolds T, Carroll D, Drayson M, Ring C. 2006. Acute stress exposure prior to influenza vaccination enhances antibody response in women. *Brain Behav Immun* 20:159–168. <https://doi.org/10.1016/j.bbi.2005.07.001>.
 410. Kohut ML, Cooper MM, Nickolaus MS, Russell DR, Cunnick JE. 2002. Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals. *J Gerontol A Biol Sci Med Sci* 57: M557–M562. <https://doi.org/10.1093/gerona/57.9.M557>.
 411. Hayney MS, Coe CL, Muller D, Obasi CN, Backonja U, Ewers T, Barrett B. 2014. Age and psychological influences on immune responses to trivalent inactivated influenza vaccine in the meditation or exercise for preventing acute respiratory infection (MEPARI) trial. *Hum Vaccin Immunother* 10:83–91. <https://doi.org/10.4161/hv.26661>.
 412. Long JE, Ring C, Bosch JA, Eves F, Drayson MT, Calver R, Say V, Allen D, Burns VE. 2013. A life-style physical activity intervention and the antibody response to pneumococcal vaccination in women. *Psychosom Med* 75:774–782. <https://doi.org/10.1097/PSY.0b013e3182a0b664>.
 413. Campbell JP, Edwards KM, Ring C, Drayson MT, Bosch JA, Inskip A, Long JE, Pulsford D, Burns VE. 2010. The effects of vaccine timing on the efficacy of an acute eccentric exercise intervention on the immune response to an influenza vaccine in young adults. *Brain Behav Immun* 24:236–242. <https://doi.org/10.1016/j.bbi.2009.10.001>.
 414. Ayling K, Fairclough L, Tighe P, Todd I, Halliday V, Garibaldi J, Royal S, Hamed A, Buchanan H, Vedhara K. 2018. Positive mood on the day of influenza vaccination predicts vaccine effectiveness: a prospective observational cohort study. *Brain Behav Immun* 67:314–323. <https://doi.org/10.1016/j.bbi.2017.09.008>.
 415. Phillips AC, Carroll D, Burns VE, Drayson M. 2009. Cardiovascular activity and the antibody response to vaccination. *J Psychosom Res* 67:37–43. <https://doi.org/10.1016/j.jpsychores.2008.12.002>.
 416. Kiecolt-Glaser JK, Glaser R, Gravenstein S, Malarkey WB, Sheridan J. 1996. Chronic stress alters the immune response to influenza virus vaccine in older adults. *Proc Natl Acad Sci U S A* 93:3043–3047. <https://doi.org/10.1073/pnas.93.7.3043>.
 417. Glaser R, Kiecolt-Glaser JK, Malarkey WB, Sheridan JF. 1998. The influence of psychological stress on the immune response to vaccines. *Ann N Y Acad Sci* 840:649–655. <https://doi.org/10.1111/j.1749-6632.1998.tb09603.x>.
 418. Vedhara K, Cox NK, Wilcock GK, Perks P, Hunt M, Anderson S, Lightman SL, Shanks NM. 1999. Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. *Lancet* 353: 627–631. [https://doi.org/10.1016/S0140-6736\(98\)06098-X](https://doi.org/10.1016/S0140-6736(98)06098-X).
 419. Segerstrom SC, Schipper LJ, Greenberg RN. 2008. Caregiving, repetitive thought, and immune response to vaccination in older adults. *Brain Behav Immun* 22:744–752. <https://doi.org/10.1016/j.bbi.2007.11.004>.
 420. Glaser R, Sheridan J, Malarkey WB, MacCallum RC, Kiecolt-Glaser JK. 2000. Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. *Psychosom Med* 62:804–807. <https://doi.org/10.1097/00006842-200011000-00010>.
 421. Burns VE, Carroll D, Drayson M, Whitham M, Ring C. 2003. Life events, perceived stress and antibody response to influenza vaccination in young, healthy adults. *J Psychosom Res* 55:569–572. [https://doi.org/10.1016/S0022-3999\(03\)00073-4](https://doi.org/10.1016/S0022-3999(03)00073-4).
 422. Miller GE, Cohen S, Pressman S, Barkin A, Rabin BS, Treanor JJ. 2004. Psychological stress and antibody response to influenza vaccination: when is the critical period for stress, and how does it get inside the body? *Psychosom Med* 66:215–223. <https://doi.org/10.1097/01.psy.0000116718.54414.9e>.
 423. Phillips AC, Burns VE, Carroll D, Ring C, Drayson M. 2005. The association between life events, social support, and antibody status following thymus-dependent and thymus-independent vaccinations in healthy young adults. *Brain Behav Immun* 19:325–333. <https://doi.org/10.1016/j.bbi.2004.10.004>.
 424. Pressman SD, Cohen S, Miller GE, Barkin A, Rabin BS, Treanor JJ. 2005. Loneliness, social network size, and immune response to influenza vaccination in college freshmen. *Health Psychol* 24:297–306. <https://doi.org/10.1037/0278-6133.24.3.297>.
 425. Kosor Krnic E, Gagro A, Kozaric-Kovacic D, Vilbich M, Grubisic-Ilic M, Folnegovic-Smalc V, Drazenovic V, Cecuk-Jelicic E, Gjenero-Margan I, Kuzman I, Jeren T, Sabioncello A, Kerhin-Brkljacic V, Kaic B, Markotic A, Gotovac K, Rabatic S, Mlinaric-Galinovic G, Dekaris D. 2007. Outcome of influenza vaccination in combat-related post-traumatic stress disorder (PTSD) patients. *Clin Exp Immunol* 149:303–310. <https://doi.org/10.1111/j.1365-2249.2007.03410.x>.
 426. Vedhara K, McDermott MP, Evans TG, Treanor JJ, Plummer S, Tallon D, Crutenden KA, Schifitto G. 2002. Chronic stress in nonelderly caregivers: psychological, endocrine and immune implications. *J Psychosom Res* 53: 1153–1161. [https://doi.org/10.1016/S0022-3999\(02\)00343-4](https://doi.org/10.1016/S0022-3999(02)00343-4).
 427. Pedersen AF, Zachariae R, Bovbjerg DH. 2009. Psychological stress and antibody response to influenza vaccination: a meta-analysis. *Brain Behav Immun* 23:427–433. <https://doi.org/10.1016/j.bbi.2009.01.004>.
 428. Phillips AC, Carroll D, Burns VE, Ring C, Macleod J, Drayson M. 2006. Bereavement and marriage are associated with antibody response to influenza vaccination in the elderly. *Brain Behav Immun* 20:279–289. <https://doi.org/10.1016/j.bbi.2005.08.003>.
 429. Moynihan JA, Larson MR, Treanor J, Duberstein PR, Power A, Shore B, Ader R. 2004. Psychosocial factors and the response to influenza vaccination in older adults. *Psychosom Med* 66:950–953. <https://doi.org/10.1097/01.psy.0000140001.49208.2d>.
 430. Burns VE, Carroll D, Ring C, Harrison LK, Drayson M. 2002. Stress, coping, and hepatitis B antibody status. *Psychosom Med* 64:287–293. <https://doi.org/10.1097/00006842-200203000-00012>.
 431. Glaser R, Kiecolt-Glaser JK, Bonneau RH, Malarkey W, Kennedy S, Hughes J. 1992. Stress-induced modulation of the immune response to recombinant hepatitis B vaccine. *Psychosom Med* 54:22–29. <https://doi.org/10.1097/00006842-199201000-00005>.
 432. Jabaaij L, Grosheide PM, Heijting RA, Duivenvoorden HJ, Ballieux RE, Vingerhoets AJ. 1993. Influence of perceived psychological stress and distress on antibody response to low dose rDNA hepatitis B vaccine. *J Psychosom Res* 37:361–369. [https://doi.org/10.1016/0022-3999\(93\)90138-6](https://doi.org/10.1016/0022-3999(93)90138-6).
 433. Petrie KJ, Booth RJ, Pennebaker JW, Davison KP, Thomas MG. 1995. Disclosure of trauma and immune response to a hepatitis B vaccination program. *J Consult Clin Psychol* 63:787–792. <https://doi.org/10.1037/0022-006X.63.5.787>.
 434. Burns VE, Drayson M, Ring C, Carroll D. 2002. Perceived stress and psychological well-being are associated with antibody status after meningitis C conjugate vaccination. *Psychosom Med* 64:963–970.
 435. Petry LJ, Weems LB, Il, Livingstone JN, Il. 1991. Relationship of stress, distress, and the immunologic response to a recombinant hepatitis B vaccine. *J Fam Pract* 32:481–486.
 436. Marsland AL, Cohen S, Rabin BS, Manuck SB. 2001. Associations between stress, trait negative affect, acute immune reactivity, and antibody response to hepatitis B injection in healthy young adults. *Health Psychol* 20:4–11. <https://doi.org/10.1037/0278-6133.20.1.4>.
 437. Jabaaij L, van Hattum J, Vingerhoets JJ, Oostveen FG, Duivenvoorden HJ, Ballieux RE. 1996. Modulation of immune response to rDNA hepatitis B vaccination by psychological stress. *J Psychosom Res* 41: 129–137. [https://doi.org/10.1016/0022-3999\(96\)00123-7](https://doi.org/10.1016/0022-3999(96)00123-7).
 438. Morag M, Morag A, Reichenberg A, Lerer B, Yirmiya R. 1999. Psychological variables as predictors of rubella antibody titers and fatigue—a

- prospective, double blind study. *J Psychiatr Res* 33:389–395. [https://doi.org/10.1016/S0022-3956\(99\)00010-2](https://doi.org/10.1016/S0022-3956(99)00010-2).
439. O'Connor TG, Moynihan JA, Wyman PA, Carnahan J, Lofthus G, Quataert SA, Bowman M, Caserta MT. 2014. Depressive symptoms and immune response to meningococcal conjugate vaccine in early adolescence. *Dev Psychopathol* 26:1567–1576. <https://doi.org/10.1017/S0954579414001242>.
 440. O'Connor TG, Wang H, Moynihan JA, Wyman PA, Carnahan J, Lofthus G, Quataert SA, Bowman M, Burke AS, Caserta MT. 2015. Observed parent-child relationship quality predicts antibody response to vaccination in children. *Brain Behav Immun* 48:265–273. <https://doi.org/10.1016/j.bbi.2015.04.002>.
 441. Boyce WT, Adams S, Tschann JM, Cohen F, Wara D, Gunnar MR. 1995. Adrenocortical and behavioral predictors of immune responses to starting school. *Pediatr Res* 38:1009–1017. <https://doi.org/10.1203/00006450-199512000-00030>.
 442. Prather AA, Hall M, Fury JM, Ross DC, Muldoon MF, Cohen S, Marsland AL. 2012. Sleep and antibody response to hepatitis B vaccination. *Sleep* 35:1063–1069. <https://doi.org/10.5665/sleep.1990>.
 443. Lange T, Perras B, Fehm HL, Born J. 2003. Sleep enhances the human antibody response to hepatitis A vaccination. *Psychosom Med* 65: 831–835. <https://doi.org/10.1097/01.PSY.0000091382.61178.F1>.
 444. Lange T, Dimitrov S, Bollinger T, Diekelmann S, Born J. 2011. Sleep after vaccination boosts immunological memory. *J Immunol* 187:283–290. <https://doi.org/10.4049/jimmunol.1100015>.
 445. Spiegel K, Sheridan JF, Van Cauter E. 2002. Effect of sleep deprivation on response to immunization. *JAMA* 288:1471–1472. <https://doi.org/10.1001/jama.288.12.1469>.
 446. Dopp JM, Wiegert NA, Moran JJ, Muller D, Weber S, Hayney MS. 2007. Humoral immune responses to influenza vaccination in patients with obstructive sleep apnea. *Pharmacotherapy* 27:1483–1489. <https://doi.org/10.1592/phco.27.11.1483>.
 447. Reuman PD, Kubilis P, Hurri W, Brown L, Nalin D. 1997. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. *Vaccine* 15:1157–1161. [https://doi.org/10.1016/S0264-410X\(96\)00310-6](https://doi.org/10.1016/S0264-410X(96)00310-6).
 448. Halsey NA, Moulton LH, O'Donovan JC, Walcher JR, Thoms ML, Margolis HS, Krause DS. 1999. Hepatitis B vaccine administered to children and adolescents at yearly intervals. *Pediatrics* 103:1243–1247. <https://doi.org/10.1542/peds.103.6.1243>.
 449. Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, Holland LA, Weir S, Noah TL, Beck MA. 2012. Obesity is associated with impaired immune response to influenza vaccination in humans. *Int J Obes* 36:1072–1077. <https://doi.org/10.1038/ijo.2011.208>.
 450. Talbot HK, Coleman LA, Crimin C, Zhu Y, Rock MT, Meece J, Shay DK, Belongia EA, Griffin MR. 2012. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. *Vaccine* 30:3937–3943. <https://doi.org/10.1016/j.vaccine.2012.03.071>.
 451. Young KM, Gray CM, Bekker LG. 2013. Is obesity a risk factor for vaccine non-responsiveness? *PLoS One* 8:e82779. <https://doi.org/10.1371/journal.pone.0082779>.
 452. Weber DJ, Rutala WA, Samsa GP, Bradshaw SE, Lemon SM. 1986. Impaired immunogenicity of hepatitis B vaccine in obese persons. *N Engl J Med* 314:1393. <https://doi.org/10.1056/NEJM198605223142120>.
 453. Simó Miñana J, Gaztambide Ganuza M, Fernández Millán P, Peña Fernández M. 1996. Hepatitis B vaccine immunoresponsiveness in adolescents: a revaccination proposal after primary vaccination. *Vaccine* 14:103–106. [https://doi.org/10.1016/0264-410X\(95\)00176-2](https://doi.org/10.1016/0264-410X(95)00176-2).
 454. Ul-Haq N, Hasnain SS, Umar M, Abbas Z, Valenzuela-Silva C, Lopez-Saura P. 2003. Immunogenicity of 10 and 20 microgram hepatitis B vaccine in a two-dose schedule. *Vaccine* 21:3179–3185. [https://doi.org/10.1016/S0264-410X\(03\)00232-9](https://doi.org/10.1016/S0264-410X(03)00232-9).
 455. el-Gamal Y, Aly RH, Hossny E, Afify E, el-Taliawy D. 1996. Response of Egyptian infants with protein calorie malnutrition to hepatitis B vaccination. *J Trop Pediatr* 42:144–145. <https://doi.org/10.1093/tropej/42.3.144>.
 456. Mohammed I, Damisah MM. 1982. The immunological response to polyvalent meningococcal vaccine in Bauchi State, Nigeria. *Trans R Soc Trop Med Hyg* 76:351–353. [https://doi.org/10.1016/0035-9203\(82\)90188-2](https://doi.org/10.1016/0035-9203(82)90188-2).
 457. Salimonu LS, Johnson AO, Williams AI, Adeleye GI, Osunkoya BO. 1982. Lymphocyte subpopulations and antibody levels in immunized malnourished children. *Br J Nutr* 48:7–14. <https://doi.org/10.1079/BJN19820082>.
 458. Idris S, El Seed AM. 1983. Measles vaccination in severely malnourished Sudanese children. *Ann Trop Paediatr* 3:63–67. <https://doi.org/10.1080/02724936.1983.11748270>.
 459. Powell GM. 1982. Response to live attenuated measles vaccine in children with severe kwashiorkor. *Ann Trop Paediatr* 2:143–145. <https://doi.org/10.1080/02724936.1982.11748247>.
 460. Gaayeb L, Pincon C, Cames C, Sarr JB, Seck M, Schacht AM, Remoue F, Hermann E, Riveau G. 2014. Immune response to Bordetella pertussis is associated with season and undernutrition in Senegalese children. *Vaccine* 32:3431–3437. <https://doi.org/10.1016/j.vaccine.2014.03.086>.
 461. Suskind R, Sirishinha S, Vithayasai V, Edelman R, Damrongsak D, Charupatana C, Olson RE. 1976. Immunoglobulins and antibody response in children with protein-calorie malnutrition. *Am J Clin Nutr* 29:836–841. <https://doi.org/10.1093/ajcn/29.8.836>.
 462. Brussow H, Sidoti J, Dirren H, Freire WB. 1995. Effect of malnutrition in Ecuadorian children on titers of serum antibodies to various microbial antigens. *Clin Diagn Lab Immunol* 2:62–68.
 463. Harland PS. 1965. Tuberculin reactions in malnourished children. *Lancet* ii:719–721.
 464. McMurray DN, Loomis SA, Casazza LJ, Rey H, Miranda R. 1981. Development of impaired cell-mediated immunity in mild and moderate malnutrition. *Am J Clin Nutr* 34:68–77. <https://doi.org/10.1093/ajcn/34.1.68>.
 465. Ziegler HD, Ziegler PB. 1975. Depression of tuberculin reaction in mild and moderate protein-calorie malnourished children following BCG vaccination. *Johns Hopkins Med J* 137:59–64.
 466. Sadarangani SP, Whitaker JA, Poland GA. 2015. "Let there be light": the role of vitamin D in the immune response to vaccines. *Expert Rev Vaccines* 14:1427–1440. <https://doi.org/10.1586/14760584.2015.1082426>.
 467. Sundaram ME, Talbot HK, Zhu Y, Griffin MR, Spencer S, Shay DK, Coleman LA. 2013. Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. *Vaccine* 31:2057–2061. <https://doi.org/10.1016/j.vaccine.2013.02.028>.
 468. Kriesel JD, Spruance J. 1999. Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. *Vaccine* 17:1883–1888. [https://doi.org/10.1016/S0264-410X\(98\)00476-9](https://doi.org/10.1016/S0264-410X(98)00476-9).
 469. Cooper C, Thorne A. 2011. Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults. *HIV Clin Trials* 12:275–276. <https://doi.org/10.1310/hct1205-275>.
 470. Principi N, Marchisio P, Terranova L, Zampiero A, Baggi E, Daleno C, Tirelli S, Pelucchi C, Esposito S. 2013. Impact of vitamin D administration on immunogenicity of trivalent inactivated influenza vaccine in previously unvaccinated children. *Hum Vaccin Immunother* 9:969–974. <https://doi.org/10.4161/hv.23540>.
 471. Lin CJ, Martin JM, Cole KS, Zimmerman RK, Susick M, Moehling KK, Levine MZ, Spencer S, Flannery B, Nowalk MP. 2017. Are children's vitamin D levels and BMI associated with antibody titers produced in response to 2014–2015 influenza vaccine? *Hum Vaccin Immunother* 13:1661–1665. <https://doi.org/10.1080/21645515.2017.1299837>.
 472. Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. 2014. Serum 25-hydroxyvitamin D level and influenza vaccine immunogenicity in children and adolescents. *PLoS One* 9:e83553. <https://doi.org/10.1371/journal.pone.0083553>.
 473. Anttonen JA, Hannula PM, Pyhala R, Saha HH, Ala-Houhala IO, Pasternack AI. 2000. Adequate seroresponse to influenza vaccination in dialysis patients. *Nephron* 86:56–61. <https://doi.org/10.1159/000045713>.
 474. Zitt E, Sprenger-Mahr H, Knoll F, Neyer U, Lhotka K. 2012. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. *Vaccine* 30:931–935. <https://doi.org/10.1016/j.vaccine.2011.11.086>.
 475. Aoun B, Dourthe ME, Davourie Salandre A, Souberbielle JC, Ulinski T. 2012. Do vitamin D plasma levels impact vaccine response in children with idiopathic nephrotic syndrome? *Pediatr Nephrol* 27:2161–2162. <https://doi.org/10.1007/s00467-012-2273-y>.
 476. Peelen E, Rijkers G, Meerveld-Eggink A, Meijvis S, Vogt M, Cohen Tervaert JW, Hupperts R, Damoiseaux J. 2013. Relatively high serum vitamin D levels do not impair the antibody response to encapsulated bacteria. *Eur J Clin Microbiol Infect Dis* 32:61–69. <https://doi.org/10.1007/s10096-012-1714-7>.
 477. Heine G, Drozdenko G, Lahl A, Unterwiesing N, Mei H, Volk HD, Dörner T, Radbruch A, Worm M. 2011. Efficient tetanus toxoid immunization on

- vitamin D supplementation. *Eur J Clin Nutr* 65:329–334. <https://doi.org/10.1038/ejcn.2010.276>.
478. Zheng Y, Li XG, Wang QZ, Ma AG, Bygbjerg IC, Sun YY, Li Y, Zheng MC, Wang X. 2014. Enhancement of vitamin A combined vitamin D supplementation on immune response to bacille Calmette-Guerin vaccine re vaccinated in Chinese infants. *Asian Pac J Trop Med* 7:130–135. [https://doi.org/10.1016/S1995-7645\(14\)60008-0](https://doi.org/10.1016/S1995-7645(14)60008-0).
 479. Bahl R, Kumar R, Bhandari N, Kant S, Srivastava R, Bhan MK. 1999. Vitamin A administered with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity. *J Nutr* 129:1569–1573. <https://doi.org/10.1093/jn/129.8.1569>.
 480. Benn CS, Balde A, George E, Kidd M, Whittle H, Lisse IM, Aaby P. 2002. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. *Lancet* 359:1313–1314. [https://doi.org/10.1016/S0140-6736\(02\)08274-0](https://doi.org/10.1016/S0140-6736(02)08274-0).
 481. Kutty PM, Mohanram M, Vinodini R. 1981. Humoral immune response in vitamin A deficient children. *Acta Vitaminol Enzymol* 3:231–235.
 482. Sundaram ME, Meydani SN, Vandermause M, Shay DK, Coleman LA. 2014. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study. *Nutr Res* 34:149–154. <https://doi.org/10.1016/j.nutres.2013.12.004>.
 483. Grzegorzewska AE, Jodłowska E, Mostowska A, Sowińska A, Jagodziński PP. 2014. Single nucleotide polymorphisms of vitamin D binding protein, vitamin D receptor and retinoid X receptor alpha genes and response to hepatitis B vaccination in renal replacement therapy patients. *Expert Rev Vaccines* 13:1395–1403. <https://doi.org/10.1586/14760584.2014.962521>.
 484. Ovsyannikova IG, Haralambieva IH, Vierkant RA, O'Byrne MM, Jacobson RM, Poland GA. 2012. Effects of vitamin A and D receptor gene polymorphisms/haplotypes on immune responses to measles vaccine. *Pharmacogenet Genomics* 22:20–31. <https://doi.org/10.1097/FPC.0b013e32834df186>.
 485. Imboumy-Limoukou RK, Oyegue-Liabagui SL, Ndi S, Pegha-Moukandja I, Kouna CL, Galaway F, Florent I, Lekana-Douki JB. 2016. Comparative antibody responses against three antimalarial vaccine candidate antigens from urban and rural exposed individuals in Gabon. *Eur J Microbiol Immunol* 6:287–297. <https://doi.org/10.1556/1886.2016.00027>.
 486. Alssamei FA, Al-Sonboli NA, Alkumaim FA, Alsayaad NS, Al-Ahdal MS, Higazi TB, Elagib AA. 2017. Assessment of immunization to hepatitis B vaccine among children under five years in rural areas of Taiz, Yemen. *Hepat Res Treat* 2017:2131627. <https://doi.org/10.1155/2017/2131627>.
 487. van Riet E, Adegnika AA, Retra K, Vieira R, Tielens AG, Lell B, Issifou S, Hartgers FC, Rimmelzwaan GF, Kremsner PG, Yazdanbakhsh M. 2007. Cellular and humoral responses to influenza in Gabonese children living in rural and semi-urban areas. *J Infect Dis* 196:1671–1678. <https://doi.org/10.1086/522010>.
 488. Edstam JS, Dulmaa N, Nymadawa P, Rinchin A, Khulan J, Kimball AM. 2002. Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. *Prev Med* 34:207–214. <https://doi.org/10.1006/pmed.2001.0972>.
 489. Hoppenbrouwers K, Kanra G, Roelants M, Ceyhan M, Vandermeulen C, Yurdakok K, Silier T, Dupuy M, Pehlivan T, Ozmert E, Desmyter J. 1999. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. *Vaccine* 17:875–886. [https://doi.org/10.1016/S0264-410X\(98\)00273-4](https://doi.org/10.1016/S0264-410X(98)00273-4).
 490. Park DE, Johnson TS, Nonyane BAS, Chandir S, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, O'Brien KL, Deloria Knoll M. 2014. The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. *Pediatr Infect Dis J* 33:S130–S139. <https://doi.org/10.1097/INF.0000000000000081>.
 491. Onoja AL, Adu FD, Tomori O. 1992. Evaluation of measles vaccination programme conducted in two separate health centres. *Vaccine* 10: 49–52. [https://doi.org/10.1016/0264-410X\(92\)90419-K](https://doi.org/10.1016/0264-410X(92)90419-K).
 492. Adu FD, Akinwolere OA, Tomori O, Uche LN. 1992. Low seroconversion rates to measles vaccine among children in Nigeria. *Bull World Health Organ* 70:457–460.
 493. Fowotade A, Okonko IO, Nwabuisi C, Bakare RA, Fadeyi A, Adu FD. 2015. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria. *J Immunoassay Immunochem* 36:195–209. <https://doi.org/10.1080/15321819.2014.920713>.
 494. Levine MM. 2010. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. *BMC Biol* 8:129. <https://doi.org/10.1186/1741-7007-8-129>.
 495. Patriarca PA, Wright PF, John TJ. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. *Rev Infect Dis* 13:926–939. <https://doi.org/10.1093/clinids/13.5.926>.
 496. Triki H, Abdallah MV, Ben Aissa R, Bouratbine A, Ben Ali Kacem M, Bouraoui S, Koubaa C, Zouari S, Mohsni E, Crainic R, Dellagi K. 1997. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. *Vaccine* 15:1123–1129. [https://doi.org/10.1016/S0264-410X\(97\)00001-7](https://doi.org/10.1016/S0264-410X(97)00001-7).
 497. Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M. 1995. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. *East Afr Med J* 72:162–164.
 498. Tabor E, Gerety RJ, Cairns J, Bayley AC. 1990. Antibody responses of adults, adolescents, and children to a plasma-derived hepatitis B vaccine in a rural African setting. *J Med Virol* 32:134–138. <https://doi.org/10.1002/jmv.1890320212>.
 499. Lalor MK, Floyd S, Gorak-Stolinska P, Ben-Smith A, Weir RE, Smith SG, Newport MJ, Blitz R, Mvula H, Branson K, McGrath N, Crampin AC, Fine PE, Dockrell HM. 2011. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. *J Infect Dis* 204:1075–1085. <https://doi.org/10.1093/infdis/jir515>.
 500. Lalor MK, Ben-Smith A, Gorak-Stolinska P, Weir RE, Floyd S, Blitz R, Mvula H, Newport MJ, Branson K, McGrath N, Crampin AC, Fine PE, Dockrell HM. 2009. Population differences in immune responses to bacille Calmette-Guerin vaccination in infancy. *J Infect Dis* 199: 795–800. <https://doi.org/10.1086/597069>.
 501. Termorshuizen F, Garssen J, Norval M, Koulu L, Laihia J, Leino L, Jansen CT, De Gruijl F, Gibbs NK, De Simone C, Van Loveren H. 2002. A review of studies on the effects of ultraviolet irradiation on the resistance to infections: evidence from rodent infection models and verification by experimental and observational human studies. *Int Immunopharmacol* 2:263–275. [https://doi.org/10.1016/S1567-5769\(01\)00178-3](https://doi.org/10.1016/S1567-5769(01)00178-3).
 502. Sleijffers A, Garssen J, de Gruijl FR, Boland GJ, van Hattum J, van Vloten WA, van Loveren H. 2001. Influence of ultraviolet B exposure on immune responses following hepatitis B vaccination in human volunteers. *J Invest Dermatol* 117:1144–1150. <https://doi.org/10.1046/j.0022-202x.2001.01542.x>.
 503. Reigart JR, Graber CD. 1976. Evaluation of the humoral immune response of children with low lead exposure. *Bull Environ Contam Toxicol* 16:112–117. <https://doi.org/10.1007/BF01753115>.
 504. Raqib R, Ahmed S, Ahsan KB, Kippler M, Akhtar E, Roy AK, Lu Y, Arifeen SE, Wagatsuma Y, Vahter M. 2017. Humoral immunity in arsenic-exposed children in rural Bangladesh: total immunoglobulins and vaccine-specific antibodies. *Environ Health Perspect* 125:067006. <https://doi.org/10.1289/EHP318>.
 505. Weisglas-Kuperus N, Patandin S, Berbers GA, Sas TC, Mulder PG, Sauer PJ, Hooijkaas H. 2000. Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children. *Environ Health Perspect* 108:1203–1207. <https://doi.org/10.1289/ehp.001081203>.
 506. Ritz N, Dutta B, Donath S, Casalaz D, Connell TG, Tebruegge M, Robins-Browne R, Hanekom WA, Britton WJ, Curtis N. 2012. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. *Am J Respir Crit Care Med* 185: 213–222. <https://doi.org/10.1164/rccm.201104-0714OC>.
 507. Ritz N, Hanekom WA, Robins-Browne R, Britton WJ, Curtis N. 2008. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. *FEMS Microbiol Rev* 32:821–841. <https://doi.org/10.1111/j.1574-6976.2008.00118.x>.
 508. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, Lee CM, Lu SN. 2009. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. *Vaccine* 27: 1858–1862. <https://doi.org/10.1016/j.vaccine.2009.01.027>.
 509. Fang Y, Chen L, Liu MQ, Zhu ZG, Zhu ZR, Hu Q. 2014. Comparison of safety and immunogenicity of PVRV and PCECV immunized in patients with WHO category II animal exposure: a study based on different age groups. *PLoS Negl Trop Dis* 8:e3412. <https://doi.org/10.1371/journal.pntd.0003412>.
 510. Levy O, Goriely S, Kollmann TR. 2013. Immune response to vaccine

- adjuvants during the first year of life. *Vaccine* 31:2500–2505. <https://doi.org/10.1016/j.vaccine.2012.10.016>.
511. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. *Sci Transl Med* 3:85ra48. <https://doi.org/10.1126/scitranslmed.3002336>.
 512. Mosca F, Trito E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio E. 2008. Molecular and cellular signatures of human vaccine adjuvants. *Proc Natl Acad Sci U S A* 105:10501–10506. <https://doi.org/10.1073/pnas.0804699105>.
 513. Jacques P, Moens G, Desombere I, Dewijngaert J, Leroux-Roels G, Wettendorff M, Thoelen S. 2002. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. *Vaccine* 20:3644–3649. [https://doi.org/10.1016/S0264-410X\(02\)00397-3](https://doi.org/10.1016/S0264-410X(02)00397-3).
 514. Salk J, Cohen H, Fillastre C, Stoeckel P, Rey JL, Schlumberger M, Nicolas A, van Steenis G, van Wezel AL, Triaui R, Saliou P, Barry LF, Moreau JP, Mérieux C. 1978. Killed poliovirus antigen titration in humans. *Dev Biol Stand* 41:119–132.
 515. Chiaramonte M, Majori S, Ngatchu T, Moschen ME, Baldo V, Renzulli G, Simoncello I, Rocco S, Bertin T, Naccarato R, Trivello R. 1996. Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity. *Vaccine* 14:135–137. [https://doi.org/10.1016/0264-410X\(95\)00148-T](https://doi.org/10.1016/0264-410X(95)00148-T).
 516. Punjabi NH, Richie EL, Simanjuntak CH, Harjanto SJ, Wangsasaputra F, Arjoso S, Rofiq A, Prijanto M, Julitasari Yela U, Herzog C, Cryz SJ. 2006. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants. *Vaccine* 24:1776–1785. <https://doi.org/10.1016/j.vaccine.2005.10.023>.
 517. DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. 2013. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009–2010 season. *Vaccine* 31:861–866. <https://doi.org/10.1016/j.vaccine.2012.12.013>.
 518. Booy R, Aitken SJ, Taylor S, Tudor-Williams G, Macfarlane JA, Moxon ER, Ashworth LA, Mayon-White RT, Griffiths H, Chapel HM. 1992. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. *Lancet* 339:507–510. [https://doi.org/10.1016/0140-6736\(92\)90336-2](https://doi.org/10.1016/0140-6736(92)90336-2).
 519. Rumke HC, Loch HP, Hoppenbrouwers K, Vandermeulen C, Malfroot A, Helm K, Douha M, Willems P. 2011. Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. *Vaccine* 29:3842–3849. <https://doi.org/10.1016/j.vaccine.2011.02.067>.
 520. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. 2005. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. *Pediatrics* 115:1039–1047. <https://doi.org/10.1542/peds.2004-2373>.
 521. Ukena T, Esber H, Bessette R, Parks T, Crocker B, Shaw FE, Jr. 1985. Site of injection and response to hepatitis B vaccine. *N Engl J Med* 313: 579–580. <https://doi.org/10.1056/NEJM198508293130911>.
 522. Anonymous. 1985. Suboptimal response to hepatitis B vaccine given by injection into the buttock. *MMWR Morb Mortal Wkly Rep* 34:105–108, 113.
 523. Shaw FE, Jr, Guess HA, Roets JM, Mohr FE, Coleman PJ, Mandel EJ, Roehm RR, Jr, Talley WS, Hadler SC. 1989. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. *Vaccine* 7:425–430. [https://doi.org/10.1016/0264-410X\(89\)90157-6](https://doi.org/10.1016/0264-410X(89)90157-6).
 524. Weber DJ, Rutala WA, Kenyear SA, Lemon SM. 1986. Response to deltoid muscle injection of hepatitis B vaccine after failure to respond to gluteal injections. *JAMA* 255:2157. <https://doi.org/10.1001/jama.1986.03370160055008>.
 525. Alves AS, Nascimento CM, Granato CH, Sato HK, Morgato MF, Pannuti CS. 2001. Hepatitis B vaccine in infants: a randomized controlled trial comparing gluteal versus anterolateral thigh muscle administration. *Rev Inst Med Trop Sao Paulo* 43:139–143. <https://doi.org/10.1590/S0036-46652001000300004>.
 526. Shi N, Luo F, Li L, Zheng D, Zhang Z, Wang Z, Yang L, Liu Z, Ai X, Bai Y, Lu Q. 2013. A randomized, controlled, blinded study of the safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine injected at different intramuscular sites in Chinese infants. *Hum Vaccin Immunother* 9:2311–2315. <https://doi.org/10.4161/hv.25526>.
 527. Cardell K, Fryden A, Normann B. 1999. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. *Scand J Infect Dis* 31:197–200.
 528. Mills DJ, Lau CL, Fearnley EJ, Weinstein P. 2011. The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule—a case series of 420 travelers. *J Travel Med* 18:327–332. <https://doi.org/10.1111/j.1708-8305.2011.00540.x>.
 529. Warrell MJ, Suntharasamai P, Nicholson KG, Warrell DA, Chanthavanich P, Viravan C, Sinhaseni A, Phanfung R, Xueref C, Vincent-Falquet JC. 1984. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. *Lancet* 323:874–876. [https://doi.org/10.1016/S0140-6736\(84\)91340-0](https://doi.org/10.1016/S0140-6736(84)91340-0).
 530. Dubois B, Bridon JM, Fayette J, Barthelemy C, Bancheau J, Caux C, Briere F. 1999. Dendritic cells directly modulate B cell growth and differentiation. *J Leukoc Biol* 66:224–230. <https://doi.org/10.1002/jlb.66.2.224>.
 531. Playford EG, Hogan PG, Bansal AS, Harrison K, Drummond D, Looke DF, Whitby M. 2002. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. *Infect Control Hosp Epidemiol* 23:87–90. <https://doi.org/10.1086/502012>.
 532. Leonardi S, Del Giudice MM, Spicuzza L, Spina M, La Rosa M. 2010. Hepatitis B vaccine administered by intradermal route in patients with celiac disease unresponsive to the intramuscular vaccination schedule: a pilot study. *Am J Gastroenterol* 105:2117–2119. <https://doi.org/10.1038/ajg.2010.195>.
 533. Charest AF, McDougall J, Goldstein MB. 2000. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. *Am J Kidney Dis* 36: 976–982. <https://doi.org/10.1053/ajkd.2000.19099>.
 534. Diggle L, Deeks JJ, Pollard AJ. 2006. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. *BMJ* 333:571. <https://doi.org/10.1136/bmj.38906.704549.7C>.
 535. Beirne PV, Hennessy S, Cadogan SL, Shiely F, Fitzgerald T, MacLeod F. 2015. Needle size for vaccination procedures in children and adolescents. *Cochrane Database Syst Rev* 2015:CD010720. <https://doi.org/10.1002/14651858.CD010720.pub2>.
 536. Long JE, Drayson MT, Taylor AE, Toellner KM, Lord JM, Phillips AC. 2016. Morning vaccination enhances antibody response over afternoon vaccination: a cluster-randomised trial. *Vaccine* 34:2679–2685. <https://doi.org/10.1016/j.vaccine.2016.04.032>.
 537. Langlois PH, Smolensky MH, Glezen WP, Keitel WA. 1995. Diurnal variation in responses to influenza vaccine. *Chronobiol Int* 12:28–36. <https://doi.org/10.3109/07420529509064497>.
 538. Phillips AC, Gallagher S, Carroll D, Drayson M. 2008. Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. *Psychophysiology* 45:663–666. <https://doi.org/10.1111/j.1469-8986.2008.00662.x>.
 539. Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q. 2015. Combination measles-mumps-rubella-varicella vaccine in healthy children: a systematic review and meta-analysis of immunogenicity and safety. *Medicine (Baltimore, MD)* 94:e1721. <https://doi.org/10.1097/MD.0000000000001721>.
 540. Leung JH, Hirai HW, Tsoi KK. 2015. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. *Expert Rev Vaccines* 14:1149–1157. <https://doi.org/10.1586/14760584.2015.1057572>.
 541. Goh P, Lim FS, Han HH, Willems P. 2007. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. *Infection* 35:326–333. <https://doi.org/10.1007/s15010-007-6337-z>.
 542. Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schodel F, Gress JO, Kuter BJ. 2006. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-Ril and Varivax. *Pediatrics* 117:265–272. <https://doi.org/10.1542/peds.2005-0092>.
 543. Gillet Y, Steri GC, Behre U, Arsene JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P. 2009. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months–2 years or 2–6 years primed with measles-mumps-rubella (MMR) vaccine. *Vaccine* 27:446–453. <https://doi.org/10.1016/j.vaccine.2008.10.064>.
 544. Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha

- M, Willems P. 2009. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. *Vaccine* 27:2701–2706. <https://doi.org/10.1016/j.vaccine.2009.02.044>.
545. Lalwani S, Chatterjee S, Balasubramanian S, Bavdekar A, Mehta S, Datta S, Povey M, Henry O. 2015. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial. *BMJ Open* 5:e007202. <https://doi.org/10.1136/bmjopen-2014-007202>.
 546. Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yoge R, Cordova J, Cho I, Mendelman PM. 2008. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. *Pediatrics* 121: 508–516. <https://doi.org/10.1542/peds.2007.1064>.
 547. Nascimento Silva JR, Camacho LAB, Siqueira MM, Freire MDS, Castro YP, Maia MDLS, Yamamura AMY, Martins RM, Leal MDLF. 2011. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. *Vaccine* 29: 6327–6334. <https://doi.org/10.1016/j.vaccine.2011.05.019>.
 548. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. *J Infect Dis* 188: 1213–1230. <https://doi.org/10.1086/378356>.
 549. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanasa-Thanan N, Feroldi E, Reid M. 2010. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity. *Hum Vaccin* 6:906–914. <https://doi.org/10.4161/hv.6.11.12854>.
 550. Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, Graepel J, Laufer D. 2006. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine. *Pediatr Infect Dis J* 25: 306–311. <https://doi.org/10.1097/01.inf.0000207409.92198.6f>.
 551. Blatter MM, Klein NP, Shepard JS, Leonardi M, Shapiro S, Schear M, Mufson MA, Martin JM, Varman M, Grogg S, London A, Cambron P, Douha M, Nicholson O, da Costa C, Innis BL. 2012. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis A and pneumococcal conjugate vaccines to children twelve to fourteen months of age. *Pediatr Infect Dis J* 31:e133–e140. <https://doi.org/10.1097/INF.0b013e318259fc8a>.
 552. Yetman RJ, Shepard JS, Duke A, Stek JE, Petrecz M, Klopfer SO, Kuter BJ, Schodel FP, Lee AW. 2013. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children. *Hum Vaccin Immunother* 9:1691–1697. <https://doi.org/10.4161/hv.24873>.
 553. Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, Dieussaert I, Schuerman L. 2010. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. *Pediatr Infect Dis J* 29:e47–e56. <https://doi.org/10.1097/INF.0b013e3181dffbfbf>.
 554. Durando P, Esposito S, Bona G, Cuccia M, Desole MG, Ferrera G, Gabutti G, Pellegrino A, Salvini F, Henry O, Povey M, Marchetti F. 2016. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: a phase IIIb, randomized, multi-center study in Italy. *Vaccine* 34:4278–4284. <https://doi.org/10.1016/j.vaccine.2016.07.009>.
 555. Dhillion S, Curran MP. 2008. Live attenuated measles, mumps, rubella, and varicella zoster virus vaccine (Priorix-Tetra). *Paediatr Drugs* 10: 337–347. <https://doi.org/10.2165/00148581-200810050-00007>.
 556. Halasa NB, O'Shea A, Shi JR, LaFleur BJ, Edwards KM. 2008. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. *J Pediatr* 153:327–332. <https://doi.org/10.1016/j.jpeds.2008.03.011>.
 557. Zimmermann P, Curtis N. 2018. The influence of BCG on vaccine responses—a systematic review. *Expert Rev Vaccines* 17:547–554. <https://doi.org/10.1080/14760584.2018.1483727>.
 558. Emperador DM, Velasquez DE, Estivariz CF, Lopman B, Jiang B, Parashar U, Anand A, Zaman K. 2016. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. *Clin Infect Dis* 62:150–156. <https://doi.org/10.1093/cid/civ807>.
 559. Patel M, Steele AD, Parashar UD. 2012. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. *Vaccine* 30(Suppl 1):A30–A35. <https://doi.org/10.1016/j.vaccine.2011.11.093>.
 560. Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, Neuzil K, Datta SK, Delem A, Suryakiran PV, Bock HL. 2009. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. *Vaccine* 27:1333–1339. <https://doi.org/10.1016/j.vaccine.2008.12.059>.
 561. Labadie J, Sundermann LC, Ru'mke HC, DPT-IPV Hib Vaccine Study Group. 1996. Multi-center study on the simultaneous administration of DPT-IPV and Hib PRP-T vaccines. Part 1. Immunogenicity. RIVM report 124001003. National Institute of Public Health and the Environment. Bilthoven, The Netherlands.
 562. Bar-On ES, Goldberg E, Hellmann S, Leibovici L. 2012. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). *Cochrane Database Syst Rev* 2012:CD005530. <https://doi.org/10.1002/14651858.CD005530.pub3>.
 563. Das RR, Panigrahi I, Naik SS. 2014. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review. *PLoS One* 9:e106629. <https://doi.org/10.1371/journal.pone.0106629>.
 564. Wysocki J, Center KJ, Brzostek J, Majda-Stanislawski E, Szymanski H, Szenborn L, Czajka H, Hasiec B, Dziduch J, Jackowska T, Witor A, Kosińska E, Konior R, Giardina PC, Sundaraiyer V, Patterson S, Gruber WC, Scott DA, Gurtman A. 2017. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. *Vaccine* 35:1926–1935. <https://doi.org/10.1016/j.vaccine.2017.02.035>.
 565. Black S, Nicolay U, Del Giudice G, Rappuoli R. 2016. Influence of statins on influenza vaccine response in elderly individuals. *J Infect Dis* 213: 1224–1228. <https://doi.org/10.1093/infdis/jiv456>.
 566. Robinson MJ, Campbell F, Powell P, Sims D, Thornton C. 1999. Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. *Arch Dis Child Fetal Neonatal Ed* 80:F69–F71. <https://doi.org/10.1136/fn.80.1.F69>.
 567. Aaby P, Martins CL, Garly ML, Rodrigues A, Benn CS, Whittle H. 2012. The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy. *BMJ Open* 2:e000761. <https://doi.org/10.1136/bmjopen-2011-000761>.
 568. van der Sande MA, Waight P, Mendy M, Rayco-Solon P, Hutt P, Fulford T, Doherty C, McConkey SJ, Jeffries D, Hall AJ, Whittle HC. 2006. Long-term protection against hepatitis B virus after infant vaccination. *J Infect Dis* 193:1528–1535. <https://doi.org/10.1086/503433>.
 569. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. 2006. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. *J Infect Dis* 193: 655–663. <https://doi.org/10.1086/500144>.
 570. Watanabe H, Okumura M, Hirayama K, Sasazuki T. 1990. HLA-Bw54-DR4-DRw53-DQw4 haplotype controls nonresponsiveness to hepatitis-B surface antigen via CD8-positive suppressor T cells. *Tissue Antigens* 36:69–74. <https://doi.org/10.1111/j.1399-0039.1990.tb01802.x>.
 571. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, Alper CA, Yunis EJ. 1991. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. *J Exp Med* 173:531–538. <https://doi.org/10.1084/jem.173.3.531>.
 572. Marseglia G, Alibrandi A, d'Annunzio G, Gulminetti R, Avanzini MA, Marconi M, Tinelli C, Lorini R. 2000. Long term persistence of anti-HBs protective levels in young patients with type 1 diabetes after recombinant hepatitis B vaccine. *Vaccine* 19:680–683. [https://doi.org/10.1016/S0264-410X\(00\)00268-1](https://doi.org/10.1016/S0264-410X(00)00268-1).
 573. Schmid S, Molteni A, Fuchtenbusch M, Naserke HE, Ziegler AG, Boni-

- facio E. 2002. Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes. *Diabetologia* 45:677–685. <https://doi.org/10.1007/s00125-002-0816-7>.
574. Smolen P, Bland R, Heiligenstein E, Lawless MR, Dillard R, Abramson J. 1983. Antibody response to oral polio vaccine in premature infants. *J Pediatr* 103:917–919. [https://doi.org/10.1016/S0022-3476\(83\)80714-8](https://doi.org/10.1016/S0022-3476(83)80714-8).
 575. Krugman S, Warren J, Eiger MS, Berman PH, Michaels RM, Sabin AB. 1961. Immunization with live attenuated poliovirus vaccine. *Am J Dis Child* 101:23–29.
 576. Greenwood BM, Bradley-Moore AM, Bradley AK, Kirkwood BR, Gilles HM. 1986. The immune response to vaccination in undernourished and well-nourished Nigerian children. *Ann Trop Med Parasitol* 80:537–544. <https://doi.org/10.1080/00034983.1986.11812062>.
 577. Karimi M, Raei A, Baghianimoghadam B, Fallahzadeh MH. 2013. Vaccine-induced anti-HBs level in 5–6 year-old malnourished children. *Hepat Mon* 13:e7048. <https://doi.org/10.5812/hepatmon.7048>.
 578. Ifekwunigwe AE, Grasset N, Glass R, Foster S. 1980. Immune responses to measles and smallpox vaccinations in malnourished children. *Am J Clin Nutr* 33:621–624. <https://doi.org/10.1093/ajcn/33.3.621>.
 579. Ekunwe EO. 1985. Malnutrition and seroconversion following measles immunization. *J Trop Pediatr* 31:290–291. <https://doi.org/10.1093/tropej/31.6.290>.
 580. Marshall R, Habicht JP, Landrigan PJ, Foege WH, Delgado H. 1974. Effectiveness of measles vaccine given simultaneously with DTP. *J Trop Pediatr Environ Child Health* 20:126–129.
 581. Kielmann AA, Ubero IS, Chandra RK, Mehra VL. 1976. The effect of nutritional status on immune capacity and immune responses in pre-school children in a rural community in India. *Bull World Health Organ* 54:477–483.
 582. Ballet JJ, Agrapart M, Monjour L, Bourdillon F, Karam M, Kyelem JM, Stoeckel P. 1982. Humoral and cellular immunity following antitetanus vaccination in malnourished and malaria-induced African children. 2. In vitro study of non-specific and specific cellular responses to tetanus anatoxin. *Bull World Health Organ* 60:597–604.

Petra Zimmermann, M.D., works as a Consultant in Paediatric Infectious Diseases at the Fribourg Hospital, Switzerland. She trained as a Paediatrician and Infectious Diseases Specialist at the University Children's Hospital of Berne, Switzerland, and at the Royal Children's Hospital in Melbourne, Australia. Dr. Zimmermann completed her thesis at the Clinic for Infectious Diseases and Travel Medicine at the University Hospital of Berne in 2013. Before her current position, she worked as a Consultant in Paediatric Infectious Diseases at the Children's Hospital in Basel. Dr. Zimmermann is currently completing her Ph.D. at the University of Melbourne. Her research interests include vaccine responses, nonspecific effects of vaccines, and the association between the intestinal microbiome and immune responses.



Nigel Curtis is a clinician scientist (M.D., Ph.D.) who trained in the United Kingdom and Canada. He is now based in Australia, where he is Head of Infectious Diseases at the Royal Children's Hospital Melbourne and Professor of Paediatric Infectious Diseases at the University of Melbourne. He is also Leader of the Infectious Diseases & Microbiology Research Group at the Murdoch Children's Research Institute. His research interests focus on the innate and cellular immune responses to childhood infection to improve the diagnosis and prevention of infectious diseases. Prof. Curtis currently leads a large randomized controlled trial to investigate the immunomodulatory heterologous (nonspecific) effects of neonatal BCG vaccination, including its ability to prevent infections, allergic disease, and asthma. The laboratory aspects of this trial include analysis of the early infant microbiome to elucidate its role in the developing immune system and its influence on the development of allergic diseases.

